Studies on the formation of thrombin : approaching physiological conditions

Citation for published version (APA):

Kessels, H. J. J. (1993). *Studies on the formation of thrombin : approaching physiological conditions*. [Doctoral Thesis, Maastricht University]. Datawyse / Universitaire Pers Maastricht.
<https://doi.org/10.26481/dis.19930930hk>

Document status and date:

Published: 01/01/1993

DOI:

[10.26481/dis.19930930hk](https://doi.org/10.26481/dis.19930930hk)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

STUDIES ON THE FORMATION OF THROMBIN

APPROACHING PHYSIOLOGICAL CONDITIONS

1960

CIP-DATA KONINKLIJKE BIBLIOTHEEK, DEN HAAG

Kessels, Henricus Johannes Josephus
Kessels, Henricus Johannes Josephus

Studies on the formation of thrombin: Approaching physiological conditions

Henricus Johannes Josephus Kessels - Maarsricht:

Universitaire Pers Maarsricht - III.

Thesis Maarsricht. - With ref. - With summary in Dutch

ISBN 90-3278-092-7

Subject headings: thrombin / blood coagulation

Omring, G. H. H.

CIP-DATA KONINKLIJKE BIBLIOTHEEK, DEN HAAG

Kessels, Henricus Johannes Josephina

Studies on the formation of thrombin: Approaching physiological conditions

Henricus Johannes Josephina Kessels - Maastricht:

Universitaire Pers Maastricht. - I11.

Thesis Maastricht. - With ref. - With summary in Dutch

ISBN 90-5278-092-7

Subject headings: thrombin / blood coagulation

Omslag: Gé Helsen

STUDIES ON THE FORMATION OF THROMBIN

APPROACHING PHYSIOLOGICAL CONDITIONS

PROEFSCHRIFT

ter verkrijging van de graad van doctor
aan de Rijksuniversiteit Limburg te Maastricht,
op gezag van de Pro-Rector, Prof. dr. L. Boon,
volgens het besluit van het College van Dekanen,
in het openbaar te verdedigen op
donderdag 30 september 1993 om 14.00 uur

door

Henricus Johannes Josephina Kessels

promotor:

Prof.dr. H.C. Hemker

beoordelingscommissie:

Prof.dr. J.F.M. Smits (voorzitter)

Dr. T.W. Barrowcliffe, Nat. Inst. for Biological Standards and Control, London

Prof.dr. F.C.S. Ramaekers

Prof.dr. J. Vermeylen, Katholieke Universiteit Leuven

Prof.dr.ir.drs. O.J. Vrieze

Financial support by the Dr. Ir. J.H.J. van de Laar Foundation, and the Netherlands Heart Foundation for the publication of this thesis is gratefully acknowledged.

De toutes les protéines du plasma sanguin, la trombine est certes celle qui offre au prodigieux et inépuisable thème de la coagulation les plus admirables ressources.

naar Willem Elsschot, Lijmen

aan pap, mam en oma
voor Marion

contents

chapter 1	introduction	11
	components and reactions	11
	control	19
	the present investigation	21
chapter 2	measurement of thrombin generation in whole blood; the effect of heparin and aspirin	31
chapter 3	analysis of thrombin generation curves	47
chapter 4	measuring activated factor VIII in plasma	67
chapter 5	the role of thrombin feedback reactions and factor Xa during clotting of human plasma	83
chapter 6	analysis of bleeding from bleeding time wounds	107
chapter 7	summary and conclusions	117
	samenvatting en conclusies	125
	curriculum vitae	135
	dankwoord	137

1. components and reactions

The proteins, cells, and other substances that make up the hemostatic system form a closely coupled and tightly regulated system. As such, they

contents

chapter 1	introduction	11
	components and reactions	11
	control	19
	the present investigation	21
chapter 2	measurement of thrombin generation in whole blood; the effect of heparin and aspirin	31
chapter 3	analysis of thrombin generation curves	47
chapter 4	measuring activated factor VIII in plasma	67
chapter 5	the role of thrombin feedback reactions and factor Xa during clotting of human plasma	83
chapter 6	analysis of bleeding from bleeding time wounds	107
chapter 7	summary and conclusions	117
	samenvatting en conclusies	125
	curriculum vitae	135
	dankwoord	137

1. components and reactions

The proteins, cells, and other substances that make up the hemostatic system form a closely coupled and tightly regulated system. As such, they

chapter 1

Introduction

Bloodclotting is of necessity a fast, dynamic, and strictly controlled process. It is a massive reaction involving a large number of blood components, both cells and proteins, that should be triggered quickly and efficiently, but only when needed. It is as important that clotting does not occur when there is no cause, as that it does when a vessel is damaged. The guiding principle in the control of this hemostatic process is localisation.

Bloodclotting is an emergency mechanism. It occurs when a blood vessel is damaged and blood is exposed to perivascular connective tissue, and the contents of damaged cells. Within seconds, processes start which, in a short timespan, lead to the formation of a seal, or plug, consisting mainly of platelets and fibrin. This plug formation, and therefore the processes involved, remain confined to the damaged area. They are not only limited in place, they are also in time, as the plug does not grow much further when the leak has been closed. Bloodclotting *in vivo* is thus a phenomenon that is strictly localised temporally and spatially. This, of course, is different from the situation *in vitro*. Bloodclotting in a test tube is always complete.

Through the years, the participants in the hemostatic process, have been identified one by one. They, clotting factors, platelets, ions, have been put in reaction schemes in order to show the 'city plan' of the events that are taking place during bloodclotting. However, like the map of a city says very little about the life in the city, a map of bloodclotting does in itself not completely reveal the true nature of this intriguing process. Missing from the reaction scheme is a set of principles that are basic to the control of coagulation. In this introduction I will, in addition to the current reaction scheme, try to describe some of these principles, and where they fit into the reaction sequence.

1. components and reactions

The proteins, cells, and other substances that make up the hemostatic system form a closely coupled and tightly regulated system. As such, they

all work closely together. It is, therefore, difficult to give a detailed description of the properties of each component separately, without touching upon functions of related components. Consequently, only a brief overview of several key components individually will be provided before discussing hemostasis as a whole.

1.1. components

thrombin

Thrombin, or factor IIa, is the product of the series of proteolytic activation reactions of the coagulation system. Thrombin has many functions, and forms an important link between the various components of the hemostatic process. It is best known for its ability to convert fibrinogen molecules into fibrin monomers that rapidly assemble to form fibrin threads. Thrombin also activates factor XIII, which then has the ability to cross-link the fibrin threads to form a rigid network. It is often less well realised that thrombin is the most potent physiological platelet activator, especially in the presence of collagen. The mechanism of platelet activation by thrombin involves cleavage of a transmembrane molecule, as has been elucidated recently (1). Thrombin has several interactions with intact endothelial cells, which are largely anticoagulant. Most important is probably that thrombin is able to form a complex with thrombomodulin, a protein present on the endothelial cell membrane. This causes a change of the specificity of the proteolytic action of thrombin so that it loses its procoagulant properties and acquires the ability to activate Protein C (2,3), which, possibly together with the cofactor Protein S, forms a potent anticoagulant. Reportedly, thrombin also has a number of extra-hemostatic actions. It has, among other things, been described to enhance wound healing by stimulating proliferation of fibroblasts and a number of other cells (4,5,6,7). Lastly, thrombin plays an important role in the reactions leading to its own formation. By its ability to activate the cofactor proteins factor V and factor VIII, thrombin accelerates its formation by several orders of magnitude.

platelets

Blood platelets are small anucleate cells that have an important role in hemostasis. They are activated by a number of substances including thrombin, collagen, and ADP. Activation induces a shape change from discoid to spherical with formation of pseudopodia. The secretory granules of the platelets then release their contents into the open canalicular system. Among the substances released are ADP, blood clotting factor V, platelet factor 4, and vasoactive substances like serotonin. Platelets are capable of

adhering to proteins of the sub-endothelial matrix, such as collagens, to various plasma proteins, e.g. fibrin and fibronectin, and to other platelets. Platelet adherence is mediated by cell surface receptors of the integrin family. A major platelet surface receptor GPIIb/IIIa (integrin $\alpha_{IIb}\beta_3$) probably has to be activated to be functional (8,9), but it is not clear whether this holds true for other members of the integrin family. Platelet activation by thrombin together with collagen also leads to loss of platelet membrane asymmetry with respect to phospholipid composition (10), resulting in the presence of negatively charged phosphatidyl serine molecules in the outer leaflet of the platelet membrane bilayer. In addition to being localised to the site of injury, a number of reactions of the coagulation system is greatly accelerated when occurring on such a membrane surface, partly because the values of the K_m are lowered by several orders of magnitude (11,12,13,14). Additionally, small micro vesicles are shed by activated platelets (15). These micro-vesicles have also lost their membrane asymmetry, and can thus serve as a surface for various membrane bound reactions of the coagulation system.

vitamin K dependent clotting factors

These include factors II, VII, IX and X. They are serine protease proenzymes that undergo a vitamin K dependent post-translational carboxylation of certain N-terminal glutamic acid residues to γ -carboxyglutamic acid residues, or Gla's (16,17,18). These Gla residues play an important role in the Ca^{2+} dependent binding of vitamin K dependent coagulation factors to negatively charged lipid membranes (19). Factor VII is proteolytically cleaved to factor VIIa by factor Xa, and, at a slower rate, by factor IXa (20,21,22,23,24,25). Factor VIIa, when complexed to its cofactor tissue factor (TF), is able to activate the factors X and IX. Factor VII is present in plasma in a relatively low concentration of 10 nM (26). It is still a matter of debate whether or not the zymogen factor VII has a physiologically important proteolytic activity (27,28,29,30) or not (31,32,33). If it does, it would be the only known clotting factor to have this capability as a zymogen, and it would provide a ready explanation for the initiation of coagulation (27).

Factor IX, which has a plasma concentration of about 80 nM, can be activated to factor IXa by the TF/VIIa complex and by factor XIa, although this latter reaction may not have physiological significance. Factor IXa's main function is the activation of factor X. To form an efficient enzyme, factor IXa complexes with its cofactor factor VIIIa on a phospholipid surface (34,35,36). Hemophilia B, a sex-linked, recessive bleeding disorder is caused by deficiency of factor IX.

Factor X, present in a concentration of approximately 160 nM (37,38), is activated by the IXa/VIIIa complex, and by the VIIa/TF complex. Factor Xa joins with factor Va on a phospholipid surface to form the prothrombinase complex (39,34), which activates prothrombin. This vitamin K dependent thrombin precursor is present in a concentration of around 1.5 μM (19).

All vitamin K dependent clotting factors retain their Gla residues when they are activated, except for prothrombin. Thus, thrombin is unable to bind to a phospholipid surface.

cofactors

The three main enzyme complexes leading to the formation of thrombin all consist of a phospholipid bound complex of a vitamin K dependent clotting factor and a protein cofactor. Tissue factor is a small transmembrane glycoprotein that is found in the plasma membranes of many cells, but not normally on the luminal side of the cells of the endothelium. It forms complexes with factor VII or VIIa (40). Unlike the other cofactors, tissue factor does not need to be activated.

Factor VIII and factor V are large proteins with similar structural properties. They are cofactors of factor IXa and factor Xa respectively, and must be proteolytically cleaved by thrombin to their active forms in order to gain cofactor activity (41,42,43,44). Both bind strongly to a phospholipid surface in a calcium independent manner. In plasma, factor VIII circulates in a complex with von Willebrand factor (45) at a low concentration ($< 1 \text{ nM}$) (46). Deficiency of factor VIII is the cause of hemophilia A. The plasma concentration of factor V is about 30 nM, but it is also present in the α -granules of blood platelets (47). Cofactors increase the catalytic constant of their enzymes by several orders of magnitude (11,12).

physiologic inhibitors of the coagulation cascade

serpins

Several members of the serine protease inhibitor (or 'serpin') super family are able to inhibit serine proteases of the coagulation system (48). These include antithrombin III (ATIII), α_2 -macroglobulin ($\alpha_2\text{M}$), heparin cofactor II, and α_1 -antitrypsin. Their mechanism of action is that of a pseudo substrate, with the reaction arrested near the Michaelis complex (49). Binding is reversible and is thought to be a two step process, with the formation of an initial loose complex which then proceeds to a tightly bound complex (50,51,52). The rate limiting step is the formation of this initial weak complex, which makes that the rate of inhibition is slow ($k_{\text{on}} = 1.5 \cdot 10^{-3} \text{ nM}^{-1}\text{min}^{-1}$). The dissociation rate of the tight complex is so

low however, that binding has long been thought to be irreversible. Very slowly, the reaction between serpin and protease also completes towards proteolysis, resulting in cleaved inhibitor and active protease. AT III based inhibition is accelerated quite considerably by heparin.

TFPI

Tissue Factor Pathway Inhibitor, a Kunitz type serine protease inhibitor circulating in plasma in a concentration of about 1.2 nM, is able to form a quaternary complex with factor Xa and TF/VIIa, thereby inhibiting both enzymes (53,54). When sufficient factor Xa has been produced, TFPI is able to completely shut off TF/VIIa activity.

protein C

A third inhibitory component is formed by protein C and protein S. Protein C, a vitamin K dependent, phospholipid binding protein, is activated by the thrombin/thrombomodulin complex on intact endothelium (2,3). In contrast to the inhibitors mentioned above, activated protein C (APC), together with protein S, is not directed against the enzymatic factors but against the cofactors Va and VIIIa, which are proteolytically inactivated (55,56).

fibrin

Fibrinogen is the most abundant coagulation protein with a concentration of about 10 μ M. Thrombin converts fibrinogen molecules into fibrin monomers by cleaving off two pairs of peptides, the fibrinopeptides A and B (57). This exposes four polymerisation sites, which combine with complementary sites of other fibrin monomers. Fibrin strands are then formed by spontaneous polymerisation of fibrin monomers. Factor XIII, which in plasma is bound to fibrinogen, is activated by thrombin in the presence of fibrin strands. After activation it is able to cross link the fibrin strands to a tight fibrin net. A significant amount of the thrombin formed during clotting binds to generating fibrin (58,59), where it is protected from inactivation by AT III, with or without heparin. Fibrin bound thrombin retains its enzymatic properties.

1.2. reactions

Basically, the coagulation system consists of a number of proenzymes of serine proteases. These proenzymes are 'activated' by one or more proteases of the clotting system, to become active proteases themselves. The backbone of this reaction sequence consists of the vitamin K dependent clotting factors VII, IX, X and II, as shown in figure 1. This scheme differs from the classical coagulation scheme, with its intrinsic-

figure 1. skeleton of the clotting cascade

Arrows designate activation, not conversion.

extrinsic dichotomy. The recognition that contact activation of coagulation is of little importance *in vivo* (60), as well as the discovery of the activation of factor IX by the TF-VIIa complex (61,62,63,64) has led to the demise of this scheme.

enzyme complexes

Factors VIIa, IXa and Xa alone are very slow enzymes. They need accessory components, a phospholipid surface and a cofactor, in order to live up to their full potential. The properties of the prothrombinase complex (the complex of Xa and Va on a phospholipid surface) have been investigated in much detail. When factor Xa is bound to a phospholipid surface, the K_m for prothrombin conversion is several orders of magnitude lower than when factor Xa is in free solution. If the cofactor factor Va is also present, the turnover number of the enzyme is about a thousand fold higher (11,12). This makes prothrombinase a very efficient enzyme that converts prothrombin into thrombin so fast that, under normal physiological conditions, the reaction rate is probably limited by diffusion of prothrombin to the phospholipid surface containing the prothrombinase

complex (65). In addition, phospholipid-bound factor Va greatly increases the affinity of factor Xa for the phospholipid surface (66,67). The other enzyme complexes, VIIa/TF and IXa/VIIIa (extrinsic and intrinsic tenase) have properties comparable to those of the prothrombinase complex (68,69,70,34,35,36). They are, however, somewhat less efficient.

Initiation

Normally, clotting enzymes and cofactors circulate in their inactive form, and no suitable phospholipid bilayer is available for coagulation reactions. It has been shown however (71), that, at a very low concentration, activated clotting factors are always present, as indicated by the presence of activation peptides of clotting factors. This 'basal' activity may be important in the initiation of coagulation. When vessel wall damage occurs at a certain location, blood is exposed to extra-vascular connective tissue, and to tissue factor. Furthermore, damaged cells may expose procoagulant phospholipids from their interiors. It is hypothesized by some investigators (27,28,29,30) that the complex of tissue factor and the zymogen factor VII has a certain proteolytic activity towards the factors X and IX. To date, however, this has not been proven conclusively, and it may not be important in the light of the steady presence of activated clotting factors in circulating blood. Thus, a little factor VIIa may always be present, and factor VII, when complexed to TF, is readily activated by factor Xa.

positive feedback

The TF/VIIa complex is a rather efficient activator of factors X and IX, but these factors do not yet have the activated cofactors available. Therefore, prothrombin conversion is initially a very inefficient and slow process, leading only to trace amounts of thrombin. These concentrations of thrombin are far from high enough to convert massive amounts of fibrinogen into fibrin, but do lead to a small scale activation of the cofactors V and VIII, and of blood platelets (fig 2). Formation of low amounts of the complete prothrombinase and intrinsic tenase enzymes ensues, which leads to a speed-up of thrombin production, since the catalytic efficiency of these complete enzyme complexes is more than five orders of magnitude higher than that of the bare enzymes. From this point, the reaction sequence exhibits the typical positive feedback pattern of a burst-like increase of reaction rates and product formation (72,73). Thrombin reaches concentrations which are more than adequate for efficient fibrin formation. In purified systems, also factor Xa is capable of activating the cofactors V (74,75) and VIII (56,76,77). This ability, however, does not seem to play a role in a plasma milieu (78, chapter 5).

figure 2. feedback reactions

Solid arrows indicate activation, dashed arrows point at the reactions that occur on a phospholipid surface (PL).

Inhibitory reactions

Several inhibitory reaction pathways run through the coagulation scheme as well (fig 3). Antithrombin III and several other serine protease inhibitors inhibit thrombin and factor Xa at a slow but concentration dependent pace. The factors IXa, XIa and VIIa are inhibited by AT III at an even lower rate. The factor VIIa-TF complex falls prey to TFPI after a certain lag. The activated cofactors may be attacked by activated protein C, possibly accompanied by protein S. Perhaps less obvious, but probably at least of equal importance are several other inhibitory mechanisms. Blood flow, leading to a dilution of the active clotting factors, is an important factor (79,80) which is very difficult to assess since the exact flow conditions at a site of wound may be very complicated and variable. Additionally, competition between different reactions should not be neglected. Competition may all but completely suppress reactions *in vivo*, that are clearly demonstrated in purified systems. This especially affects limited resources, such as procoagulant phospholipid surface, and enzymes

with many substrates, such as thrombin. The initial complex of thrombin with serpins for example is formed rather slowly (50,51,52). Therefore, they effectively do not compete for thrombin in the first stages of the clotting process when thrombin concentrations are low, so that positive feedback may proceed unhindered.

figure 3. Inhibitory reactions

Arrows designate the targets of these physiologically occurring inhibitor proteins.

2. control

The myriad of activations, complexes and inhibitions involved in the hemostatic process, may give the impression of an extremely complicated not very well organised bunch of reactions which, almost magically, seem to produce the desired effect. Things fall into place a little better when one realises that most of these reactions occur only at specific places and times. The concept of localisation, both in space and time, of the coagulation reactions may shed a different light on hemostasis.

2.1 space localisation

Hemostasis is needed only at a particular place, the site of vessel lesion. This space confinement is reflected in several aspects of the underlying reactions.

First, the reactions of the backbone of the coagulation system all take place with the components, enzyme, cofactor and substrate, bound to a negatively charged phospholipid membrane, which is not normally accessible. Where cells are damaged, the negatively charged inner leaflet necessary for the clotting reactions may become exposed. As mentioned before, blood platelets even provide a mechanism for transversal movement of phospholipid molecules, which is triggered when the platelets are activated. All vitamin K dependent clotting factors and their

cofactors bind to a negatively charged phospholipid surface. Their activated forms also bind, with the exception of thrombin. Thrombin, however, is in part bound by fibrin, which protects it from being inactivated. Thus, thrombin is only partly confined to the site of injury, and may exert some action downstream the lesion site. Since thrombin binds thrombomodulin on intact endothelium, this downstream action of thrombin may mainly be anticoagulant.

Second, platelets contain a number of receptors enabling them to adhere to components of the subendothelial connective tissue. This leads among other things to the release of ADP from the platelet dense bodies, which causes activation and aggregation of other platelets.

Third, intact endothelium provides a number of mechanisms for inhibiting procoagulant reactions. Active thrombin, for instance, binds to thrombomodulin which is present on the surface of endothelial cells. The complex of thrombin and thrombomodulin has an anticoagulant action by proteolytically cleaving protein C to form activated protein C (APC). APC is able to shut off thrombin formation by proteolytic destruction of the cofactors Va and VIIIa. This may help suppressing thrombin activity where it is not needed.

Fourth, blood flow keeps hemostatic reactions localised since it dilutes activated components of the hemostatic system as they drift further away from the lesion site.

It should be noted that studying spatial localisation is not an easy undertaking. Classical test tube experiments are suitable only to a limited extent.

2.2. time localisation

The general flavour of the concept of time localisation is that procoagulant reactions are fast but short-lived, and that anticoagulant reactions are slow but persistent. The character of hemostasis as an emergency process is reflected by the rapid increase of the reaction rates of the procoagulant reactions. This is a consequence of both the fact that coagulation is a multistep process, with the intermediate steps acting as amplifiers, and of the various positive feedback mechanisms.

It is of great importance that the hemostatic reactions at the lesion site are efficiently shut down after a while, but neither too soon nor too late. Thus, inhibitory mechanisms should initially keep a slack reign on the procoagulant reactions, but must halt them a little later on. The initial trigger of the coagulation system, the TF/VIIa complex is blocked within minutes, or even seconds, by TFPI, which starts being effective as soon as sufficient factor Xa is present. This, however, does not stop the activation of factor X by the intrinsic tenase complex, or the formation of thrombin

by the prothrombinase complex. Here ATIII and a number of other serpins, which are all present in a relatively high concentration in plasma, come into play. They have a remarkable mode of action as they first bind their target enzymes in a weak reversible manner. This initial complex is converted into a nearly irreversible one, but since the rate of inhibition is determined by the speed of the initial complex formation, it is slow, in spite of the high concentration of the inhibitor. On the other hand, the inhibition rate is also linearly dependent on the enzyme concentration, a property that eventually limits the concentration of free enzyme as the inhibitory rate starts balancing the formation rate of the enzyme. Consequently, the inhibitory capacity of the serpins is initially overpowered by the burst-like procoagulant reactions, but dominates in the end when the speed of the procoagulant reactions fades. Another phenomenon that conceivably favours, and later counteracts procoagulant reactions is impediment of blood flow inside the forming fibrin and platelet clot. Dilution of active clotting factors is diminished, which initially works procoagulant. Eventually, consumption of clotting factor zymogens, caused by insufficient supply, leads to a decreasing rate of activation.

2.3. combination

It is noteworthy that some of the same mechanisms that cause spatial localisation also lead to temporal localisation. An example of this is the occurrence of clotting reactions on negatively charged phospholipid surfaces. As mentioned above, this confines clotting factors to the site of vessel damage. But it also accelerates those reactions quite considerably by effectively increasing the enzyme size to include a relatively large area of phospholipid surface, thereby concomitantly increasing the collision rate. As described above, the interplay between the initially fast procoagulant and the slow anticoagulant reactions is responsible for the time characteristics of the hemostatic process. Another example is blood flow. Dilution causes spatial localisation whereas impediment of flow at the site of clot formation should ultimately limit the coagulatory respons.

3. the present investigation

This thesis describes a number of studies which deal with thrombin and the positive feedback mechanisms which it triggers. The central role of thrombin in the hemostatic mechanism is depicted in fig.4. The importance of thrombin lies in the fact that it is both the effector enzyme, being the end product of the coagulation cascade and able to clot

fibrinogen and to activate platelets, and a central regulatory protein, being at the origin of several important positive and negative feedback loops of the coagulation system. It should, therefore, not come as a surprise that thrombin involvement has been observed in venous as well as arterial thrombosis (81,82,83,84). The latter observation provides further evidence that the classical distinction between 'primary hemostasis', viewed as a platelet process, and 'secondary hemostasis' or 'coagulation', with thrombin as its main actor, is obsolete.

figure 4. central role of thrombin

Platelets are both on the *effect* and on the *feedback* side since, on the one hand, they build the primary hemostatic plug, and, on the other hand, provide the phospholipid surface necessary for several of the coagulation reactions.

As thrombin is involved in so many reactions simultaneously, the task of predicting its behaviour *in vivo*, from experiments carried out in purified systems becomes daunting (Like looking at the climatological situation in an air conditioned building, and using the information gained in this manner to predict the weather outside). We therefore chose to stay close to the physiological milieu of the coagulation system, and set up measurements in plasma or whole blood. In doing so it was inevitable that we sacrificed, to a certain extent, the exact definition of the experimental system used. But it should be kept in mind that we could fall back on a solid base of knowledge about the proteins involved and their interactions, and that experiments in purified or partially purified systems still served us

as valuable tools for testing hypotheses developed from the integral system.

Chapter two describes a technique we developed for measuring thrombin concentrations in clotting whole blood which has not been anticoagulated upon its collection. In this way we could study the coagulation process in an environment that more closely approximates the physiological reaction environment. We first compared thrombin generation in this system with thrombin generation in whole blood that has gone through the usual procedure of citration and recalcification. Subsequently the influence of aspirin treatment on thrombin generation was investigated in an attempt to demonstrate the interdependence of coagulation and platelet reactions. Aspirin inhibits the thromboxane synthesis of platelets but has no direct effect on the coagulation system.

In Chapter three we analyse time curves of thrombin concentration in plasma, and curves of the time integral of the free thrombin concentration. The latter were measured using a new continuous measurement of thrombin activity in plasma. It is shown how the confounding influence of the α_2 -macroglobulin thrombin complex can be accounted for, and how several important parameters can be obtained from the experimental data. These include the time course of prothrombin activation in plasma, and the thrombin potential. It is also shown why, even in the presence of heparin, thrombin inhibition by antithrombin III is a second order process.

Chapter four presents a technique for measuring concentrations of activated factor VIII in plasma. It deals with the extreme instability of factor VIIIa, and the ability of factor Xa to activate the non-activated factor VIII which is present in plasma samples. This method allowed us to investigate one of the thrombin induced positive feedback mechanisms of coagulation in plasma.

In chapter 5 we investigate the initial phase of the coagulation process in plasma, combining a newly developed assay of low factor Xa concentrations with the measurement of the clotting factors Va, VIIIa and thrombin. Coagulation in these experiments was triggered with physiologically low concentrations of tissue factor. The importance of Tissue Factor Pathway Inhibitor, and the role of the alternative extrinsic pathway are shown. A synthetic thrombin inhibitor was used to study positive feedback through cofactor activation. The data presented in this chapter shine a new light on the initial phase of the coagulation process in plasma.

As mentioned before, we tried to approach the *in vivo* situation of the blood coagulation process by setting up measurements of clotting factors in plasma and whole blood. We attempted to go one step beyond this and extend our measurements to blood flowing from bleeding time wounds. Whether the coagulation system plays a role in bleeding time hemostasis is still a matter of debate. Many of the published experiments suggesting no influence of thrombin could also be interpreted differently, viz. thrombin being required in trace amounts. The large variability of the present day bleeding time measurements precludes obtaining convincing evidence for either possibility. Chapter six describes an attempt at minimizing bleeding time variability by using an automated bleeding time monitor.

references

1. Vu T-KH, Hund DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. *Cell* 1991;64:1057-68.
2. Esmon NL, Owen WG, Esmon CT. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. *J Biol Chem* 1982;257(2):859-64.
3. Comp PC, Jacocks RM, Ferrell GL, Esmon CT. Activation of protein C in vivo. *J Clin Invest* 1982;70:127-34.
4. Chen LB, Buchanan JM. Mitogenic activity of blood components. I. Thrombin and prothrombin. *Proc Natl Acad Sci USA* 1975;72:131-5.
5. Teng NNH, Chen LB. The role of surface proteins in cell proliferation as studied with thrombin and other proteases. *Proc Natl Acad Sci USA* 1975;72:413-7.
6. Zetter BR, Sun TT, Chen LB, Buchanan JM. Thrombin potentiates the mitogenic response of cultured fibroblasts to serum and other growth promoting agents. *J Cell Physiol* 1977;92:233-40.
7. Pohjanpleto P. Proteases stimulate proliferation of human fibroblasts. *J Cell Physiol* 1977;91:387-92.
8. Kieffer N, Phillips DR. Platelet membrane glycoproteins: Functions in cellular interactions. *Annu Rev Cell Biol* 1990;6:329-57.
9. O'Toole TE, Loftus JC, Du X, Glass AA, Ruggeri ZM, Shattil SJ, et al. Affinity modulation of the $\alpha_{IIb}\beta_3$ integrin (platelet GPIIb-IIIa) is an intrinsic property of the receptor. *Cell Reg* 1990;1:883-93.
10. Bevers E, Comfurius P, van Rijn JMML, Hemker HC, Zwaal RFA. Generation of prothrombin converting activity and the exposure of phosphatidylserine at the outer surface of platelets. *Eur J Biochem* 1982;122:429-36.

11. Rosing J, Tans G, Govers-Riemslog JWP, Zwaal RFA, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. *J Biol Chem* 1980;255(1):274-83.
12. Nesheim ME, Taswell JB, Mann KG. The contribution of bovine factor V and factor Va to the activity of prothrombinase. *J Biol Chem* 1979;254(21):10952-62.
13. Rijn van JLML, Govers-Riemslog JWP, Zwaal RFA, Rosing J. Kinetic studies on prothrombin activation: Effect of factor Va and phospholipids on the formation of the enzyme substrate complex. *Biochemistry* 1984;23:4557-63.
14. Lindhout T, Govers-Riemslog JWO, Waart van de P, Hemker HC, Rosing J. Factor Va - factor Xa interaction. Effects of phospholipid vesicles of varying composition. *Biochemistry* 1982;21:5494-502.
15. Sandberg H, Andersson L, Hoglund S. Isolation and characterization of lipid-protein particles containing platelet factor 3 released from human platelets. *Biochem J* 1992;203:303-11.
16. Hemker HC, Veltkamp JJ, Hensen A, Loeliger EA. Nature of prothrombin biosynthesis: preprothrombinemia in vitamin K deficiency. *Nature* 1963;200:589-90.
17. Nelstuen GL. role of γ -carboxyglutamic acid. An unusual protein transition required for the calcium-dependent binding of prothrombin to phospholipid. *J Biol Chem* 1976;251(18):5648-56.
18. Suttie JW. Mechanism of action of vitamin K: Synthesis of γ -carboxyglutamic acid. *CRC Crit Rev Biochem* 1980;8(2):189.
19. Suttie JW, Jackson CM. Prothrombin structure, activation and biosynthesis. *Physiol Rev* 1977;57:1-65.
20. Radcliffe R, Nemerson Y. Activation and control of factor VII by activated factor X and thrombin. Isolation and characterization of a single chain form of factor VII. *J Biol Chem* 1975;250:388-95.
21. Seligsohn U, Osterud B, Brown SF, Griffin JH, Rapaport SI. Activation of human factor VII in plasma and in purified systems. Roles of activated factor IX, kallikrein, and activated factor XII. *J Clin Invest* 1979;64:1056-65.
22. Masys DR, Bajaj SP, Rapaport SI. Activation of human factor VII by activated factor IX and X. *Blood* 1982;60:1143-50.
23. Nemerson Y, Repke D. Tissue factor accelerates the activation of coagulation factor VII. The role of a bifunctional cofactor. *Thromb Res* 1985;40:351-58.
24. Rao LVM, Bajaj SP, Rapaport SI. Activation of human factor VII during clotting in vitro. *Blood* 1985;65:218-26.
25. Rao LVM, Rapaport SI. Activation of factor VII bound to tissue factor: A key early step in the tissue factor pathway of blood coagulation. *Proc Natl Acad Sci USA* 1988;85:6687-91.
26. Bajaj SP, Rapaport SI, Brown SF. Isolation and characterisation of human factor VII. Activation of factor VII by factor Xa. *J Biol Chem* 1981;256:253-9.

27. Fujikawa K, Coan MH, Legaz ME, Davie EW. The mechanism of activation of bovine factor X (Stuart factor) by intrinsic and extrinsic pathways. *Biochemistry* 1974;13:5290-9.
28. Kisiel W, Davie EA. Isolation and characterization of bovine factor VII. *Biochemistry* 1975;14(22):4928-34.
29. Zur M, Nemerson Y. The esterase activity of coagulation factor VII. Evidence for intrinsic activity of the zymogen. *J Biol Chem* 1978;253(7):2203-9.
30. Nemerson Y. Regulation of the initiation of coagulation by factor VII. *Haemostasis* 1983;13:150-5.
31. Williams EB, Krishnaswamy S, Mann KG. Zymogen/enzyme discrimination using peptide chloromethyl ketones. *J Biol Chem* 1989;264:7536-45.
32. Wildgoose P, Kisiel W. Activation of human factor VII by factors IXa and Xa on human bladder carcinoma cells. *Blood* 1989;73(7):1888-95.
33. Lawson JH, Butenast S, Mann KG. The evaluation of complex-dependent alterations in human factor VIIa. *J Biol Chem* 1992;267:4834-43.
34. Hemker HC, Kahn MJP. Reaction sequence of blood coagulation. *Nature* 1967;215:1201.
35. Dieijen van G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor VIIIa in the activation of bovine factor X. *J Biol Chem* 1981;256:3433-42.
36. Dieijen van G, Rijn van JLML, Govers Riemsdag JWP, Hemker HC, Rosing J. Assembly of the intrinsic factor X activation complex - Interactions between factor IXa, factor VIIIa and phospholipid. *Thromb Haemost* 1985;53(3):396-400.
37. Fujikawa K, Legaz ME, Davie EW. Bovine factor X₁ (Stuart factor). Mechanism of activation by a protein from Russell's viper venom. *Biochemistry* 1972;11(26):4892-9.
38. Fair DS, Plow EF, Edgington TS. Combined functional and immunochemical analysis of normal and abnormal factor X. *J Clin Invest* 1979;64:884-94.
39. Papahadjopoulos D, Hanahan DJ. Observations on the interaction of phospholipids and certain clotting factors in prothrombin activator formation. *Biochim Biophys Acta* 1964;90:436-9.
40. Nemerson Y. Tissue factor and hemostasis. *Blood* 1988;71:1-8.
41. Rapaport SI, Schiffman S, Patch MJ, Ames SB. The importance of activation of antihemophilic globulin and proaccelerin by traces of thrombin in the generation of intrinsic prothrombinase activity. *Blood* 1963;21:221-36.
42. Rapaport SI, Hjort PF, Patch MJ. Further evidence that thrombin activation of factor VIII is an essential step in intrinsic clotting. *Scand J Clin Lab Invest suppl* 1965; 17: 84-8.
43. Biggs R, Macfarlane RG, Denson WE, Ash BJ. Thrombin and the interaction of factors VIII and IX. *Brit J Haemat* 1965; 11: 276-295.

44. Colman RW. The effect of proteolytic enzymes on bovine factor V. Kinetics of activation and inactivation by bovine thrombin. *Biochemistry* 1969; 4: 1438-44.
45. Zimmerman TS, Fulcher CA. Factor VIII procoagulant protein. *Clinics in Haematology* 1985;14(2):343-58.
46. Fulcher CA, Zimmerman TS. Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody. *Proc Natl Acad Sci USA* 1982;79:1648.
47. Tracy PB, Eide LL, Bowie EJW, Mann KG. Radioimmunoassay of factor V in human plasma and platelets. *Blood* 1982;60(1):59-63.
48. Carrel RW, Christey PB, Boswell DR. Serpins: antithrombin and other inhibitors of coagulation and fibrinolysis. Evidence from amino acid sequences. In Verstraete M, Vermeylen J, Lijnen R, Arnout J (eds): *Thrombosis and Haemostasis* 1987, Leuven University Press, Leuven pp 1.
49. Longstaff C, Gaffney PJ. Serpin-serine protease binding kinetics: α_2 -antiplasmin as a model inhibitor. *Biochemistry* 1991;30(4):979-86.
50. Olson ST, Shore JD. Demonstration of a two-step reaction mechanism for inhibition of α -thrombin by antithrombin III and identification of the step affected by heparin. *J Biol Chem* 1982;257:14891-95.
51. Olson ST, Shore JD. Transient kinetics of heparin-catalyzed protease inactivation by antithrombin III. The reaction step limiting heparin turnover in thrombin neutralization. *J Biol Chem* 1986;266(28):13151-9.
52. Shore JD, Olson ST, Craig PA, Choay J, Björk I. Kinetics of heparin action. *Ann NY Acad Sci* 1989;556:75-80.
53. Rao LVM, Rapaport SI. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. *Blood* 1987;69:645-51.
54. Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. *Blood* 1988;71:335-43.
55. Kiesel W, Canfield WM, Ericsson LH, Davie EW. Anticoagulant properties of bovine plasma protein C following activation by thrombin. *Biochemistry* 1977;16(26):5824-31.
56. Vehar GA, Davie EW. Preparation and properties of bovine factor VIII (Antihemophilic factor). *Biochemistry* 1980;19(3):401-10.
57. Lorand L. Interaction of thrombin and fibrinogen. *Physiol Rev* 1954;34:742.
58. Seegers WH, Nieft ML, Loomis EC. Note on the adsorption of thrombin on fibrin. *Science* 1945;100:520-1.
59. Quick AJ, Favre-Gilly JE. Fibrin: A factor influencing the consumption of prothrombin in coagulation. *Am J Physiol* 1949;158:387.
60. Jackson CM, Nemerson Y. Blood coagulation. *Ann rev biochem* 1980;49:765-811.

61. Joso F, Prou-Wartelle O. Interaction of tissue factor and factor VII at the earliest phase of coagulation. *Thromb Diath Hemorrh* 1965;171:35-44.
62. Østerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation. *Proc Natl Acad Sci USA*. 1977;74(12):5260-4.
63. Østerud B, Rapaport SI. Activation of ^{125}I -factor IX and ^{125}I -factor X: Effect of tissue factor and factor VII, factor Xa and thrombin. *Scand J Haematol* 1980;24:213-26.
64. Marlar RA, Kleiss AJ, Griffin JH. An alternative extrinsic pathway of human blood coagulation. *Blood* 1982;60(6):1353-8.
65. Giesen PLA, Willems GM, Hermens WTh. Production of thrombin by the prothrombinase complex is regulated by membrane-mediated transport of prothrombin. *J Biol Chem* 1991;266(3):1379-82.
66. Krishnaswamy S, Jones KC, Mann KG. Prothrombinase complex assembly. Kinetic mechanism of enzyme assembly on phospholipid vesicles. *J Biol Chem* 1988; 263(8):3823-34.
67. Giesen PLA, Willems GM, Hemker HC, Hermens WTh. Membrane-mediated assembly of the prothrombinase complex. *J Biol Chem* 1991;266(28):18720-5.
68. Jesty J, Nemerson Y. Purification of factor VII from bovine plasma. Reaction with tissue factor and activation of factor X. *J Biol Chem* 1974;25:509-15.
69. Zur M, Nemerson Y. Kinetics of factor IX activation via the extrinsic pathway. *J Biol Chem* 1980;255(12):5703-7.
70. Silverberg SA, Nemerson Y, Zur M. Kinetics of the activation of bovine coagulation factor X by components of the extrinsic pathway. Kinetic behavior of two-chain factor VII in the presence and absence of tissue factor. *J Biol Chem* 1977;252:8481-8.
71. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: Insights gained from studies using markers of hemostatic system activation. *Blood* 1987;70(2):343-50.
72. Hemker HC, Kessels H. Feedback mechanisms in coagulation. *Haemostasis* 1991;21:189-96.
73. Willems GM, Lindhout T, Hermens WTh, Hemker HC. Simulation model for thrombin generation in plasma. *Haemostasis* 1991;21:197-207.
74. Foster WB, Nesheim ME, Mann KG. The factor Xa-catalyzed activation of factor V. *J Biol Chem* 1983;258:13970.
75. Monkovic DD, Tracy PB. Activation of human factor V by factor Xa and thrombin. *Biochemistry* 1990;29:1118-28.
76. Hultin MB. Role of human factor VIII in factor X activation. *J Clin Invest* 1982;69:950-5.
77. Lollar P, Knutson GJ, Fass DN. Activation of porcine factor VIII by thrombin and factor Xa. *Biochemistry* 1985;24:8056-64.

78. Pieters J, Lindhout T, Hemker HC. In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. *Blood* 1989;74:1021-4.
79. Goldsmith HL, Turrilo VT. Rheological aspects of thrombosis and haemostasis: Basic principles and applications. *Thromb Haemost* 1986;55:415-35.
80. Leonard EF. Rheology of thrombosis. In: Hemostasis and thrombosis. Basic principles and clinical practice, 2nd edition (Eds Colman RW, Hirsh J, Marder VJ, Salzman EW) JP Lippincott Company, Philadelphia 1987, 1111-22.
81. The sixty plus reinfarction study research group. A double-blind trial to assess longterm oral anticoagulant therapy in elderly patients after myocardial infarction. *Lancet* 1980;2:989-94.
82. Neri-Serneri GG, Rovelli F, Gensine GF, Pirelli S, Carnovali M, Fortini A. Effectiveness of low-dose heparin prevention of myocardial reinfarction. *Lancet* 1987;25:937-42.
83. Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Penny WJ, et al. Hirudin, heparin, and placebo during deep arterial injury in the pig. *Circulation* 1990;82:1476-84.
84. Badimon L, Badimon JJ, Lassila R, Heras M, Chesebro JH, Fuster V. Thrombin isolated collagen type 1 at arterial flow conditions in a porcine model: effects of hirudins, heparin and calcium chelation. *Blood* 1991;78:423-34.

Introduction

Thrombin is a central enzyme in the process of haemostasis, being at the cross-roads of coagulation and platelet reactions. Measurement of thrombin generation in clotting plasma has provided much insight in the mechanism of action of the coagulation system (1). Moreover, platelet rich plasma has proven a rich source of data on the interplay of the enzymatic and the cellular pathways in a near-physiological system (2). Usually, plasma is prepared from blood which has been collected on citrate. The plasma is recalcified when coagulation is triggered. This

* based on: Koster H, Bigan S, Hemker H.C., submitted for publication

chapter 2

measurement of thrombin generation in whole blood; the effect of heparin and aspirin.*

summary

A technique has been developed for the measurement of thrombin concentrations in freshly collected whole blood in the absence of anticoagulants. It is based on the centrifugal separation of the cellular components from subsamples of blood drawn from non-anticoagulated clotting whole blood which are diluted in buffer containing a chromogenic substrate. Using this technique it is shown that the burst of thrombin generation after triggering coagulation with trace amounts of tissue thromboplastin occurs sooner in non-anticoagulated whole blood than in citrated whole blood. This reduction of the lag time of thrombin generation is relatively larger in the presence of heparin. In addition, it is demonstrated that intake of 500 mg of aspirin delays and inhibits thrombin generation in non-anticoagulated, thromboplastin triggered whole blood, demonstrating that platelet reactions and the coagulation system are closely linked processes. It further lends support to the hypothesis that inhibition of thrombin generation is a common denominator of antithrombotic therapy.

introduction

Thrombin is a central enzyme in the process of haemostasis, being at the cross-roads of coagulation and platelet reactions. Measurement of thrombin generation in clotting plasma has provided much insight in the mechanisms of action of the coagulation system (1). Moreover, platelet rich plasma has proven a rich source of data on the interplay of the enzymatic and the cellular pathways in a near-physiological system (2). Usually, plasma is prepared from blood which has been collected on citrate. The plasma is recalcified when coagulation is triggered. This

* based on: Kessels H, Béguin S, Hemker H.C. submitted for publication

process of citration and recalcification, however, may influence the function of platelets and the coagulation system.

In order to remain closer to the physiological circumstances under which hemostasis takes place, we developed a technique for measuring thrombin concentrations in non-anticoagulated whole blood. Chromogenic assays in whole blood are hampered by the presence of hemoglobin, with a broad light absorption peak around 420 nm. Erythrocytes were discarded by centrifugation of subsamples which were taken from clotting whole blood and diluted in buffer containing a chromogenic substrate. In order to investigate possible influences of citration on coagulation, this technique was employed to compare thrombin generation in untreated and citrated whole blood, after addition of trace amounts of human brain thromboplastin, in the presence and absence of heparin.

The coagulation system and platelet activation are closely coupled, since activated platelets provide the negatively charged phospholipid surface necessary for various reactions of the coagulation system, and since thrombin, especially in combination with collagen, is the most potent physiological activator of platelets. Therefore, inhibition of platelet function may be expected to affect thrombin generation. Acetylsalicylic acid (aspirin) inhibits platelet function by irreversibly acetylating platelet cyclooxygenase (7). It causes a prolongation of the bleeding time (8) and has been reported to reduce the incidence of thromboembolic disease in several populations at risk (3,4,5,6). However, no influence of aspirin on thrombin generation was known. This has cast considerable doubts on the involvement of thrombin in primary hemostasis. It seems, furthermore, not compatible with a close linkage of coagulation and platelet reactions. To prevent obscuring influences of de- and recalcification, we investigated the possible effect of aspirin on the coagulation system by measuring thrombin generation in whole blood without added anticoagulants, triggered with trace amounts of thromboplastin.

materials and methods

materials

Buffers used were 50 mM Tris-HCl, 100 mM NaCl and 0.5 g/l bovine serum albumin (Sigma), pH 7.35 (buffer A), and 50 mM Tris-HCl, 100 mM NaCl, 20 mM EDTA (ethylene dinitrilo tetra-acetic acid) and 0.5 g/l bovine serum albumin, pH 7.9 (buffer B).

4th International standard heparin was obtained from the National Bureau of Standards and Control (London). Enoxaparin was from Rhone-Poulenc-Rorer (Paris). The stable synthetic prostacyclin analog Ilomedine (ZK36374) was from Schering AG (Berlin).

Chromogenic substrate for thrombin was S2238 (H-D-Phe-Pip-Arg-pNA.2HCl, from Kabi, Sweden).

Human brain thromboplastin was prepared as described by Owren (9). It was subsequently centrifuged at 1000 rpm for 5 min and stored in 50 μ l aliquots at -80 °C. It was thawed and diluted in buffer A containing 2 mM CaCl_2 (for untreated whole blood) or 100 mM CaCl_2 (for blood collected on citrate). Subsequently, it was incubated at 37 °C for 30 min before use. Final dilution after addition was 1 in 3600. Tenfold less diluted thromboplastin produces a clotting time of 70 s in platelet poor plasma.

methods

measurement of thrombin generation in non-anticoagulated whole blood

Blood was obtained by antecubital venipuncture. The first 2 to 3 ml were discarded and then 5 ml were collected in a plastic tube not containing an anticoagulant, and immediately transferred to a water bath at 37 °C.

1 Volume of buffer A was added to 9 volumes of whole blood, to obtain a dilution of blood equal to that of citrated blood. The active, or cell free, volume (V_{act}) of this mixture is obtained by subtracting the volume occupied by the cells, as determined from a haematocrit measurement, from the total volume. 0.25· V_{act} of buffer A containing any substance under investigation was added, and coagulation was triggered by addition of 0.25· V_{act} of buffer A containing 1/600 diluted thromboplastin (final dilution 1/3600). This last addition was at exactly 1 min after collection of blood. All additions contained 2 mM of CaCl_2 .

At timed intervals 10 μ l subsamples were taken from the whole blood mixture and transferred to tubes containing 190 μ l buffer B with 200 μ M of the chromogenic substrate S2238. Within 10 s a second dilution was made by transferring 40 μ l of the obtained mixture to a microcentrifuge tube containing 760 μ l buffer B, again containing S2238 (final concentration 200 μ M). This amounts to an overall dilution of 1 in 400 of the original subsample. In addition to providing the measurable signal, S2238 competitively inhibits inactivation of thrombin in the reaction mixture. It is for this reason that in the intermediate mixture S2238 was included as well.

As soon as the clot tended to interfere with subsampling, it was removed. This appeared not to influence thrombin generation (data not shown). The micro centrifugation tubes were kept on ice until subsampling had finished. They were subsequently centrifuged for 1 min at high speed. Supernatants were transferred to disposable microcuvettes and prewarmed for at least 3 min at 37 °C. The rate of conversion of S2238 was then determined photometrically at 405 nm by a two point measurement of

optical density. This rate was converted to thrombin concentration in the whole blood sample using a conversion factor of 9.06 pM thrombin / (mOD/min), obtained using active site-titrated pure human α -thrombin. The thrombin concentration was then corrected for the void volume occupied by the erythrocytes in the original subsample. This void volume decreases during the course of bloodclotting. This was shown (cf. fig 1) to be due only to cells getting entrapped in the clot when it is in the process of being formed. Thus, it seemed appropriate to use the initial Ht values for samples until clot formation, and the final Ht values for samples starting from clot formation.

thrombin measurement in whole blood collected on citrate

Blood was collected on 0.13M trisodium citrate, nine parts of blood on one part of citrate solution. It was immediately transferred to a waterbath. To this mixture were added a volume of $0.25 \cdot V_{act}$ of buffer A, with or without various concentrations of standard heparin and enoxaparin, and, at 1 min after collection, $0.25 \cdot V_{act}$ of thromboplastin diluted 1/600 (final dilution 1/3600) in 100 mM $CaCl_2$ (final added concentration 16.7 mM). Further processing was carried out as described above for thrombin measurement in untreated whole blood.

thrombin measurement in platelet rich plasma

This was carried out as previously described (2). Briefly, platelet rich plasma (PRP) was prepared from citrated whole blood by centrifugation (10 min, 1000 rpm). To 240 μ l of PRP were added 60 μ l of buffer A, and 60 μ l of 1/600 diluted thromboplastin (final dilution 1/3600) in 100 mM $CaCl_2$ (final added concentration 16.7 mM). Thrombin generation was then monitored by diluting timed subsamples in buffer B containing 200 μ M S2238, and assessing the S2238 conversion rate by an end-point measurement of optical density (10).

determination of calcium dependency of clotting times

Blood was collected in an empty PVC tube and immediately placed in a waterbath. At registered times within 2 min after collection, 500 μ l were added to a tube containing 55.6 μ l of trisodium citrate, $0.25 \cdot V_{act}$ of a mixture containing one of several $CaCl_2$ concentrations, with or without 1.2 U/ml of standard heparin (final concentration 0.2 U/ml), and $0.25 \cdot V_{act}$ of 1/600 diluted thromboplastin (final dilution 1/3600) in buffer A. Also, 500 μ l of blood were added to a tube with 55.6 μ l of buffer A containing 2 mM $CaCl_2$, $0.25 \cdot V_{act}$ of a mixture containing 2 mM $CaCl_2$, with or without 1.2 U/ml of standard heparin (final concentration 0.2 U/ml), and $0.25 \cdot V_{act}$ of 1/600 diluted thromboplastin (final dilution 1/3600) in buffer A, again with 2 mM $CaCl_2$.

aspirin

The effect of intake of a single dose of 500 mg of aspirin on thrombin generation in whole blood was investigated in 10 healthy male volunteers, none of whom had taken any medication for at least one week. Thrombin generation in non-anticoagulated whole blood, after triggering coagulation with thromboplastin (final dilution 1/3600), was measured 5 min before, and 1.5 h after aspirin ingestion.

lag times

Lag times of thrombin formation were defined as the time necessary to reach a level of 50 nM of thrombin, as determined by linear interpolation.

haematocrit

Haematocrit values were measured by centrifugation of standard heparinized haematocrit capillaries.

results

The plasma volume of a sample of whole blood can be determined as the difference between the total sample volume, and the volume occupied by cells. The latter is equal to the total sample volume multiplied by the haematocrit. To investigate whether this cell volume does not change during coagulation, we measured the haematocrit at timed intervals during a thrombin generation experiment.

Fig. 1 shows that the cell volume remains constant during the first few minutes, jumps to a lower level at the timed clot formation, and then remains constant again. For calculation of thrombin concentrations, we used the preclot value of the Ht until the moment that 10 nM of thrombin had formed, which is roughly equal to the moment of clotting, and the postclot value afterwards.

When collected blood is not anticoagulated, a slow intrinsic initiation of the coagulation system may occur, resulting in clot formation after 15 to 20 min (when PVC tubes are used). Several precautions were taken to minimize this activation: The first 2 to 3 ml of blood collected were discarded since traces of tissue factor might be present. Additionally, the collected blood was pipetted carefully and not mixed using vortex type mixers.

figure 1. time course of cell volume during clot formation.

Blood from a healthy donor was collected in a PVC tube without anticoagulant, and placed in a waterbath at 37°C. Thromboplastin (final dilution 1 to 3600) was added exactly at 1 min after collection. Samples were drawn and processed for thrombin measurement as described in the materials and methods section. In addition, at two min intervals, 50 μ l of the mixture was transferred to empty PVC tubes, from which heparinized haematocrit capillaries were filled. ●-●: thrombin concentration. O-O: haematocrit.

figure 2. thrombin generation in non-triggered whole blood.

Blood from a healthy donor was collected in an empty PVC tube at time zero and immediately placed in a waterbath at 37°C. At timed intervals samples, were drawn and assessed for thrombin as described in the materials and methods section.

figure 3. thrombin generation in whole blood triggered at a variable time after collection.

Blood from a healthy donor was collected in an empty plastic tube at time zero, and immediately placed in a waterbath at 37°C. Thromboplastin (final dilution 1 to 3600) was added 1 min (●), 3 min (○), 5 min (□) or 7 min (■) after collection. At intervals, samples were drawn and processed for thrombin measurement as described in the materials and methods section. The origin of the graph represents the moment of addition of thromboplastin.

In order to quantify the extent of activation of the coagulation system, we attempted to measure thrombin in non triggered whole blood during the first minutes after collection, but concentrations remained below our detection limit (0.2 nM) for more than 10 min (fig.2). Fig. 3 shows that the time delay between blood collection and triggering coagulation with thromboplastin can be extended to 5 min without a detectable influence on thrombin generation. Only when thromboplastin was added at 7 min or more after collection, we observed a slightly accelerated thrombin generation curve. In all further experiments, blood was triggered at exactly 1 min after collection.

The optimal amount of Ca^{2+} for recalcifying citrated whole blood was determined by measuring the clotting times of citrated whole blood recalcified with different Ca^{2+} concentrations, in the presence and absence of standard heparin (0.2 U/ml, final concentration). fig. 4 shows the existence of a relatively broad Ca^{2+} optimum. The figure also shows that no citrate - calcium ratio can rival non-anticoagulated whole blood with regard to sheer speed of clotting.

figure 4. Influence of the citrate/calcium ratio on the clotting times of whole blood in the presence and absence of standard heparin.

Blood from a healthy donor was collected in an empty plastic tube, and immediately transferred to a waterbath at 37°C. Clotting times were measured as described in the materials and methods section, after addition of diluted thromboplastin (1/3600), in the presence (○) or absence (●) of 0.2 U/ml of standard heparin. The citrate/Ca²⁺ ratio was varied by adding different Ca²⁺ concentrations to one citrate concentration. Dotted line: clotting time of non-anticoagulated whole blood.

Fig.5 (upper panel) compares thrombin generation in citrated and non-anticoagulated whole blood in the presence of standard heparin. Blood was collected three times from the same volunteer, each time both on citrate and in an empty plastic tube. Thrombin generation was measured upon addition of thromboplastin (1/3600), with or without addition of 0.1 or 0.2 U/ml of standard heparin. Measurements of thrombin generation in citrated and non-anticoagulated whole blood were always carried out in parallel, starting 1 min after collection. The lower panel of fig. 5 shows the same experiment, performed with and without 1 µg/ml of enoxaparin. The lag phase between triggering and the burst of thrombin generation was shorter in untreated whole blood than in citrated whole blood. Increasing concentrations of heparin cause a lag time that is progressively longer in citrated whole blood than in non-anticoagulated whole blood.

figure 5. thrombin generation in untreated and citrated whole blood, effect of standard heparin and the low molecular weight heparin exoxaparin. Blood from a healthy donor was collected both on citrate, and in an empty plastic tube. Both were transferred to a waterbath at 37°C. Standard heparin (upper graph, final concentrations 0 (○), 0.1(□) or 0.2 (Δ) U/ml) or exoxaparin (lower graph, final concentrations 0 (○) or 1 (□) µg/ml) was added . Clotting was triggered by addition of thromboplastin (1/3600 final dilution), at exactly 1 min after collection for the untreated whole blood, and at 1 min 30 s for the citrated whole blood. The experiment was run in separate series, one for each heparin concentration, on the same day with the same donor. Thrombin generation in untreated (closed symbols) and citrated (open symbols) whole blood was measured in parallel.

Table 1 shows the effect of aspirin intake on thrombin in generation in non-anticoagulated whole blood from 10 healthy male volunteers. The influence on the timecourse of thrombin of 500 mg of aspirin was measured 1.5 hours after ingestion. Pedersen et.al. have shown that the inhibition of thromboxane B₂ formation by orally administered aspirin was maximal within 30 min (11). Thrombin generation appeared to be both delayed and diminished 1.5 h after aspirin intake (table 1). The average increase of the lag time, $37 \text{ s} \pm 8 \text{ (s.e.m.)}$, was statistically significant ($p < 0.005$, t-test for paired observations, two tailed). Inhibition of thrombin peak values of thrombin generation after aspirin was significant as well ($16 \text{ nM} \pm 6$, $p < 0.05$). The observed aspirin induced delay is similar to the delay caused by addition of 0.03 U/ml of standard heparin in non-anticoagulated whole blood.

lag of thrombin generation (s $\pm$ s.e.m.)		paired t-test (two-tailed)
before aspirin	after aspirin	
335 $\pm$ 11	372 $\pm$ 13	t = 4.53, P < 0.005 n = 10
thrombin peak (nM $\pm$ s.e.m.)		paired t-test (two-tailed)
before aspirin	after aspirin	
163 $\pm$ 8	147 $\pm$ 6	t = 2.46, P < 0.05 n = 10

table 1. effect of aspirin on thrombin generation.

The time course of thrombin concentrations was measured in non-anticoagulated whole blood, triggered with thromboplastin 1/3600, as described in the materials and methods section, 5 min before and 1.5 h after intake of 500 mg acetylsalicylic acid. The lag of thrombin generation defined as the exact time when 50 nM of thrombin had formed, was determined by linear interpolation from surrounding data points. Data were evaluated using Student's t-test for paired observations.

In order to determine the maximal effect on thrombin generation in whole blood that can be obtained by inhibiting blood platelets, we collected blood on 10 μM (final concentration) of the stable synthetic prostacyclin analog Ilomedine (ZK36374). This substance is known to completely inhibit platelet activation by thrombin (12). Platelets from blood collected on Ilomedine did not aggregate after addition of collagen. Blood was also collected on citrate and Ilomedine in order to be able to assess the effect of Ilomedine in platelet rich plasma. Fig. 6 shows that both in non-anticoagulated whole blood and platelet rich plasma Ilomedine caused a small (2 min) delay of thrombin generation. In whole blood the

amount of thrombin generated was reduced by about 15% whereas the inhibition in PRP was much larger.

figure 6. influence of Ilomedine on thrombin generation in non-coagulated whole blood and platelet rich plasma.

upper panel: Whole blood. Blood from a healthy donor was collected both on Ilomedine (●) (100 μ M, 9 vol blood on 1 vol of Ilomedine) and in an empty plastic tube (O), and placed on a water bath at 37°C. Clotting was triggered by addition of thromboplastin (1/3600 final dilution) exactly at 1 min after collection.

lower panel: PRP. Blood from the same donor was collected both on citrate (O), and on citrate/Ilomedine (●). PRP was prepared as described in the materials and methods section, and placed in a water bath at 37°C. Clotting was triggered by addition of thromboplastin (1/3600 final dilution). In both cases thrombin concentrations were measured as described in the materials and methods section.

discussion

Hemoglobin, having a high light absorbance peak around 420 nm, hampers the photometric measurement of para-nitroaniline at 405 nm, and is therefore the main obstacle to a chromogenic assay in whole blood. Hemoglobin, however, is conveniently packed in erythrocytes which can be spun down easily. After triggering coagulation in a sample of whole blood, subsamples were drawn and diluted in buffer containing EDTA and a chromogenic substrate. Centrifugation of these diluted subsamples enabled a photometric determination of thrombin concentrations in the supernatants.

Thrombin formation in the subsample is halted by the presence of EDTA in the sample buffer. At the same time the chromogenic thrombin substrate S2238 competitively inhibits the calcium-independent binding of thrombin to protease inhibitors. The rate of chromogenic substrate conversion remains constant until the absorbance at 405 nm exceeds 0.9 OD units. If the conditions are chosen appropriately, this allows for a centrifugation step before measuring amidolytic activity. With a 400 fold dilution, as used during our experiments, one typically obtains a maximum amidolytic activity of no more than 30 mOD/min, which translates to about 30 min of constant reaction rate.

Erythrocytes get entrapped in the clot as it is being formed, giving rise to a decreasing cell volume in the samples drawn. They do not seem to bind actively to fibrin or other constituents of the clot, since the cell volume does not diminish any further after clot formation has completed. Accordingly, the cell volume is measured both before and after clotting, and thrombin concentrations are adjusted appropriately.

Without the addition of a trigger, the burst of thrombin formation in blood in a plastic tube occurred between 15 and 25 min after collection. Thrombin concentrations in these samples remained below a detection limit of about 0.2 nM until well over 10 min. When triggered at 1 min after collection with a trace amount of thromboplastin, the variance of the lag time had largely disappeared. More importantly, there were no consistent differences between the lag times of blood activated up to 5 min after collection. Thus we feel confident that no detectable degree of activation has occurred before triggering thrombin generation at 1 min.

Comparison of thrombin generation in the absence and presence of heparin in citrated whole blood with thrombin generation in platelet rich plasma in a similar experimental system, as measured by Béguin et al. (2) showed little differences both in lag times and in peak thrombin concentrations. In contrast to this, we observed that the burst of thrombin

generation occurs earlier after triggering in blood without added anticoagulant. Furthermore, the influence of heparin on the lag time of thrombin generation is considerably smaller in untreated whole blood than in recalcified citrated whole blood. Fig. 4 shows that this effect is not due to a suboptimal citrate to calcium ratio in the case of citrated whole blood. It therefore must be related to the presence of citrate.

The influence of citration on the hemostatic process may have several causes. Citrate establishes a weak Ca^{2+} buffer, since it binds Ca^{2+} with a relatively low affinity ($K_d \approx 0.25 \text{ mM}$). Moreover, Mg^{2+} is bound by citrate with equal affinity, resulting in a decreased concentration of free Mg^{2+} after recalcification, which may affect platelet function. Also, citrate may have a slight basic influence on the pH of the reaction mixture. Finally, a direct modulating effect of citrate on platelets, perhaps reducing platelet sensitivity to thrombin cannot completely be excluded. Apart from providing a procoagulant surface, activated platelets release a number of proteins which are able to influence hemostasis. Among these are platelet factor 4, the main heparin scavenging protein, and blood coagulation factor V. It is therefore conceivable that the presence of citrate modifies thrombin generation when platelets participate in the process.

Aspirin has been reported to reduce the incidence of thromboembolic disease in several populations at risk (3,4,5,6). Since its acts by irreversibly acetylating platelet cyclooxygenase, the blood coagulation system has not generally been thought to be involved in its antithrombotic and bleeding time prolonging effect. However, we observed that aspirin intake delayed and inhibited thrombin generation in non-anticoagulated whole blood triggered with a trace amount of brain thromboplastin immediately after venipuncture. The extent of the effect is comparable to that of a moderate concentration (0.03 U/ml) of standard heparin. It has not been found in citrated blood or platelet rich plasma. A similar effect of aspirin on coagulation in non-anticoagulated whole blood in an otherwise completely different experimental system was recently observed by Basic-Micic et.al. (13). Furthermore, Kyrle et. al. showed that FPA concentrations in blood from bleeding time wounds were decreased after aspirin treatment (14).

An estimate of the maximal effect of platelet inhibition on thrombin generation in whole blood and platelet rich plasma, as measured by the effect of $10 \mu\text{M}$ of Ilomedine, shows a relatively small delay of thrombin generation (about 2 min). Additionally, in PRP and, but to a much smaller extent, in whole blood, a reduction of the amount of generated thrombin was observed. This difference between PRP and whole blood can probably be attributed to the presence of erythrocytes in whole blood, as addition of

the leucocyte fraction to PRP had no effect on thrombin generation (not shown). In the light of the modest maximal effect attainable by platelet inhibition the influence of aspirin on thrombin generation is easily overlooked. On the other hand, the Ilomedine experiment shows that thrombin generation in whole blood is not all that sensitive as a test of platelet inhibition, although a delay of thrombin generation may be quite important in a flowing system.

Classically a distinction is made between arterial thrombosis and primary haemostasis which are viewed as predominately platelet mediated processes, and venous thrombosis and secondary haemostasis where the coagulation system plays the major role. Yet recent insights tend to stress the importance of thrombin in the pathogenesis of arterial thrombosis (15,16) and major clinical trials show that anticoagulant drugs such as heparin and oral anticoagulants, are effective anti-thrombotics not only in the venous but also in the arterial circulation (17,18,19). This suggests that affecting the concentration of free thrombin may be a shared mechanism of action of anti-thrombotic drugs. The observation that inhibitors of platelet function, like aspirin, do affect thrombin generation in non-anticoagulated whole blood, lends support to this notion of a common pathway for the various sorts of anti-thrombotic therapy. Reduction of thrombin concentrations, then, may be achieved by inhibition of thrombin formation (oral anticoagulation), by increase of thrombin inactivation (heparin) or by inhibition of platelet function (aspirin).

In conclusion, a precise chromogenic thrombin measurement in whole blood samples is feasible using the technique described in this chapter. Using this technique, it has been shown that collection of blood on citrate causes thrombin formation to be delayed, and the effect of heparin to be overestimated. In addition a delaying and inhibiting effect of aspirin on thromboplastin triggered thrombin generation in non-anticoagulated whole blood has been demonstrated, stressing the linkage between platelet reactions and coagulation.

The technique described in this chapter enables the measurement of thrombin, and thereby investigation of the effect of a variety of anticoagulant drugs on thrombin generation in blood without the necessity of additional processing. This property of the assay may permit measurement of thrombin generation in physiological haemostasis, e.g. in blood flowing from a wound.

acknowledgements

We thank 'De Broeders van Den Beijaard' for their generous donations of blood.

references

1. Biggs R, Macfarlane RG. Human blood coagulation and its disorders. Blackwell Scientific Publications, Oxford 1953.
2. Béguin S, Lindhout MT, Hemker HC. The effect of trace amounts of tissue thromboplastin on thrombin generation in platelet rich plasma, its inhibition by heparin. *Thromb Haemost* 1989;60:25-9.
3. Chesebro JH, Clements IP, Fuster V, Elveback LR, Smith HC, Bardsley WT, et al. A platelet-inhibitor-drug trial in coronary-artery bypass operations. *N Engl J Med* 1982;307:73-8.
4. Lewis DH, Davis J, Archibald DG, Steinke WE, Smitherman TC, Doherty EJ, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. *N Engl J Med* 1983;309:396-403.
5. Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, et al. Aspirin, sulfinpyrazone, or both in unstable angina. *N Engl J Med* 1985;313:1369-75.
6. UK TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. *Br Med J* 1988;296:316-20.
7. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. *J Clin Invest* 1975;56:624-32.
8. Rodgers RPC, Levin J. A critical reappraisal of the bleeding time. *Semin Thromb Hemost* 1990;16:1-20.
9. Owren PA, Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. *Scand J Clin Lab Invest* 1951;3:201-18.
10. Hemker HC, Willems GM, Béguin SA. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. *Thromb Haemostas* 1986;56:9-17.
11. Pedersen AK, Fitzgerald GA. Dose-related kinetics of aspirin. *New Engl J Med* 1984;311(19):1206-11.
12. Baruch D, Hemker HC, Lindhout T. Kinetics of thrombin-induced release and activation of platelet factor V. *Eur J Biochem* 1986;154:213-18.
13. Basic-Micic M, Breddin HK. PITT and detection of a risk of venous and arterial thrombosis. Abstract, XIIIth congress ISTH, Amsterdam. *Thromb Haemostas* 1991;65(6):1318.

14. Kyrle PA, Westwick J, Scully MF, Kakkar VV, Lewis GP. Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation in vivo in man - Effect of low-dose aspirin. *Thromb Haemostas* 1987;57(1):62-6.
15. Weiss HJ, Lages B. Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. *Blood* 1988;71:629-35.
16. Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Penny WJ, et al. Heparin, heparin, and placebo during deep arterial injury in the pig. *Circulation* 1990;82:1476-84.
17. The sixty plus reinfarction study research group. A double-blind trial to assess longterm oral anticoagulant therapy in elderly patients after myocardial infarction. *Lancet* 1980;2:989-94.
18. Turpie AG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. *N Engl J Med* 1986;315:925-9.
19. Théroux P, Ouimet H, McCans J, Latour JG, Joly P, Lévy G, et al. Aspirin, heparin, or both to treat acute unstable angina. *N Engl J Med* 1988;319:1105-11.

chapter 3

analysis of thrombin generation curves*

summary

Measurement of thrombin generation in plasma using small oligopeptide chromogenic substrates gives rise to a signal that is not only a measure of the concentration of free thrombin, but also a reflection of the presence of the complex of thrombin with α_2 -macroglobulin. This chapter describes a mathematical procedure to extract from the obtained curves the signal due to free thrombin only. In addition, it is described how the time course of prothrombin conversion can be obtained from thrombin generation curves when the constants governing thrombin decay are known. The thrombin potential, a parameter conveying much useful information about the state of the coagulation system can also be calculated from thrombin generation curves.

Pseudo-continuous measurement of the time integral of the thrombin concentration promises clinical applicability of thrombin generation tests. It is shown how the curves produced by these tests can be analysed analogously to curves measured by subsampling from clotting plasma.

Introduction

Thrombin is the central enzyme of the coagulation system. Its adequate production at the site of a vascular lesion is pivotal in arresting bleeding. Initial traces of thrombin are formed upon the exposure to blood or plasma of tissue factor from damaged tissue. These traces trigger the activation of much larger amounts of thrombin by feedback activating platelets, and the cofactors V and VIII. The generation of thrombin is influenced by every type of antithrombotic therapy, as well as by most coagulation disorders

* based on: - Kessels H, Willems G, Hemker HC. submitted for publication
- Béguin S, Kessels H, Dol F, Hemker HC. *Thromb Haemostas* 1992;68(2):136-42.
- Hemker HC, Wielders S, Kessels H, Béguin S. *Thromb Haemostas*, in press.

(1). Measurement of the time course of thrombin concentrations in clotting plasma, giving a rise to a so called thrombin generation curve, therefore yields important information about the functioning of the coagulation system. One of the parameters which condenses much information of a thrombin generation curve is the thrombin potential (2). It is defined as the surface under the time curve of the free thrombin concentration.

The time course of free thrombin is the result of prothrombin conversion on the one hand, and thrombin breakdown on the other. It is often useful to be able to differentiate between these possibilities when thrombin generation is abnormal. This chapter describes how both the thrombin potential and the time course of prothrombin conversion can be obtained from thrombin generation curves. It also describes how these parameters can be distilled from curves of the time integral of the thrombin concentration.

Measurement of thrombin concentrations using chromogenic substrates is based on the amidolytic liberation by thrombin of the para-nitroaniline (pNA) group of the substrate, altering its light absorption spectrum. The thrombin concentration then determines the rate of change of optical density at 405 nm (3). Using this method, thrombin concentrations are measured in subsamples drawn from clotting plasma at timed intervals.

This method to measure thrombin generation in clotting plasma is not a routine undertaking, as it takes an experienced technician more than an hours work. We recently described a technique to measure the integral of the thrombin concentration pseudo-continuously in a cuvette (4). Since no subsampling is required, the technique has the potential of being automated and used routinely in a hospital laboratory. It is based on the presence of a chromogenic substrate in clotting plasma. Thrombin being generated in the plasma converts the chromogenic substrate. The rate of conversion of chromogenic substrate at any moment indicates the amount of enzyme, so that the optical density vs. time curve represents the time integral of the enzyme concentration. The thrombin potential, in this case, is equal to the steady endlevel of the resulting integral free thrombin curve, and can easily be obtained.

Chromogenic substrates are not as specific for thrombin as fibrinogen is. In particular, the physiologically inactive complex of thrombin with one of its minor inhibitors, α_2 -macroglobulin proteolyses small chromogenic substrates almost as well as free thrombin does (5,6,7). This is because α_2 -macroglobulin does not bind the active centre of thrombin, but still impedes the binding and conversion of large (protein) substrates. Therefore, the conversion of chromogenic substrate is due to both free

thrombin and the α_2 -macroglobulin-thrombin complex. This chapter describes a mathematical procedure to reduce a time curve of chromogenic substrate converting activity to a true thrombin generation curve. Analogously, time curves of optical density, measured using the pseudo continuous method, can be transformed into a time curves of the integral of the free thrombin concentration.

In order to be able to calculate the time course of prothrombin conversion, information is needed about thrombin breakdown in plasma. Thrombin is not only inhibited by α_2 -macroglobulin, but also, and mainly, by antithrombin III. Several other inhibitors, such as α_1 -antitrypsin are active as well, but their contribution is relatively minor. One inhibitor, heparin cofactor II, is only active if a potentiating compound, dermatan sulphate or one of its derivatives, or a very high concentration of heparin is present (8). These inhibitors all operate according to the same principle. They bind thrombin to form an essentially irreversible, inactive complex.

The concentration of antithrombin III is not in a large excess over the prothrombin concentration. Thus, a considerable amount of antithrombin III is consumed during blood clotting in a plasma sample (9,10,11). Since the rate of complex formation between thrombin and antithrombin III is dependent on both the concentration of free thrombin and the concentration of antithrombin III, this rate decreases as the concentration of antithrombin III decreases (11). A procedure is delineated to calculate the velocity of thrombin breakdown at any time during the clotting process. This information is then used to calculate the time course of prothrombin conversion, or the prothrombinase activity, in plasma during the process of haemostasis.

thrombin generation measured by chromogenic assay of subsamples from clotting plasma.

experimental method

This method is described in full detail in ref. 3. Briefly, to 240 μ l of plasma are added 60 μ l of a buffer (buffer A, 50 mM Tris-HCl, 100 mM NaCl, 0.5 mg/ml bovine albumin, pH 7.35), containing any substance under investigation. Clotting is initiated by addition of 60 μ l of a solution containing 100 mM CaCl_2 and human brain thromboplastin in as suitable dilution. At timed intervals, 10 μ l subsamples are diluted into a cuvette with 490 μ l of a buffer (buffer B, 50 mM Tris-HCl, 175 mM NaCl, 20 mM EDTA, 0.5 mg/ml bovine albumin, pH 7.90) containing 200 μ M of the chromogenic substrate S2238 (Kabi, Sweden). Amidolysis

of the chromogenic substrate in the cuvette is allowed to proceed for approximately 2 minutes. This reaction is then halted by the addition of 300 μ l of 1 M citric acid. The precise moments of subsampling and stopping are recorded on a personal computer by means of push-button equipped pipettes. Optical densities are measured at 405 nm and converted into amidolytic activities (mOD/min) by dividing by the reaction times. Thus, the result of such a thrombin generation experiment is a series of amidolytic activities with corresponding time points. Fig. 1 shows a typical curve of amidolytic activity obtained in pooled normal plasma. The steady endlevel of this curve is caused by the activity of the α_2 M-thrombin complex.

figure 1. the time course of the amidolytic activity.

This was measured in a subsampled thrombin generation experiment carried out as described in normal pooled plasma. Coagulation was triggered at time zero with human brain thromboplastin diluted 240 fold and Ca^{2+} (16.7 mM).

calculation of the free thrombin concentration

The experimentally determined amidolytic activity E at time point t is the result of both the thrombin concentration T and the concentration of the α_2 -macroglobulin-thrombin complex MT at time t . Since the K_m values of thrombin and the α_2 M-thrombin complex for conversion of S2238 are very much lower than the actual concentration of S2238, the reaction velocity is linear with the thrombin and α_2 M-thrombin concentrations.

$$E(t) = \gamma (T(t) + f \cdot MT(t)), \quad \gamma \approx k_{cat1} \quad (1)$$

with k_{cat1} and k_{cat2} being the catalytic constants for conversion of S2238 of thrombin and α_2 M-thrombin respectively, and f being the reaction rate of substrate conversion by α_2 M-thrombin relative to the reaction rate of an equal concentration of thrombin, i.e. $f = k_{cat2} / k_{cat1}$. The value of f has been determined at 0.556 (3).

Thrombin breakdown by α_2 M is a first order process (3) so that the rate at which the complex of thrombin and α_2 M forms is linearly dependent on the thrombin concentration:

$$\frac{dMT}{dt} = k_2 \cdot T(t) \quad (2)$$

When the time between two subsequent samples is not too long (less than about 45 s for a usual thrombin generation curve), it can be adequately approximated by the discrete case:

$$MT(t_i) = MT(t_{i-1}) + k_2 \cdot T(t_{i-1}) \quad (3)$$

figure 2. a thrombin generation curve and the calculated time course of the free thrombin concentration.

O: The experimentally determined amidolytic activity ●: Free thrombin as calculated from the amidolytic activity and the α_2 M dependent decay constant (k_2).

Once the value of the first order decay constant for α_2M (k_2) is known, the time curve of the free thrombin concentration can be obtained by applying equations (3) and (1) to the series of amidolytic activities. Fig. 2 shows a measured time curve of optical density, and the thrombin vs. time curve derived from it.

estimation of the α_2 -macroglobulin dependent decay constant

Since the complex of α_2M and thrombin has residual amidolytic activity, the α_2M dependent decay constant k_2 can be estimated directly from curves of amidolytic activity vs. time. First, time courses of the free thrombin concentration are calculated from the amidolytic activity values as described above, using a range of values κ for $f \cdot k_2$. These calculated thrombin concentrations T_κ are related to the real (but unknown) thrombin concentrations T in the following manner:

$$T_\kappa(t) = T(t) + (f \cdot k_2 - \kappa) \int_t^0 e^{-\kappa(t-s)} T(s) ds \quad (4)$$

If it is assumed that prothrombin conversion has stopped at a time point t_0 then:

$$T(t) = T(t_0) \cdot e^{-(k_1 + k_2)(t-t_0)}, \quad t \geq t_0 \quad (5)$$

If it is further assumed that $T(t) = 0$ after t_0 and that $k_1 + k_2 > \kappa$, then it follows from (4) and (5) that:

$$T_\kappa(t) \approx (f \cdot k_2 - \kappa) C \cdot e^{-\kappa(t-t_0)} \quad (6)$$

where C is the following constant:

$$C = \int_{t_0}^0 e^{-\kappa(t_0-s)} T(s) ds \quad (7)$$

Thus, $T_\kappa(t) / e^{-\kappa(t-t_0)}$ remains constant value for a given κ after time point t_0 , which can be used to test the validity of the assumptions. It is equal to zero when κ is equal to $f \cdot k_2$. $T_\kappa(t) / e^{-\kappa(t-t_0)}$ is then plotted as a function of κ , and k_2 is determined from the intersection of this function with the horizontal axis. It proved practical to estimate this intersect by fitting the function to the following exponential:

$$T_{\kappa}(t) / e^{-\kappa(t-t_0)} = a \cdot e^{b \cdot \kappa} + c \quad (8)$$

so that:

$$f \cdot k_2 = \frac{\ln(-c) - \ln(a)}{b} \quad (9)$$

calculation of the rate of prothrombin conversion from time curves of the free thrombin concentration

The rate of change (V) of the thrombin concentration (T) in plasma is the difference of the rate of prothrombin conversion (prothrombinase activity, P) and the rate of thrombin breakdown (D):

$$V(t) = dT/dt = P(t) - D(t) \quad (10)$$

V(t) can be obtained from the series of thrombin concentrations T(t) which are calculated from the measured course of the amidolytic activity E(t). D(t) is determined from the independently measured thrombin decay constants and the thrombin concentration T(t). The rate of prothrombin conversion P(t) is then calculated by summing D(t) and V(t) for each time point

thrombin decay

Thrombin in plasma is inhibited by a number of serine protease inhibitor proteins (I), giving rise to an essentially irreversible complex IT :

The rate of formation of IT is then given by the second order rate equation:

$$\frac{dIT}{dt} = - \frac{dI}{dt} = k' \cdot I(t) \cdot T(t) \quad (11)$$

Serine protease inhibitors relevant to thrombin breakdown in plasma are antithrombin III (AT III), α_2 -macroglobulin (α_2 M), heparin cofactor II (HC II), and a number of serpins with a relatively unimportant anti-thrombin activity (R). The concentration of the most important physiological thrombin inhibitor AT III is not much higher than the

prothrombin concentration, so that during the course of coagulation the concentration of AT III decreases considerably (9,10,11). The rate of thrombin breakdown due to AT III decreases to the same extent, since the it is linearly proportional to the AT III concentration. In the presence of dermatan sulphate, consumption of the inhibitor plays an even bigger role in the decay of thrombin due to heparin cofactor II, since the plasma concentration of HC II is about two thirds the plasma concentration of prothrombin. If no dermatan sulphate is present, no inhibitory action of HC II can be detected. The plasma concentration of $\alpha_2\text{M}$ is relatively high ($3.5 \mu\text{M}$) and does not decrease significantly during coagulation, nor does the concentration of the group of inhibitors of secondary importance. Therefore, it is reasonable to assume first order kinetics for the inactivation of thrombin by these inhibitors:

$$-\frac{dT}{dt} = D(t) = (k_1' \cdot \text{ATIII}(t) + k_4' \cdot \text{HCII}(t) + k_2 + k_3) \cdot T(t) \quad (12)$$

with $k_2 = k_2' \cdot \alpha_2\text{M}$ and $k_3 = k_3' \cdot R$

figure 3. velocities of decay and formation of thrombin

The velocity of thrombin decay (□) was determined from the thrombin generation curve of figure 2 and the independently measured thrombin decay constants. Together with the first derivative of the thrombin concentration in time (○), this determines the velocity of prothrombin conversion, also known as the prothrombinase activity (●).

figure 4. thrombin inhibitor complexes

The time course of the concentrations of various thrombin inhibitor complexes as calculated from thrombin generation curve of fig.2 and the measured thrombin decay constants. ○: Thrombin-AT III; ●: Thrombin- α_2 M; □: the complex of thrombin with other minor thrombin inhibitors

The series of values for D and the concentrations of the thrombin inhibitor complexes can be calculated iteratively from curves of the free thrombin concentration once the decay constants and the initial AT III concentration are known, using the discrete forms of equations 11 and 12. Figure 3 shows $D(t)$, $V(t)$ and $P(t)$ for a typical thrombin generation experiment. Figure 4 shows the time course of the thrombin-inhibitor complexes.

experimental determination of the decay constants of thrombin and the AT III concentration

The overall decay constant k_{tot} of thrombin in plasma can be determined experimentally (3) by addition of thrombin to plasma and measuring the time course of its disappearance. This is done essentially in the same way as described above for measurement of thrombin generation. The amidolytic activities $E(t)$ as obtained in the experiment can be fitted to the following exponential:

$$E(t) = E(\infty) + (E(0) - E(\infty)) e^{-k_{\text{tot}} t} \quad (13)$$

where $E(0)$ is the initial amidolytic activity, and $E(\infty)$ is the steady end level of amidolytic activity due to the α_2 M-thrombin complex. The steady end level $E(\infty)$ can reliably be determined by measuring several late points of the curve, and thus needs not be fitted. The overall decay constant k_{tot} obtained is the sum of the AT III dependent decay constant k_1 , the α_2 -macroglobulin dependent decay constant k_2 , and k_3 , the overall constant of a number of minor inhibitors. The value of k_3 has been found to be fairly invariable between individuals at 0.17 min^{-1} (11). The value of k_2 can be obtained experimentally as reported (3). Alternatively, it can be obtained from the amidolytic activity vs. time curve as described above. The value of k_1 is then calculated as $k_{\text{tot}} - k_2 - k_3$. The second order constant k_1' for the AT III - thrombin reaction in the absence of any potentiating substance like heparin and heparin derivatives has been determined at $1.508 \text{ min}^{-1} \cdot \mu\text{M}^{-1}$ (11). This value can then be used to calculate the initial AT III concentration from the first order constant k_1 as follows:

$$\text{ATIII}(0) = k_1 / k_1' \quad (14)$$

If, in subsequent experiments with the same plasma, heparin or one of its derivatives is added, its influence on the second order decay constant k_1' can be inferred as follows:

$$k_{1\text{hep}}' = k_{1\text{hep}} / \text{ATIII}(0) \quad (15)$$

Heparin increases the inhibitory capacity of AT III for thrombin. It acts as a catalyst, since it associates reversibly with AT III and it is liberated upon formation of the irreversible AT III - thrombin complex. The affinity for thrombin of the AT III-heparin complex is several orders of magnitude higher than the affinity of AT III alone, but the rate constant for the formation of the irreversible AT III-thrombin complex from the initial reversible AT III-thrombin complex is not altered (12). Heparin binds to AT III with a K_d of about 160 nM, and is normally present in concentrations much less than the concentration of AT III which is about ten times this K_d . This would mean that essentially all heparin would be bound to AT III so that an increase or decrease in the AT III concentration would not have a significant influence on the decay rate of thrombin. It therefore may come as a surprise that the thrombin decay velocity in the presence of heparin is still linearly proportional to the AT III concentration. However, heparin is known to bind many plasma proteins and competition between these proteins for heparin easily explains the AT III dependence of thrombin decay (11). One example of a heparin binding protein is Histidin Rich Glycoprotein (HRGP), which has a plasma

concentration of $\sim 5 \mu\text{M}$ and binds heparin with high affinity ($K_d = 7 \text{ nM}$). The concentration of the AT III heparin complex (AH) in the presence of heparin (H), AT III, with dissociation constant K_{Da} , and one other heparin binding protein (B) with a dissociation constant K_{Db} is given by:

$$\text{AH} = H_{\text{tot}} \frac{\lambda \cdot \text{ATIII}_{\text{tot}}}{\lambda \cdot \text{ATIII}_{\text{tot}} + K_{Da}} \quad (16)$$

where

$$\lambda = 1 - \frac{B_{\text{tot}}}{B_{\text{tot}} + K_{Db}}$$

in the case of $K_{Da} \gg \lambda \cdot \text{ATIII}_{\text{tot}}$, as is true for HRGP ($K_{Da} \sim 160 \text{ nM}$, $\lambda \cdot \text{ATIII}_{\text{tot}} \sim 2 \text{ nM}$), equation 16 reduces to:

$$\text{AH} = \frac{\lambda}{K_{Da}} H_{\text{tot}} \cdot \text{ATIII}_{\text{tot}} \quad (17)$$

which shows that AH, and therefore the AT III dependent thrombin decay velocity, is indeed linearly proportional to the AT III concentration in the presence of heparin under the above conditions. The presence of more heparin binding proteins does not affect this property. Equation 17 is the basis for the definition of the specific antithrombin activity of a heparin. This is defined as the increase of k_1 caused by $1 \mu\text{g}$ of heparin per ml plasma normalised to an AT III level of $1 \mu\text{M}$.

The decay of thrombin brought about by heparin cofactor II is normally of no importance. If, however, dermatan sulphate or a related substance is present in plasma, it has to be considered (8). In such a case, the initial concentration of HC II has to be determined in plasma devoid of AT III.

thrombin generation measured by pseudo-continuous recording of the time integral of thrombin

experimental method

The method for measuring thrombin generation pseudo-continuously is described in detail in ref. 4. In brief, $400 \mu\text{l}$ of reptilase defibrinated plasma, $100 \mu\text{l}$ of buffer A containing any substance under investigation,

and 60 μl of the chromogenic substrate SQ 68 (methylmalonyl-methylalanyl-arginyl-pNA, from Serbio, France) are added to a cuvette at 37°C. The chromogenic substrate SQ 68 is used in these experiments instead of S2238, because of its more suitable kinetic properties, as discussed further below. Clotting is triggered by addition of 40 μl of tissue factor in 0.25 M CaCl_2 . The time course of optical density at 405 nm is then recorded pseudo-continuously at a rate of two optical density readings per second. Fig 5 shows an example of a typical time course of optical density in pooled normal plasma.

The chromogenic substrate in the cuvette is continuously converted by the thrombin being generated and broken down. The resulting optical density vs. time curve is the integral of the thrombin generation curve. The final slope of this curve is the consequence of the end level of $\alpha_2\text{M}$ -thrombin.

Using this approach it is inevitable that the presence of the chromogenic substrate influences the reactions of thrombin in plasma. SQ 68 will compete with both the thrombin breakdown reactions by AT III, $\alpha_2\text{M}$ and others, and the positive feedback reactions exerted by thrombin, i.e.

figure 5. continuous measurement of enzyme activity

The time course of the optical density (in mOD) as measured with a pseudo-continuous thrombin generation experiment carried out as described, in normal pooled plasma. Coagulation was triggered at time zero with human brain thromboplastin diluted 240 fold and Ca^{2+} (16.7 mM). The SQ 68 concentration was 500 μM .

activation of the cofactors V and VIII. The ideal chromogenic substrate, the one with the least influence on the reactions of thrombin, would have a very high K_m , so that only a very limited amount is in complex with thrombin, and a relatively high k_{cat} , so that its high K_m still results in a measurable signal. The substrate SQ 68, comes closest to the ideal kinetic properties of the substrates available to date (table 1), but might be improved upon.

enzyme	conditions	K_m (μM) $\pm$ s.e.	k_{cat} (s^{-1}) $\pm$ s.e.
thrombin	heated plasma	819 ± 19	0.38 ± 0.002
thrombin	buffer A	830 ± 48	0.46 ± 0.04
$\alpha_2\text{M}$ -thrombin	serum	788 ± 11	0.29 ± 0.01

table 1. kinetic parameters of SQ 68.

The kinetic parameters for thrombin conversion of the chromogenic substrate SQ 68 were measured by measuring the rate of hydrolysis of a SQ 68 values in the range of 0 to 2000 μM by thrombin in a concentration of 100 nM, at 37°C. The k_{cat} and K_m values were extracted from the substrate vs. reaction rate curves using a non-linear fit procedure.

influence of SQ 68 on thrombin decay.

The reaction of thrombin with its serine protease inhibitors goes through an initial, low affinity complex, which can then be converted to a tight, nearly irreversible complex (13). The K_d of the initial complex between thrombin and AT III is very high (1.4 mM, ref. 14) compared to the plasma AT III concentration, so that the presence of SQ 68 (S), in spite of its own relatively high K_m , effectively competes with the serine proteases for thrombin. Therefore the rate of thrombin inhibition by serine proteases (I) is decreased:

$$IT(t) = T_{tox}(1 - e^{-I \cdot k_{app} \cdot t}) \quad (18)$$

with

$$k_{app} = k_{dec} \left(\frac{K_m}{S + K_m} \right)$$

Thus, the apparent AT III dependent decay constant of thrombin is reduced by a factor $K_m / (S + K_m)$. For a concentration of chromogenic substrate of 1 mM the apparent decay of thrombin inactivation by AT III would be about 40% of k_{dec} . The situation is somewhat different for α_2 -macroglobulin. While this protein is also a member of the serpin family, and might therefore be expected to exhibit the same kind of behaviour as

AT III, there is one important difference in its mode of action: it does not bind thrombin at the active site. Thus, a molecule of SQ 68 bound to thrombin may hinder the formation of a complex between $\alpha_2\text{M}$ and thrombin, it does not necessarily prevent it.

influence of SQ 68 on thrombin formation

Theoretically, the presence of SQ 68 might also affect prothrombinase activity, by competing with feedback activation of the cofactors V and VIII by thrombin. However, there are several reasons why this effect can be expected to be much less important. First, the affinity of thrombin for these cofactors is high with K_d values in the nanomolar range, so that it takes higher substrate concentrations to produce appreciable inhibition. Second, thrombin concentrations soon rise above the concentrations of its natural substrates ($[\text{VIII}] < 1 \text{ nM}$, $[\text{V}] \approx 25 \text{ nM}$) so that complexing of a part of the thrombin with chromogenic substrate has relatively little effect.

measurement of the influence of SQ 68

Thrombin decay in the presence of various concentrations of SQ 68 was measured. Table 2 shows that indeed there is a dependence of the k_{dec} of thrombin on the SQ 68 concentration. The decay constants as function of the SQ 68 concentration were fitted to equation 18. The resulting K_m ($600 \mu\text{M} \pm 60$) was in good agreement with the value of K_m obtained by direct measurement of reaction rates ($660 \mu\text{M} \pm 100$) (4).

Measurement of thrombin generation curves in the presence of SQ 68 allows for estimation of the k_{dec} values for $\alpha_2\text{M}$ mediated thrombin decay

[SQ 68] (μM)	k_{dec} (min^{-1})	k_1 (min^{-1})	k_2 (min^{-1})
0	2.446	2.223	0.223
100	2.072	1.858	0.214
200	1.863	1.669	0.194
500	1.425	1.254	0.171
1000	0.885	0.758	0.127
1500	0.578	0.477	0.101
2000	0.478	0.399	0.079

table 2. Influence of SQ 68 on thrombin decay constants

Decay constants of thrombin were measured after addition of 100 nM of thrombin to plasma containing the indicated concentrations of SQ 68. Timed subsamples from this plasma were diluted in buffer containing the chromogenic substrate S2238 for measurement of the thrombin concentrations as described (3). Contribution of the SQ 68 in the plasma to the optical density in the dilution was not measurable. Values for the k_2 were extracted from thrombin generation curves as described in this chapter.

figure 6. Influence of SQ 68 on the prothrombinase activity in plasma.

Prothrombinase activities were calculated from thrombin generation curves measured using the subsampled method in the presence of various concentrations of SQ 68, and the decay constants of table 2. ○: no SQ 68; ●: 200 μM ; □: 500 μM ; ■: 1 mM.

(k_2), as described above. The K_m obtained by fitting to equation 18 is much higher now (1400 μM), which probably reflects the fact that $\alpha_2\text{M}$ bound to thrombin leaves the active site of thrombin still accessible.

Knowledge of the decay constants of thrombin for AT III and $\alpha_2\text{M}$ makes it possible to calculate the prothrombinase activity from the thrombin generation curves as described in this chapter. Fig 6 shows that up to 500 μM of SQ 68 may be present without inhibiting prothrombinase activity (data from ref. 4).

consumption of SQ 68

Since the concentration of SQ 68 is at or below the K_m value, the concentration of SQ 68 should not drop very much, as the conversion rate of SQ 68 by thrombin is almost linearly dependent on the SQ 68 in this concentration range. Simulation of a measured integral thrombin curve, starting from a known (measured) normal thrombin generation curve, showed that the reaction rate at 15 minutes was still above 94% of the reaction rate at time zero when the SQ 68 concentration was 500 μM . Since the amount of SQ 68 that is converted at any given moment is

known from the optical density, the substrate consumption phenomenon can easily be accounted for as described below.

calculation of the time integral of the free thrombin concentration

The pseudo-continuous method for measuring thrombin generation records a range of optical density readings together with corresponding time values. These discrete optical density - time pairs reflect both the integral of the thrombin concentration and the integral of the α_2 M-thrombin complex concentration. At any moment, the conversion velocity of the substrate (S) is the sum of the conversion velocities by thrombin and the α_2 M-thrombin complex. As is evident from table 1, the K_m for SQ 68 by thrombin and α_2 M-thrombin are about equal, whereas their k_{cat} values differ:

$$-\frac{dS}{dt} = k_{cat1} \cdot T(t) \cdot \frac{S(t)}{S(t)+K_m} + k_{cat2} \cdot \alpha_2 M(t) \cdot \frac{S(t)}{S(t)+K_m} \quad (19)$$

which resolves into:

$$\int_0^t T(\tau) d\tau = \frac{S(0) - S(t) + K_m (\ln S(0) - \ln S(t))}{k_{cat1}} - f \cdot \int_0^t \alpha_2 M(\tau) d\tau \quad (20)$$

with f again equal to k_{cat2} / k_{cat1} . This equation accounts for the consumption of chromogenic substrate during the measurement.

$S(t)$ can be obtained from the measured optical density (OD) value at time t as follows:

$$S(t) = S(0) - OD(t) / \epsilon \quad (21)$$

ϵ being the molar absorption coefficient of para-nitroaniline at a wavelength of 405 nm.

Integration of equation 2 gives the relationship between the time integral of the α_2 M concentration and the time integral of the thrombin concentration. Since optical density is monitored continuously in a cuvette, the time interval between 2 optical density readings can be made almost arbitrarily small. It is sufficient, however, to have readings at 30 s intervals. Now, the discrete form of the differential equation can again safely be used:

figure 7. the time integral of the free thrombin concentration

The time course of the time integral of the thrombin concentration (—) as calculated from the time course of optical density measured during a pseudo-continuous thrombin generation experiment. The dashed line (- - -) shows the time course of the integral of the α_2 -macroglobulin thrombin concentration.

$$\int_0^{t_i} \alpha_2 M(\tau) d\tau = \int_0^{t_{i-1}} \alpha_2 M(\tau) d\tau + k_2 \cdot \int_0^{t_{i-1}} T(\tau) d\tau \quad (22)$$

By applying equations 20, 21 and 22 to the array of optical density values constituting the result of a continuous measurement of thrombin generation, the time course of the integral of the thrombin concentration can be calculated, provided k_2 is known. The value of k_2 can be determined directly from an experimental curve as delineated above. Figure 7 shows an integral thrombin curve derived from a time curve of optical density.

conclusions

Measurement of thrombin generation in clotting plasma has undergone a revival during the last decade spurred by the invention of chromogenic substrates in the mid seventies. Thrombin, being the central enzyme in

haemostasis, is able to convey much useful information about the coagulation process. Extracting this information from thrombin generation curves is often non-trivial however. The first hurdle is the amidolytic activity of the complex of thrombin and α_2 -macroglobulin, which adds considerably to the signal measured both in subsampled and pseudo-continuous thrombin generation experiments. This chapter describes a mathematical procedure to strip the experimental data from its unwanted clothing. Much of the useful information from both normal and integral thrombin generation curves can be concentrated in one parameter, the thrombin potential, which is the time integral of the free thrombin concentration. It is sensitive to all known types of anticoagulant therapy. The time course of prothrombin conversion, indicating the activity of the prothrombinase complex, can be calculated once the decay constants of thrombin in plasma are known. Lowered thrombin concentrations can thus be shown to be due to increased inhibition of thrombin or to decreased formation of thrombin.

Measurement of thrombin generation in clotting plasma may even enter into the realm of clinical laboratory analysis. The impetus for this has been given by the development of a pseudo-continuous, automatable, thrombin generation test. Since a chromogenic substrate is present during thrombin generation and decay in plasma, what really is recorded, after subtracting the signal brought about by α_2 -macroglobulin, is the time integral of free thrombin during clotting. It is shown that the presence of the chromogenic substrate SQ 68 in concentrations of 500 μM or thereabouts does not interfere too much with the coagulation process while still retaining a signal that is well measurable. The inevitable consumption of the substrate during the clotting process is accounted for.

All calculations presented in this article have been implemented in several computer programs (for IBM compatibles) which can be obtained from the authors.

references

1. Hemker HC. Thrombin generation, an essential step in haemostasis and thrombosis. In: Haemostasis and thrombosis. Ed. Bloom et. al. Churchill Livingstone, Edinburgh 1993.
2. Hemker HC, Wielders S, Béguin S. The thrombin potential. A parameter to assess the effect of antithrombotic drugs on thrombin generation. Fraxiparine, second international symposium. Recent pharmacological and clinical data. Eds Bounameaux H, Samama M, ten Cate J. 1990;89-101. Schattauer, Stuttgart-New York.

3. Hemker HC, Willems GM, Béguin SA. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. *Thromb Haemostas* 1986;56:9-17.
4. Hemker HC, Wielders S, Kessels H, Béguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the endogenous thrombin potential. *Thromb Haemostas*, in press.
5. Barret AJ, Starkey PM. The interaction of α_2 -macroglobulin with proteinases. *Biochem J* 1973;133:709-15.
6. Rinderknecht H, Feling RM, Geokas MC. Effect of α_2 -macroglobulin in some kinetic parameters of trypsin. *Biochim Biophys Acta* 1975;377:150-65.
7. Fischer AM, Tapon-Bretaudière J, Bros A, Josso F. Respective roles of antithrombin III and α_2 -macroglobulin in thrombin inactivation. *Thromb Haemostas* 1981;45:51-4.
8. Tollefsen DM. Activation of heparin cofactor II by heparin and dermatan sulfate. *N Rev Fr Hematol* 1984;26:233-7.
9. Hensen A, Loeliger EA. Antithrombin III, its metabolism and its function in blood coagulation. *Thromb Haemost* 1963; Suppl 1.
10. Fagerhol MK, Abilgaard U. Immunological studies on human antithrombin III. Influence of age, sex and use of oral contraceptives on serum concentration. *Scand J Haematol* 1970;7:10-7.
11. Béguin S, Kessels H, Dol F, Hemker HC. The consumption of antithrombin III during coagulation, its consequences for the calculation of prothrombinase activity and the standardisation of heparin activity. *Thromb Haemostas* 1992;68(2):136-42.
12. Olson ST, Shore JD. Transient kinetics of heparin-catalyzed protease inactivation by antithrombin III. The reaction step limiting heparin turnover in thrombin neutralization. *J Biol Chem* 1986;266(28):13151-9.
13. Longstaff C, Gaffney PJ. Serpin-serine protease binding kinetics: α_2 -antiplasmin as a model inhibitor. *Biochemistry* 1991;30(4):979-86.
14. Olson ST, Shore JD. Demonstration of a two-step reaction mechanism for inhibition of α -thrombin by antithrombin III and identification of the step affected by heparin. *J Biol Chem* 1982;257:14891-95.

introduction

Clot formation in plasma is initiated by the serial enzymatic activation of clotting factors, which results in the appearance of small traces of

Received: Kessels H, Béguin S, Wagenvoort R, Hemker HC. *Thromb Haemostasis* 1993;69:4-1994.

chapter 4

measurement of activated factor VIII in plasma*

summary

A method is described which enables an accurate quantitative measurement of the concentration of activated factor VIII (VIIIa) in plasma. Based on the ability of factor VIIIa to accelerate the activation of factor X by factor IXa, phospholipid and calcium ions, the course of factor X activation in time is measured using a chromogenic substrate. Free factor Xa is able to activate non-activated factor VIII present in a plasma sample, which increases the factor X activation velocity, and thus disturbs the measurement of factor VIIIa. Furthermore, factor Xa was found to be inactivated by serine protease inhibitors from the plasma sample. By adding surplus chromogenic substrate these reactions of factor Xa are inhibited and at the same time the rate of substrate conversion is a measure of the amount of factor Xa present. Factor X activation and amidolysis of chromogenic substrate then take place simultaneously. It is shown that under proper conditions the factor X activation velocity is linearly proportional to the factor VIIIa concentration. This causes the optical density to increase as a parabolic function of time. The concentration of factor VIIIa can be obtained from the quadratic coefficient of the equation describing the parabola. The method is specific for factor VIIIa in that the extrinsic factor X activator, the factor VIIa - tissue factor complex, is shown to have no influence on the measurement of factor VIIIa in thromboplastin activated plasma. We conclude that a sensitive and reliable method for assessing factor VIIIa concentrations in plasma has been developed on the basis of simultaneous inhibition and measurement of factor Xa by a high concentration of chromogenic substrate.

introduction

Clot formation in plasma is initiated by the serial enzymatic activation of clotting factors, which results in the appearance of small traces of

* Based on: Kessels H, Béguin S, Wagenvoort R, Hemker HC. *Thromb Haemost* 1990;66(4):430-4.

thrombin (1). The explosive nature of the coagulation process is a consequence of the positive feedback reactions that these thrombin traces exert on the cofactors V (2, 3, 4) and VIII (4, 5, 6, 7, 8, 9), and on platelets (10). Activated factors V and VIII boost the performance of factors Xa and IXa, whereas activated platelets provide, among other things, the negatively charged surface necessary for most coagulation reactions (11).

As the line separating thrombosis and bleeding seems to be thin, the importance of control mechanisms that steer the hemostatic process is obvious. In spite of the enormous progress that has been made by studies in systems with purified clotting factors, the fine tuning of hemostasis *in vivo* still remains a largely unsolved riddle. The initial traces of thrombin and the feedback reactions they provoke, are likely to play a crucial role in the overall process of hemostasis. Therefore, we set out to develop a method to directly assess one of those feedback reactions in plasma, viz. the activation of factor VIII.

Traditionally, factor VIII concentrations, and also factor VIII activation in plasma were measured using coagulation assays, involving factor VIII deficient plasma (12, 13, 14). The occurrence of various feedback reactions made it impossible to relate, in a quantitatively reliable way, obtained values to amounts of factor VIII activated. The advent of a chromogenic substrate for factor Xa made a more direct way of determining functional factor VIIIa conceivable. The property of activated factor VIII, to accelerate the activation of factor X by factor IXa, phospholipid and calcium ions, by several orders of magnitude, was molded into a sensitive assay procedure for VIIIa (15, 16). However, feedback reactions of factor Xa on factor VIII (17, 18, 19, 20) and factor X (21), and the inactivation of factor Xa by the antithrombin III and α_1 -antitrypsin present in plasma can seriously hamper the feasibility of using the same type of assay for the measurement of factor VIIIa in plasma. On the basis of a method by Pieters et.al.(4) we developed a scheme for measuring factor VIIIa in plasma, that circumvents these difficulties.

materials and methods

materials

Factor Xa chromogenic substrate ($\text{CH}_3\text{OCO-D-Chg-Gly-Arg-pNA.AcOH}$) and the competitive thrombin inhibitor α -NAPAP (N- α -(2-Naphthylsulfonyl) - glycyl - D,L-amidino - phenylalanine-piperidine.HCl) were obtained from Pentapharm (Basel, Switzerland). The factor Xa

chromogenic substrate has K_m and V_{max} values of 142 μM and 230 mA/min/nM for bovine factor Xa (22). α -NAPAP has a K_i for thrombin of 6.6 nM and a K_i for factor Xa of 7.2 μM (23). Buffer used was 50 mM Tris, 175 mM NaCl, 0.5 g/l ovalbumin, pH 7.9. All chemicals were the highest grade commercially available.

proteins

Bovine factors X, Xa, IXa and IIa were purified as previously described (24, 25, 30, 26).

phospholipid

phospholipid vesicles (PL) used were 80 mole-% egg phosphatidyl choline and 20 mole-% brain phosphatidyl serine (Sigma). They were prepared as described (27).

plasma and euglobulins

Plasma was prepared (28) from blood from 12 healthy male donors, 9 volumes collected on one volume of trisodium citrate (0.13 M). Plasma was defibrinated by mixing an aliquot of plasma with 1/50 volume of reptilase reagent (Boehringer Mannheim), letting a clot form for 5 min at 37°C and keeping the clotted plasma at 0°C for 10 min. The fibrin formed was discarded by winding on a small plastic spatula. Euglobulins were prepared from plasma by precipitation at low ionic strength, pH 5.2 (plasma diluted 1 in 20 in a 0.016 vol-% acetic acid solution), on ice for 30 min. After centrifugation (10 min, 4000 rpm, 4°C), they were resuspended in 5 volumes NaCl-aq (9 g/l) and 1 volume trisodium citrate (0.13 M), so as to contain a concentration of factor VIII that was not lower than 75% of the plasma concentration. 10 nM Factor Xa remains stable in this solution for over 1 hour, in the presence of 0.1 U/ml heparin. Hemophilia A plasma was obtained from a single donor and it contained less than 1% factor VIII activity.

thromboplastin

Human brain thromboplastin was prepared as described (29). It was subsequently centrifuged at 1000 rpm for 5 min and stored in 50 μl aliquots at -80 °C. It was thawed and diluted 1 in 18 with buffer containing 167 mM $CaCl_2$, then incubated at 37 °C for one hour, and kept at room temperature.

methods

experimental conditions

Final concentrations of the reactants used were: factor IXa: 100 nM, PL: 20 μM , Ca^{2+} : 5 mM and factor X: 330 nM. These are reported (30)

to be optimal for factor X activation in a bovine system with human factor VIIIa. The same holds for pH (7.9) and PS:PC ratio of the phospholipid vesicles (20/80 mole/mole). All experiments were performed at 37°C.

factor Xa assay

300 μ l from a factor X activation mixture was subsampled in 372 μ l buffer containing 20 mM EDTA. This can be shown to stop factor X activation instantaneously. After addition of 28 μ l of the chromogenic substrate for factor Xa, to a final concentration of 80 μ M, absorbance was read kinetically for 2 min. The factor Xa concentration could be inferred from the initial linear increase in absorbance, using a linear least squares fit procedure. All mixtures that were assayed for factor Xa, contained 2.33 μ M α -NAPAP, resulting in a final concentration of 1 μ M.

measurement of absorbance

All photometry was carried out at 405 nm in a sensitive dual wavelength photometer.

results

Since factor VIIIa is not an enzyme, its functional concentration cannot be measured directly by way of a chromogenic substrate. Instead, the ability of factor VIIIa to enhance factor X activation by factor IXa, phospholipid, and Ca^{2+} , must be exploited. The concentration of factor Xa can be determined chromogenically, which permits an estimation of the factor VIIIa level.

activation of factor VIII by factor Xa

It is well known (17, 18, 19) that factor Xa is able to activate factor VIII, be it less effectively than thrombin. Since in plasma, the intended medium for the factor VIIIa assay, both activated and non-activated factor VIII may be present, this feature of factor Xa is a potential hazard to the reliability of the assay.

The effect of factor Xa on the time course of factor X activation was investigated by adding a small quantity of factor Xa to a mixture containing factors IXa and X, PS:PC vesicles, Ca^{2+} and non-activated plasma. Thrombin mediated activation of factor VIII was prevented by the presence the thrombin inhibitor α -NAPAP. If the added factor Xa would activate factor VIII by the added factor Xa, complete tenase would be formed, the complex of the factors IXa and VIIIa on a phospholipid surface, leading to an increase of the factor Xa concentration. If, on the

other hand, factor Xa would not activate factor VIII, the factor Xa concentration would remain unaltered.

Rather surprisingly, fig. 1 (upper panel) shows an initial drop of the factor Xa concentration which is followed by an increase. When the experiment was repeated with hemophilia A plasma instead of normal plasma, the initial decrease of the factor Xa concentration was absent. Using the euglobulin fraction of normal plasma (no serine protease inhibitors), the upward bend of the curve was found to disappear. Using buffer instead of plasma causes the factor Xa concentration to remain constant.

Thus it seems likely that factor Xa indirectly causes factor X activation by activating factor VIII, and also that factor Xa is subject to inactivation by inhibitors (probably ATIII or α_1 -antitrypsin) present in the diluted plasma. When the experiments were repeated with a high concentration of the highly specific potent thrombin inhibitor hirudin (1.25 μ M) instead of α -NAPAP, a similar course of X activation was obtained (results not shown).

Both activation of factor VIII by factor Xa, and inactivation of factor Xa directly affect the signal used for the determination of factor VIIIa. Because the measurement is based on the ability of factor Xa to split a chromogenic substrate, adding a factor Xa inhibitor will effectively inhibit these undesired reactions, as well as the factor Xa measurement itself.

inhibition of factor Xa by chromogenic substrate

The only 'inhibitor' that can slow down the side reactions without interfering with signal generation is the chromogenic substrate for factor Xa, at a concentration sufficiently above K_m . This would prevent all reactions of factor Xa but amidolysis of chromogenic substrate. It means that factor X activation by the tenase complex and chromogenic substrate conversion by factor Xa are two concurrent processes.

The following equations describe these simultaneous reactions in the mixture:

$$d[Xa]/dt = f([VIIIa]) \quad (I)$$

$$dA/dt = k_2 \cdot [Xa] \quad (II)$$

'A' being absorbance, and $f([VIIIa])$, a function of the factor VIIIa concentration.

figure 1. Influence of factor Xa on factor X activation.

upper panel: without chromogenic substrate for factor Xa in the tenase mixture.

Factor X (final concentration 0.33 μM) was added to a mixture of factor IXa (100 nM), PL (20 μM), Ca^{2+} (5 mM) and $\alpha\text{-NAPAP}$ (2.33 μM). At one minute, plasma (■), hemophilia A plasma (□), euglobulin fraction (●) or buffer (○) were diluted 1 in 30 in this mixture. One minute later, factor Xa was added to a final concentration of 1 nM. At intervals 300 μl were taken from this mixture for assay of factor Xa, as described in the materials and methods section.

lower panel: with chromogenic substrate for factor Xa in the tenase mixture.

Factor X (final concentration 0.33 μM) was added to a mixture of factor IXa (100 nM), PL (20 μM), Ca^{2+} (5 mM), $\alpha\text{-NAPAP}$ (1 μM), chromogenic substrate (400 μM) and a 1 in 30 dilution of plasma (■), hemophilia A plasma (□), euglobulin fraction (●) or buffer (○). After 10 seconds 1 nM of factor Xa was added, and the amidolytic activity was measured every min at 405 nM.

These equations resolve in:

$$A(t) = A_0 + k_2 \cdot [Xa]_0 \cdot t + \frac{1}{2} \cdot k_2 \cdot f([VIIIa]) \cdot t^2 \quad (III)$$

' A_0 ' and ' $[Xa]_0$ ' being 'absorbance at time zero' and 'factor Xa concentration at time zero' respectively.

The quadratic coefficient ($\frac{1}{2} \cdot k_2 \cdot f([VIIIa])$) which is a function of the factor VIIIa concentration can easily be obtained from the absorbance-time curve using a simple linear least squares fit to a second order polynomial. The value of k_2 (equation II) was found to be 170 mA/nM. This is in accordance with the K_m and V_{max} of the chromogenic substrate, and a substrate concentration of 400 μM .

In practice, the course of absorbance in time was determined using the following scheme: A sample from the mixture being assayed, usually a plasma subsample, was diluted in a cuvette containing IXa (100 nM), PL (20 μM), Ca^{2+} (5 mM) and α -NAPAP (1 μM). After 10 seconds, chromogenic substrate for factor Xa was added, to a concentration of 400 μM . Factor X activation was started after another 10 seconds by addition of factor X to a concentration of 0.33 μM (all concentrations are final concentrations). The course of the absorbance in time was then measured at 405 nm.

The influence of factor Xa in this system was again investigated by adding a small quantity (1 nM) of factor Xa to the factor X activating mixture. This was carried out essentially as described in the general scheme above, but with factor Xa (1 nM) added 10 seconds after the addition of factor X. The experiment was performed with pooled normal plasma, hemophilia A plasma, euglobulin solution or buffer. The lower panel of fig. 1 shows that indeed all reactions of factor Xa, except for the amidolysis of the chromogenic substrate, were effectively inhibited.

standard curve

For the concentrations used, i.e. factor IXa: 100 nM, PL: 20 μM and factor VIIIa: < 50 pM, the amount of complete tenase that is formed is expected to depend linearly on the concentration of factor VIIIa, since published apparent K_d values for factor IXa in a mixture of phospholipid and factor VIIIa are below 10 nM (20, 26). To establish this linearity, the concentration of factor VIII in plasma was varied by mixing normal plasma with Hemophilia A plasma. Then all factor VIII could be activated by addition of a high concentration of thrombin. However, factor VIIIa is very unstable in plasma. Therefore, we first had to find a way to stabilize

figure 2. stabilization of factor VIIIa.

Plasma was diluted 100 fold in a cuvette containing IXa (100 nM), PL (20 μ M) and Ca^{2+} (5 mM). At 30 seconds thrombin was added to concentrations of 100 nM (●, mean of 3 experiments) or 200 nM (Δ). After a variable time, chromogenic substrate for factor Xa (400 μ M) and α -NAPAP (1 μ M) were added. The course of absorbance in time was measured upon addition of factor X (0.33 μ M), 10 seconds later. On the vertical axis are the values of the quadratic coefficient (QC) of the equation describing the absorbance time curves ($\frac{1}{2}k_2 \cdot f([\text{VIIIa}])$, see eq. III).

factor VIIIa, so that all factor VIII in a plasma sample could be activated without inactivation going on simultaneously.

Purified factor VIIIa has been found to be stabilized by complex formation with factor IXa on a negatively charged phospholipid surface in the presence of Ca^{2+} (31). It turned out that stability of plasma factor VIIIa was achieved for about 20 seconds when the plasma was diluted first in a mixture of factor IXa, PL, and Ca^{2+} , and then activated with a large amount of thrombin (100 nM) (fig 2).

Fig. 2 also shows that the value of the quadratic coefficient did not increase when the double amount (200 nM) of thrombin was used, indicating that all factor VIII had indeed been activated.

Plasma samples with different factor VIII concentrations were obtained by mixing pooled normal plasma and hemophilia A plasma in various ratios. The factor VIII in these samples was completely activated as described above. Chromogenic substrate for factor Xa and α -NAPAP were added at 45 seconds, that is 15 seconds after thrombin addition.

figure 3. proportionality of the factor X activation velocity to the concentration of factor VIIIa.

At time zero, plasma, containing various concentrations of factor VIII, was diluted 100 fold in a cuvette containing IXa (100 nM), PL (20 μ M) and Ca^{2+} (5 mM). At 30 seconds thrombin was added, to a concentration of 100 nM. It was allowed to activate factor VIII for 15 seconds, when chromogenic substrate for factor Xa (400 μ M) and α -NAPAP (1 μ M) were added. The course of absorbance in time was measured upon addition of factor X (0.33 μ M) after another 10 seconds. On the vertical axis are the values of the quadratic coefficient (QC) of the equation describing the absorbance time curves ($\frac{1}{2}k_2 \cdot f([\text{VIIIa}])$), see eq. III). The concentration of factor VIII in the plasma was varied by mixing pooled normal plasma with hemophilia A plasma.

Fig. 3 shows that the quadratic coefficient, and therefore also $f([\text{VIIIa}])$ is linearly proportional to factor VIIIa concentrations ranging from 0 to 100% in pooled normal plasma. This reduces equation (I) to

$$f([\text{VIIIa}]) = k_1 \cdot [\text{VIIIa}] \quad (\text{IV})$$

so that equation (III) becomes:

$$A(t) = A_0 + k_2 \cdot [\text{Xa}]_0 \cdot t + \frac{1}{2} \cdot k_1 \cdot k_2 \cdot [\text{VIIIa}] \cdot t^2 \quad (\text{V})$$

The value of $\frac{1}{2} \cdot k_1 \cdot k_2$ was found to be 1.164 ± 0.011 (S.E.) $\text{mA/min}^2/\% \text{VIIIa}$. Assuming 100% VIII to be 1 nM (32, 33), and using a

value of 170 mA/nM for k_2 (as previously mentioned), k_1 is estimated to be $137 \text{ min}^{-1} \cdot (\text{nM Xa} / \text{nM VIIIa})$.

specificity of the assay

Non-specificity of the factor VIIIa assay can be introduced at two levels: conversion of chromogenic substrate by anything other than factor Xa generated in the assay mixture, and activation of factor X in the assay mixture by anything else than the IXa-VIIIa complex. The first means of non-specificity happens not to have an influence on the assay at all, since it only affects the linear coefficient of the quadratic equation describing the absorbance time curves (eq. V), whereas the factor VIIIa concentration only appears in the quadratic coefficient.

A constant small amount of activation of factor X is of course expected to be caused by factor IXa not complexed to factor VIIIa. Since the assay is intended to measure factor VIIIa concentrations in a plasma environment, non-specific activation of factor X in the assay mixture may also come from the extrinsic factor X activator, the complex of tissue factor with factor VIIa.

The specificity of the factor VIIIa assay scheme was tested using buffer, non-activated plasma and thromboplastin (final dilution 1 in 180) activated plasma. This dilution of thromboplastin clotted uninhibited plasma in 70 seconds. When we employed the general scheme described above to measure factor VIIIa activity in buffer and non-activated plasma, identical control values for the quadratic coefficient of 0.6 mA/min^2 were found. As already mentioned, this value is the result of the slow activation of factor X by IXa in the presence of phospholipid and Ca^{2+} , but without factor VIIIa.

In order to be able to determine any non-specificity from thromboplastin activated plasma, we suppressed the factor VIIIa based acceleration of factor X activation. This was done by excluding factor IXa from the factor X activating mixture, so that factor X activation, if any, would be caused by constituents from the thromboplastin activated plasma, most likely the tissue factor - VIIa complex. Fig. 4 shows that very little factor X activation could be detected. The absorbance values obtained in the absence of factor IXa were so low, that a quadratic curve could not reliably be fitted to the experimental absorbance-time data. Instead, we made an estimation of the maximal values of the quadratic coefficient by assuming the constant and linear coefficient to be zero, and calculating the quadratic coefficient from $\frac{1}{2} \cdot k_1 \cdot k_2 \cdot [\text{VIIIa}] = A(t)/t^2$ at $t = 2 \text{ min}$.

figure 4. specificity of the factor VIIIa assay in thromboplastin activated plasma.

10 μ l of a 1 in 18 dilution of thromboplastin in a 167 mM CaCl_2 solution were added to 90 μ l of defibrinated plasma (final dilution of 1 in 180). At various times, a sample of this mixture was diluted 1 in 90 in a cuvette containing factor IXa (100 nM) (○) or no factor IXa (●). PL (20 μ M), Ca^{2+} (5 mM) and α -NAPAP (1 μ M) in buffer, so as to obtain a final dilution of the plasma of 1 in 100. After 10 seconds, factor Xa chromogenic substrate was added, to a concentration of 400 μ M. After another 10 seconds, factor X (0.33 μ M) was added to initiate the activation reaction, and absorbance was measured during 2 min. Factor VIIIa concentrations are plotted as a percentage of the total factor VIII level.

discussion

Although thrombin appears to be the only physiological activator (4), factor Xa was shown to be able to activate factor VIII in purified systems (17, 18, 19, 20). Factor X activated in a system containing factor IXa, factor VIII, phospholipid and Ca^{2+} causes generation of factor VIIIa that in turn will accelerate the activation of factor X. In a method used for determining factor VIIIa concentrations this effect has to be carefully avoided, since it renders factor Xa concentrations not solely dependent on factor VIIIa but also on non-activated factor VIII (fig 1). The possibility that thrombin activates factor VIII in our experiments was excluded by replacing hirudin, in a large excess over thrombin, for the somewhat less

potent thrombin inhibitor α -NAPAP. Although factor Xa is also reported to be able to feedback activate factor X (21), this could not be demonstrated in our system.

As shown in the upper panel of fig. 1, there is another phenomenon that needs consideration if factor VIIIa concentrations are to be measured in a plasma sample. Anti-proteases from plasma which is diluted up to 100-fold are apparently still able to neutralize factor Xa to a quite considerable extent. Thus factor Xa concentrations would also depend on the anti-Xa potential of plasma, a parameter that can be influenced by a variety of antithrombotic drugs.

Since these 'side reactions' both involve the active site of factor Xa, the obvious way to suppress them would be an inhibition of this active site. The conversion of chromogenic substrate should not be affected however. This was accomplished (cf, fig. 1, lower panel) by the presence of a high concentration of chromogenic substrate for factor Xa during the factor X activation stage. Factor Xa, then, is inhibited and measured in the same time.

Then, the course of absorbance in time is the result of two simultaneous reactions: the activation of factor X, and the amidolysis by factor Xa of chromogenic substrate. The latter reaction can initially be considered to be of first order, until an absorbance value of about 0.4 O.D. units.

In case of linearity between amidolysis and factor Xa concentration, the first derivative of the absorbance-time curve, dA/dt , is a function only of the factor X activation in time by the tenase complex (equation I). In all experiments performed, with activated factor VIII ranging from 0 to 100%, factor X activation was linear in time for at least 1 min. Care was taken to use only this part of the absorbance-time curve for parameter estimation (eq. III and V).

Lollar et.al. have shown that purified porcine factor VIIIa is markedly stabilized by factor IXa, PC:PS vesicles, and Ca^{2+} , which prolong the half-life time from 7 min to about 1 hour (31). As thrombin-activated factor VIII in plasma is much more unstable than its purified counterpart, so is factor VIIIa in plasma that is diluted 1 in 100 in a mixture containing factor IXa, phospholipid and Ca^{2+} . Stability is achieved for about 20 seconds, but this is followed by a rapid decrease of the factor VIIIa concentration, with a 50% reduction in less than 3 min. The question about the cause of this difference in stability of native compared to purified VIIIa remains unanswered. It seems unlikely that protein C is activated in our system, as we found that factor Va is quite stable under similar conditions (chapter 5). Furthermore, it is reported that loss of cofactor activity of factor VIIIa does not have to be concomitant with a major alteration of its primary structure (31). Perhaps the recently

published pH dependence of the stability of porcine factor VIIIa provides an explanation (34).

The shortlived stability of factor VIIIa proved sufficient to allow complete activation of all factor VIII, and thus enabled us to reliably vary the factor VIIIa concentration in order to determine how factor X activation is a function of factor VIIIa concentration. The observed linearity is in agreement with published apparent K_d values for the tenase complex, which are lower than 10 nM (20, 26), so that factor IXa in a concentration of 100 nM is predicted to saturate factor VIIIa in concentrations that prevail in our system (0 - 50 pM). Wagenvoort (22) showed that factor IXa at concentrations higher than 50 nM binds factor VIIIa optimally in a similar system.

The factor VIIIa assay we arrived at does in fact not measure factor VIIIa concentrations *per se*, but rather factor X activating potency. By choosing the proper conditions, it was made specific for factor VIIIa. All unwanted side-reactions involving factor Xa could be inhibited. Any substance present in the sample diluted in the assay mixture, which has the capability to split the chromogenic substrate (e.g. Xa that would be present in plasma) will only change the linear coefficient in the quadratic equation describing the course of absorbance in time, and will therefore not influence the estimation of the factor VIIIa concentration. Factor IXa in the presence of PS/PC vesicles and Ca^{2+} ions, slowly activates factor X. As the concentration of IXa is fixed at 100 nM this will always produce the same small (control) value of the quadratic coefficient. Furthermore, factor X activation by everything but factor VIIIa from thromboplastin activated plasma, notably the extrinsic factor X activator, the complex of factor VIIa with tissue factor, appeared to be negligible (fig. 4).

A number of reports have appeared describing assay systems of activated factor VIII in purified systems (16,18,19,20). In all of those systems extreme care should be taken to avoid activation of factor VIII by factor Xa. This could be done by careful selection of the concentration of the reactants and by limiting the time the reaction is allowed to proceed. However, when attempting to measure factor VIII activation in plasma an additional problem pops up, i.e. factor Xa inactivation by protease inhibitors. This is a phenomenon that cannot be dealt with by adaptation of concentrations and reaction times. It is all the more dangerous because it will not affect the calibration curve, where the large quantity of thrombin, added to the diluted plasma in order to activate the factor VIII present in that sample, will also titrate all available antiproteases, so that factor Xa

inactivation is precluded. As shown, the present method effectively deals with both side reactions in a relatively simple way.

Because the factor VIIIa assay is specific, sensitive and has a well defined theoretical base, it should make possible a thorough investigation of the physiology of factor VIII activation and inactivation, and its role in the overall process of coagulation in a close to physiological environment.

references

1. Hurlet-Birk Jensen A, Béguin S, Josso F. Factor V and VIII activation «in vivo» during bleeding. Evidence of thrombin formation at the early stage of hemostasis. *Path Biol* 1976;24:6-10.
2. Colman RW. The effect of proteolytic enzymes on bovine factor V. Kinetics of activation and inactivation by bovine thrombin. *Biochemistry* 1969; 4: 1438-44.
3. Lindhout MJ. Activation of bovine factor V by thrombin and a protease from Russell's viper venom (RVV). *Thromb Haemostas* 1979;42:491.
4. Pieters J, Lindhout T, Hemker HC. In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. *Blood* 1989;74:1021-4.
5. Rapaport SI, Hjort PF, Patch MJ. Further evidence that thrombin activation of factor VIII is an essential step in intrinsic clotting. *Scand J Clin Lab Invest suppl* 1965; 17: 84-8.
6. Biggs R, Macfarlane RG, Denson WE, Ash BJ. Thrombin and the interaction of factors VIII and IX. *Brit J Haemat* 1965; 11: 276-295.
7. Hemker HC, Kahn MJP. Reaction sequence of blood coagulation. *Nature* 1967;215:1201.
8. Østerud B, Rapaport SI, Schiffman S, Chong MMY. Formation of intrinsic factor X activator with special reference to the role of thrombin. *Br J Haematol* 1971;21:643-60.
9. Hultin MB, Nemerson Y. Activation of factor X by factors IXa and VIII; a specific assay for factor IXa in the presence of thrombin-activated factor VIII. *Blood* 1978;52:928-40.
10. Davey MG, Luscher EF. Actions of thrombin and other proteolytic enzymes on blood platelets. *Nature* 1967;216:857-8.
11. Bevers E, Comfurius P, van Rijn JMML, Hemker HC, Zwaal RFA. Generation of prothrombin converting activity and the exposure of phosphatidylserine at the outer surface of platelets. *Eur J Biochem* 1982;122:429-36.
12. Rapaport SI, Schiffman S, Patch MJ, Ware AG. A simple, specific one-stage assay for plasma thromboplastin antecedent activity. *J Lab clin Med* 1961;57:771-80.

13. Hardisty RM, Macpherson JC. A one-stage factor VIII (antihemophilic globulin) assay and its use on venous and capillary plasma. *Thrombos Diathes Haemorrh* 1962;7:215-29.
14. Veltkamp JJ, Drion EF, Loeliger EA. Detection of the carrier state in hereditary coagulation disorders. *Thrombos Diathes haemorrh* 1968;19:279-303 and 403-22.
15. Suomela H, Blomback B. The activation of factor X evaluated by using synthetic substrates. *Thromb Res* 1977;1:267-81.
16. Dieijen van G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor VIIIa in the activation of bovine factor X. *J Biol Chem* 1981;256:3433-42.
17. Vehar GA, Davie EW. Preparation and properties of bovine factor VIII (Antihemophilic factor). *Biochemistry* 1980;19(3):401-10.
18. Hultin MB. Role of human factor VIII in factor X activation. *J Clin Invest* 1982;69:950-5.
19. Lollar P, Knutson GJ, Fass DN. Activation of porcine factor VIII by thrombin and factor Xa. *Biochemistry* 1985;24:8056-64.
20. Neuenschwander P, Jesty J. A comparison of phospholipid and platelets in the activation of human factor VIII by thrombin and factor Xa, and in the activation of factor X. *Blood* 1988;72:1761-70.
21. Jesty J, Nemerson Y. Purification of factor VII from bovine plasma. Reaction with tissue factor and activation of factor X. *J Biol Chem* 1974;25:509-15.
22. Wagenvoord R, Hendrix H, Hemker HC. Development of a simple chromogenic factor VIII-assay for clinical use. *Haemostasis* 1989;19:196-204.
23. Hauptmann J, Kaiser B, Nowak G, Stürzebecher J, Markwardt F. Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors. *Thromb Haemostas* 1990;63(2):220-3.
24. Fujikawa K, Legaz ME, Davie EW. Bovine factor X₁ (Stuart factor). Mechanism of activation by a protein from Russel's viper venom. *Biochemistry* 1972;11(26):4892-9.
25. Fujikawa K, Legaz ME, Davie EW. Bovine factor X₁ and X₂ (Stuart factor). Isolation and characterization. *Biochemistry* 1972;11:4882-91.
26. Dieijen van G, Rijn van JLML, Govers Riemslog JWP, Hemker HC, Rosing J. Assembly of the intrinsic factor X activation complex - Interactions between factor IXa, factor VIIIa and phospholipid. *Thromb Haemost* 1985;53(3):396-400.
27. Rosing J, Tans G, Govers-Riemslog JWP, Zwaal RFA, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. *J Biol Chem* 1980;255(1):274-83.
28. Hemker HC, Willems GM, Béguin SA. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. *Thromb Haemostas* 1986;56:9-17.

29. Owren PA, Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. *Scand J Clin Lab Invest* 1951;3:201-18.
30. Wagenvoord R, Hendrix H, Soria C, Hemker HC. Localization of the inhibitory site(s) of pentosan polysulphate in blood coagulation. *Tromb Haemostas* 1988;60:220-5.
31. Lollar P, Knutson GJ, Fass DN. Stabilization of thrombin-activated porcine factor VIII by factor IXa and phospholipid. *Blood* 1984;63:1303-8.
32. Kane WH, Davie EW. Blood coagulation factors V and VIII: Structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. *Blood* 1988;71:539-55.
33. Hoyer LW. The factor VIII complex. Structure and function. *Blood* 1981;58:1-13.
34. Lollar P, Parker CG. pH-dependent denaturation of thrombin-activated porcine factor VIII. *J Biol Chem* 1990;265:1688-92.

the role of thrombin feedback reactions and factor Xa during clotting of human plasma*

summary

Minute amounts of tissue factor are sufficient to start an efficient procoagulant response. After a short lag, this results in the explosive formation of thrombin. Development of a sensitive assay, which enables to measure factor Xa, and is not hindered by the presence of thrombin at concentrations of up to 4 orders of magnitude higher, made it possible to investigate the time course of factor Xa in plasma after triggering coagulation with physiologically low concentrations of tissue factor. It was observed that the peak concentration of factor Xa, which was dependent on the tissue factor concentration, was reached within 20 seconds after triggering. This early peak value was shown to be a consequence of the presence of Tissue Factor Pathway Inhibitor (TFPI), which shuts down factor Xa generation by the complex of VIIa and tissue factor. The decrease of the factor Xa concentration in plasma was observed to be relatively slow so that a considerable amount was still present at the moment of factor V activation, even when this was artificially delayed quite considerably by the presence of a thrombin inhibitor. Part of the slow decrease seems to be due to enduring activation of factor X by intrinsic tenase, since factor Xa concentrations fall considerably faster in plasma containing no factor VIII.

A synthetic tight binding inhibitor of thrombin was used to uncouple thrombin and factor Xa generation in order to investigate the role of the feedback activation of the cofactors V and VIII. Cofactor activation was observed to be concomitant with thrombin generation and not with factor Xa generation. The kinetic behaviour of the cofactors Va and VIIIa after slow activation differed markedly due to the large difference in their stability. The minimal first order rate constant necessary for complete inhibition of cofactor activation could be estimated at approximately 2 s^{-1} .

* based on: Kessels H, Béguin S, Hemker HC. submitted for publication

Introduction

Qualitatively, the course of events during coagulation in plasma is largely known. Mostly, the reactions involved and their consequences have been deduced from observations in systems of purified proteins. Plasma, however, contains a large number of proteins, among which, presumably, a considerable number still unknown. As the number of reactions that has to be taken into account grows bigger, the effort of analysis increases rapidly. Thus, making reliable quantitative predictions about reactions in plasma is extremely difficult. Even a qualitative deduction involves significant uncertainty. Therefore, the measurement of the time course of the concentrations of coagulation enzymes in plasma during clotting may yield important clues.

Techniques for accurately measuring concentrations of activated clotting factors in plasma are the *sine qua non* of this type of experiment. This is not always a triviality. Complicating factors in general include the interference of other clotting factors that are present in plasma, the low prevailing concentrations of several coagulation enzymes, and the instability of some of these proteins. Methods for measuring the factors thrombin and Va were known beforehand (1,2). A technique for measuring the very unstable, low concentration cofactor VIIIa has been described (3, chapter 4). This chapter introduces a novel technique to measure the apparently very low concentrations of factor Xa that occur in plasma when clotting is triggered with physiologically low concentrations of tissue factor. These low concentrations, in combination with the concomitant high concentrations of thrombin that occur simultaneously in clotting plasma, made existing assays of factor Xa unusable. The main asset of this new technique is that it separates the signals due to thrombin and factor Xa.

We used the measurements of the factors Xa, Va, VIIIa and thrombin to investigate the roles they play during coagulation after triggering with relatively low concentrations of tissue factor. Although it is difficult to appoint certain concentrations of tissue factor 'in the physiological range', we feel that the concentrations we used, (0.2 to 1 pM) are more appropriate than the ones used in many standard clinical coagulation assays such as the PT. As an example, full endotoxin induced expression of tissue factor in monocytes leads to an average of about $1.7 \cdot 10^4$ molecules per monocyte (4), which is equivalent to an overall concentration of roughly 5 to 10 pM of tissue factor, assuming 200 - 400 monocytes per μl . This, however, is an extreme situation which would very likely be incompatible with life as it would give rise to a massive diffuse intravascular

coagulation. We tried to be in the important concentration domain where it is 'decided' whether or not coagulation is going to ensue.

The effect of the synthetic reversible boro-arginin type thrombin inhibitor BIBG 64 BF on clotting in human plasma was investigated as well. Its kinetic parameters are such that activation of the feedback activation of the cofactors is not completely inhibited at lower inhibitor concentrations, thus allowing for an estimation of the minimum inhibitory potency necessary to completely prevent these reactions. We further used this inhibitor to investigate the process of feedback activation of the cofactors V and VIII in greater detail.

materials and methods

materials

proteins

Bovine factors V and Va (5), X (6), Xa (7), and IXa (8) were purified as previously described. Human prothrombin and α -thrombin were purified according to (9) and (10). Human factor Xa was prepared by activation of purified factor X (11) with the factor X activating protein from Russell's Viper Venom (KabiVitrum, Stockholm, Sweden) and isolated as described for the bovine protein (12). Polyclonal rabbit anti-TFPI antibodies were a kind gift of dr. Valentin from Novo Nordisk (Denmark). Purified human factor VIII was kindly provided by dr. Spaargaren of the Central Laboratory for Blood transfusion (CLB) of Amsterdam. It contained Von Willebrand factor in a concentration about equimolar to the factor VIII concentration (40 nM).

substrates

Chromogenic substrates for thrombin were S2238 (H-D-Phe-Pip-Arg-pNA.2HCl, from Kabi Diagnostica Sweden) and SQ76 (isobutyloxycarbonyl-Pro-Arg-pNA.AcOH, from Serbio France). Factor Xa chromogenic substrate (CH₃OCO-D-Chg-Gly-Arg-pNA.AcOH) and thrombin inhibitor α -NAPAP (N- α -(2-Naphtylsulfonyl)-glycyl-D,L-amidinophenylalanine-piperidine.HCl) were obtained from Pentapharm (Basel, Switzerland).

BIBG 64 BF

The boroarginin type thrombin inhibitor BIBG 64 BF was a kind gift of dr. Th. Müller of Thomae, Biberach Germany.

buffers

Buffers used were A: 50 mM Tris-HCl, 100 mM NaCl and 0.5 g/l bovine serum albumin (Sigma), pH 7.35, B: 50 mM Tris-HCl, 100 mM NaCl, 20 mM EDTA and 0.5 g/l bovine serum albumin, pH 7.9 and C: 50 mM Tris-HCl, 175 mM NaCl, 0.5 g/l bovine serum albumin, pH 7.9, except where indicated otherwise (pH values set at 20°C). All chemicals were the highest grade commercially available.

phospholipid

Phospholipids used were dioleoyl phosphatidyl choline (DOPC) and dioleoyl phosphatidyl serine (DOPS). They were purchased from Avanti Polar Lipids. Suspensions of small unilamellar vesicles were prepared by sonication of a 20% DOPS / 80% DOPC mixture in 50 mM Tris-HCl (pH 7.9) containing 175 mM NaCl, as described (13).

plasma

Plasma was prepared (14) from blood from 10 healthy male donors, 9 volumes collected on one volume of trisodium citrate (0.13 M). Hemophilia A plasma was obtained from a single donor and it did not contain detectable factor VIII activity.

tissue factor

Recombinant tissue factor (recomboplastin) was from Baxter-Dade (Düdingen, Switzerland).

methods**triggering of coagulation**

20 μ l of buffer A, containing any substance under investigation, was added to 340 μ l of fibrinogen containing human plasma, incubated for at least 3 min at 37°C. Coagulation was triggered by addition of 40 μ l of a mixture of recombinant tissue factor (in dilutions ranging from 1/45 to 1/225, final dilutions 1/450 to 1/2250, which corresponds to concentrations of approx. 1 to 0.2 pM), CaCl_2 (167 mM, final added concentration 16.7 mM), and a 20%/80% PS/PC vesicle suspension (15 μ M, final concentration 1.5 μ M) in buffer A.

measurement of thrombin concentrations in plasma

Thrombin concentrations were measured as described before (1). Briefly, 10 μ l subsamples were drawn from clotting plasma, and diluted 50 fold in buffer B containing 200 μ M of S2238. Thrombin concentrations were inferred from the rate of change of optical density at 405 nm.

measurement of factor Va concentrations in plasma

Measurement of factor Va was carried out essentially as reported (2). In short, 10 μ l bovine factor Va containing subsamples were diluted 200 fold in buffer C containing 0.1 U/ml of standard heparin and 5 mM CaCl_2 on ice. 10 μ l of this solution was diluted in 105 μ l of a mixture containing human factor Xa (20 pM final concentration in 125 μ l), CaCl_2 (final concentration 5 mM) and phospholipid in the form of vesicles of 20% PS and 80% PC (final concentration 10 μ M). After 1 minute incubation, the prothrombinase reaction was started by addition of 10 μ l of human prothrombin to a final concentration of 200 nM. After 2 minutes, thrombin generation was halted by addition of 350 μ l buffer C containing 20 mM EDTA. The rate of change of optical density at 405 nm was recorded after addition of 25 μ l of S2238 (final concentration 200 μ M).

measurement of factor VIIIa concentrations in plasma

Factor VIIIa concentrations were measured as described (3, and chapter 5). This measurement is based on the ability of factor VIIIa to accelerate factor Xa generation by factor IXa, PS/PC vesicles and Ca^{2+} . Chromogenic substrate for factor Xa is present during factor X activation in the assay mixture, in order to competitively inhibit activation of remaining factor VIII by the generated factor Xa. Briefly, factor VIIIa containing subsamples of 5.6 μ l were added to 387.8 μ l of a mixture of CaCl_2 (final concentration 5 mM), thrombin inhibitor α -NAPAP (final concentration 1 μ M), PS/PC (20/80) vesicles (final concentration 20 μ M), and bovine factor IXa (final concentration 100 nM). After 10 seconds, 100 μ l of chromogenic substrate for factor Xa is added to a final concentration of 400 μ M. After another 10 seconds 6.7 μ l of bovine factor X are added (final concentration 333 nM) and an optical density vs. time curve is measured at 405 nm. Optical density follows a parabolic path in time. From the quadratic coefficient of the equation describing this parabola, the factor VIIIa concentration is inferred.

measurement of factor Xa concentration in plasma

The concentration of factor Xa in plasma cannot be determined using a chromogenic substrate since all available substrates for factor Xa show cross-reactivity with thrombin, which is present in much higher concentrations in clotting plasma. Instead its concentration can be measured using a prothrombinase assay, in which factor Xa is the rate limiting component. The factor Xa concentration then determines the rate of formation of thrombin. However, we could not make use of this approach because the factor Xa concentrations in plasma after triggering with dilute tissue factor remained so low that interference of thrombin from the plasma sample was much too high for a reliable measurement.

However, when a chromogenic substrate for thrombin is present during thrombin generation in the prothrombinase assay, the optical density at 405 nm increases parabolically in time. Equation I describes this parabola:

$$A(t) = A_0 + k_1 \cdot [IIa]_0 \cdot t + 1/2 \cdot k_2 \cdot k_1 \cdot [Xa] \cdot t^2 \quad (I)$$

where $[IIa]_0$ is the thrombin concentration at time zero, and $[Xa]$ is the factor Xa concentration.

k_1 and k_2 are the proportionality constants of optical density formation with thrombin, and thrombin formation with Xa, respectively. The factor Xa concentration is responsible for the 'acceleration' of the increase of optical density, and the thrombin concentration for the initial velocity of the optical density vs. time curve. Thus, the presence of thrombin in a plasma sample should not interfere with the measurement of factor Xa. That indeed the quadratic parameter is linear with the Xa concentration and the linear parameter proportional to the thrombin concentration is evident from the standard lines in fig 1.

In practice, 10 μ l subsamples were drawn from the triggered plasma and diluted 20 fold in buffer C on ice. 420 μ l of a mixture of bovine factor Va (final concentration 0.6 nM), PS/PC (20/80) vesicles (final concentration 20 μ M phospholipid) and $CaCl_2$ (final concentration 5 mM) in buffer C in a disposable microcuvette were incubated at 37°C for at least 3 minutes. To this mixture were added 25 μ l of prewarmed S2238 (final concentration 200 μ M) and 50 μ l of the diluted plasma sample (final plasma dilution 1 in 200). After an incubation of 1 minute, the prothrombinase reaction was started by the addition of 5 μ l of human prothrombin (final concentration 1.5 μ M). The time course of optical density formation at 405 nm was then recorded in a thermostated dual wavelength photometer. The optical density vs. time curves were fitted to equation I using a least squares fit procedure to a quadratic curve.

In this way, thrombin and factor Xa concentrations can be measured simultaneously, whereas thrombin concentrations of up to 4 orders of magnitude higher than factor Xa concentrations do not significantly influence the obtained factor Xa concentrations.

measurement of the kinetic constants of BIBG 64 BF

Progress curves for BIBG 64 BF with thrombin and factor Xa were recorded as follows: Thrombin or factor Xa were diluted in buffer C to final concentrations of 50 pM, and warmed at 37°C. After 5 minutes, chromogenic substrate was added, 15 seconds later followed by inhibitor. Both chromogenic substrate and inhibitor concentrations were varied. Optical density at 405 nm was then recorded as a function of time. For

thrombin we used the chromogenic substrate SQ76 for which thrombin has a lower k_{cat} (8.65 s^{-1} , $K_m = 26.6 \mu\text{M}$) compared to S2238 (128 s^{-1} , $K_m = 5.1 \mu\text{M}$), so that progress curves could continue for a longer time period without a significant decrease in substrate concentration.

The recorded optical density vs. time curves were fitted to the equation (15):

$$P(t) = v_s \cdot t + (v_0 - v)(1 - e^{-kt}) / k \quad (\text{II})$$

where $P(t)$ is the product (pNA) formation in time, and v_0 , v_s and k represent the initial velocity, the steady-state velocity and the apparent first-order rate constant respectively. Values for k_{on} were estimated by fitting to

$$k(S, I) = k_{off} + \frac{k_{on} \cdot I}{1 + S/K_m} \quad (\text{III})$$

(15,16) with S being the concentration of chromogenic substrate, and I the inhibitor concentration.

In case of thrombin inhibition, the k_{off} values were too low to be reliably obtained in this manner. Instead k_{off} was obtained from the following relationship between v_s and v_0 (16):

$$v_s = v_0 \cdot \frac{k_{off}}{k} \quad (\text{IV})$$

K_i can then be calculated as:

$$K_i = k_{off} / k_{on} \quad (\text{V})$$

Additionally, the steady state velocity was determined by linear regression on a late part of the optical density time curve, and K_i was also estimated from:

$$v_s(S, I) = v_{max} \cdot \frac{S}{S + K_m (1 + I / K_i)} \quad (\text{VI})$$

figure 1. standard lines for the measurement of factor Xa in plasma.
upper graph: The quadratic coefficient of the parabola describing the measured time curves of optical density, plotted as a function of the concentration of pure human factor Xa added to the prothrombinase assay.
lower graph: The linear coefficient of the parabola describing the measured time curves of optical density vs. the concentration of human α -thrombin added to the prothrombinase assay.

results

factor Xa assay in plasma

Fig. 1 shows the standard lines for the factor Xa assay as described in the materials and methods section with purified human thrombin and factor Xa. Clearly, the fitted linear coefficient of the parabola describing the optical density vs. time curve is linearly proportional with thrombin concentrations up to 2 nM in the cuvette. The quadratic coefficient is linear with factor Xa concentrations in the range of 0 to 2.5 pM. Pure

figure 2. the effect of thrombin on the 'acceleration' of optical density in time.

The quadratic coefficient of the parabola describing the measured time curves of optical density as a function of the concentration of pure human α -thrombin added to the prothrombinase assay.

human thrombin has a small, as yet unexplained effect on the quadratic coefficient as well, as shown in fig. 2. When measuring factor Xa concentrations in plasma, the quadratic coefficient was corrected for this effect. Also, the linear coefficient is affected by the time interval (t_{lag}) between starting the prothrombinase reaction in the cuvette and starting the recording of the optical density time curve. The actual linear coefficient (lc) is obtained from the fitted linear coefficient (lc_{app}) as follows:

$$lc = lc_{app} - 2 \cdot qc \cdot t_{lag} \tag{VII}$$

where qc is the quadratic coefficient.

figure 3. factor Xa and thrombin generation in plasma triggered with varying amounts of tissue factor.

Coagulation was triggered by addition of Ca^{2+} (16.7 mM), PS/PC vesicles (1.5 μ M), and tissue factor in a dilution of 1/450 (○), 1/900 (●), and 1/ 2250 (□). The time courses of the concentrations of factor Xa (upper panel) and thrombin (lower panel) were measured.

triggering plasma with low concentrations of recombinant thromboplastin

The time courses of the concentrations of factor Xa in plasma were measured after triggering with three concentrations of recombinant tissue factor. Tissue factor in a final dilution of 1 in 450, about 1 pM, gives rise to a clotting time of 40 seconds. We also used tissue factor dilutions of 1 in 900 and 1 in 2250. Fig. 3 shows that the peak of the factor Xa concentration decreases as a function of the tissue factor concentration. There is, however, no appreciable delay of factor Xa generation, since the peak amount of factor Xa is always measured within 20 seconds after triggering. The peak amount of thrombin is also decreased but not as much as for factor Xa. The burst of thrombin generation is delayed for about two minutes with a tissue factor dilution of 1 in 2250 (equivalent to a concentration of 0.2 pM).

The rate of decay of factor Xa in plasma is relatively slow so that it remains available for more than 10 minutes.

When no tissue factor is present, factor Xa may be formed via the intrinsic route. That this pathway does not play a role initially is shown in fig 4, where factor Xa is not detectable for over 10 minutes.

figure 4. factor Xa generation in plasma without triggering with tissue factor. Factor Xa concentrations in plasma were measured after addition of Ca^{2+} (10.7 mM) and PS/PC (20/80) vesicles (1.5 μM), with (O), and without (●) tissue factor (1 pM).

The contribution of the alternative extrinsic pathway, or 'Josso loop', was investigated by measuring factor Xa generation in plasma from a patient with Hemophilia A with and without addition of the normal plasma concentration of purified human factor VIII (fig. 5). The peak concentration of factor Xa was found to be the same in both cases, but the factor Xa concentrations decreased markedly more rapid when no factor

figure 5. factor Xa and thrombin generation in hemophilia A plasma with and without purified human factor VIII. Factor Xa (upper part) and thrombin (lower part) concentrations were measured in plasma from a hemophilia A patient with (●) and without (○) added human factor VIII in a final concentration of 0.4 nM.

figure 6. factor Xa generation in plasma containing an anti-TFPI antibody. Coagulation was triggered by addition of tissue factor (1/2250) to plasma with (●) and without (○) 24 µg/ml of a rabbit polyclonal anti-TFPI antibody.

VIII was present. The thrombin peak concentration, as determined from the linear parameter of the time-curve of optical density, was decreased by 35%.

The effect of an anti-TFPI antibody on the generation of factor Xa is depicted in fig. 6. Without functional TFPI the factor Xa peak is not reached within the first half minute, but rises several minutes more to a maximum that is more than 10 times higher.

kinetic parameters of BIBG 64 BF

The kinetic parameters of the slow binding thrombin inhibitor BIBG 64 BF were determined as described in the materials and methods section. For thrombin, the concentrations of SQ76 and BIBG 64 BF were varied from 0 to 400 µM and from 0 to 10 nM. For factor Xa the concentrations of chromogenic substrate and BIBG 64 BF ranged from 0 to 600 µM and from 0 to 100 nM respectively. Table 1 shows that agreement of the K_i values determined from the steady state velocities with the K_i value estimated from the k_{on} and k_{off} values is reasonable for thrombin and excellent for factor Xa. BIBG 64 BF is a potent inhibitor of thrombin with a K_i of around 100 pM. The association with factor Xa is more than 2 orders of magnitude weaker. The low k_{off} values for both thrombin and

factor Xa make that BIBG 64 BF has the kinetic characteristics of a slow binding type inhibitor.

	thrombin	factor Xa
$k_{on} (M^{-1}s^{-1})$	$3.0 \cdot 10^6$	$1.1 \cdot 10^5$
$k_{off} (s^{-1})$	$2.5 \cdot 10^{-4}$	$3.5 \cdot 10^{-3}$
$k_{on} / k_{off} (M)$	$8.3 \cdot 10^{-11}$	$3.1 \cdot 10^{-8}$
$K_i (M)$	$1.4 \cdot 10^{-10}$	$3.3 \cdot 10^{-8}$

table 1. kinetic parameters of BIBG 64 BF

The values for k_{on} , k_{off} and K_i of BIBG 64 BF were determined as described in the materials and methods section.

Effect of BIBG 64 BF in plasma

A range of concentrations of BIBG 64 BF was incubated in plasma before triggering with tissue factor in a final dilution of 1 in 450. fig. 7 to 10 show the influence of this inhibitor on the concentrations of thrombin and the factors Va, VIIla, and Xa. Increasing concentrations of this inhibitor induce a delay of thrombin and factor Va and VIIla formation,

figure 7. thrombin generation in plasma containing various concentrations of BIBG 64 BF.

Thrombin generation was measured in plasma containing BIBG 64 BF in a concentration of 200 nM (○), 300 nM (■), 400 nM (□), 500 nM (▲), and 750 nM (△), or containing no BIBG 64 BF (●). Coagulation was initiated with Ca^{2+} (16.67 mM), PS/PS (20/80) vesicles (1.5 μ M) and tissue factor (1/450).

whereas factor Xa formation is not delayed. This delay seems to increase exponentially with the inhibitor concentration. In concentrations of up to 500 nM of BIBG 64 BF, an initial slow rate of activation of factor Va and factor VIIIa is detectable. These initial rates are reciprocally proportional to the inhibitor concentration as depicted in the inset of fig. 8 and 9. After the slow initial activation, factor Va concentrations increase burst-like to a peak that is dependent on the concentration of BIBG 64 BF. Inactivation of Va thereafter is slow. Factor VIIIa in contrast reaches a peak that is inversely proportional to the inhibitor concentration. Its low plasma

figure 8. factor Va generation in plasma containing various concentrations of BIBG 64 BF.

In plasma containing BIBG 64 BF in a concentration of 200 nM (○), 300 nM (■), 400 nM (□), 500 nM (▲), and 750 nM (△), or containing no BIBG 64 BF (●), coagulation was initiated with Ca^{2+} (16.67 mM), PS/PS (20/80) vesicles (1.5 μM) and tissue factor (1/450).

concentration and its fast decay are responsible for this behaviour.

Thrombin is delayed to the same extent as are factor Va and factor VIIIa. Like factor Va thrombin increases burst-like after an initial slow generation. Thrombin peak values decrease as the amount of inhibitor increases. Factor Xa peaks are also inhibited somewhat by BIBG 64 BF. At BIBG 64 BF concentrations of 750 nM and 1 μM both thrombin and the activated cofactors are not measurable for more than 20 minutes. Factor Xa, however, still reaches its peak concentration within 20 seconds after triggering.

figure 9. factor VIIIa generation in plasma containing various concentrations of BIBG 64 BF.

In plasma containing BIBG 64 BF in a concentration of 200 nM (○), 300 nM (■), 400 nM (□), 500 nM (▲), and 750 nM (△), or containing no BIBG 64 BF (●), coagulation was initiated with Ca^{2+} (16.67 mM), PS/PS (20/80) vesicles (1.5 μM) and tissue factor (1/450).

figure 10. factor Xa generation in plasma containing various concentrations of BIBG 64 BF.

In plasma containing BIBG 64 BF in a concentration of 200 nM (○), 400 nM (■), and 1000 nM (□), or containing no BIBG 64 BF (●), coagulation was initiated with Ca^{2+} (16.67 mM), PS/PS (20/80) vesicles (1.5 μM) and tissue factor (1/450).

Discussion

In-vivo clotting is usually initiated upon vessel-wall damage. The clotting factors circulating in blood plasma are then exposed to tissue factor present on the cell membranes of cells of the perivascular tissues. Procoagulant surfaces are provided by damaged cells and activated platelets. In the experiments described in this chapter we investigated the initial course of events in human plasma after addition of sub-picomolar concentrations of tissue factor. A phospholipid surface was provided by a limited amount of small procoagulant phospholipid vesicles. We used these reaction conditions in order to mimic to a certain extent the conditions prevailing during clotting *in-vivo*. Although it will be clear that our environment is certainly not equal to the *in vivo* situation, it seems a necessary step up from measurements in systems of purified proteins.

measurement of factor Xa

Triggering coagulation in plasma with low amounts of tissue factor (< 1 pM) results in relatively low concentrations of factor Xa in plasma. These concentrations are too low to be measured directly with chromogenic substrates for factor Xa. This is because the binding affinity and the catalytic constant (k_{cat}) of known chromogenic factor Xa substrates are relatively low. Also, those substrates in general are not entirely specific for factor Xa. Most are converted by thrombin as well. Thus, the high concentrations of thrombin that prevail during coagulation would disturb such measurements. Determining factor Xa in a two-stage prothrombinase assay was also found to be not feasible for concentrations of factor Xa in plasma below 0.5 nM. Again, this is mainly because the low plasma factor Xa concentration prohibits a high dilution of plasma in the prothrombinase assay. This gives thrombin generated in the plasma sample the opportunity to interfere with the assay. Our present assay combines the two stages of the prothrombinase assay into one step. Both formation of thrombin by prothrombinase and the liberation of pNA from S2238 by thrombin occur simultaneously. The linear dependencies of the thrombin formation rate on the factor Xa concentration, and the amidolytic activity on the thrombin concentration, make that the optical density increases according to a quadratic equation. The factor Xa concentration shows up in the quadratic coefficient of this equation where it is separated from the thrombin concentration which appears in the linear coefficient. Thrombin concentrations of several orders of magnitude higher than the factor Xa concentration do not influence the measurement of factor Xa in this case, so that a low dilution of a plasma subsample in the prothrombinase assay becomes possible.

factor Xa generation in plasma

Factor Xa formation by the complex of tissue factor and factor VIIa on a phospholipid surface is a very efficient process. Factor Xa formation can be detected immediately after addition of tissue factor to plasma and reaches its peak within 20 seconds. The fact that at that moment only a fraction (25 to 200 pM) of the available factor X (180 nM) has been converted, in combination with the relatively slow inactivation of factor Xa afterwards, strongly suggests that factor Xa generation is halted or severely inhibited from that point on. Indeed, addition of an anti-TFPI antibody causes the factor Xa concentration to rise for several minutes longer until it reaches a plateau at a concentration that is more than one order of magnitude higher. Thus TFPI appears to play a very important role in shutting off the VIIa/TF activity early in the coagulation process.

Initially no factor Va is present, and factor Xa alone will have to activate enough thrombin to cause factor V activation. The time necessary for sufficient thrombin formation is dependent on the concentration of factor Xa, and thus on the concentration of tissue factor added. During this initial period, factor Va is the limiting factor of prothrombinase activity.

Factor Xa has a high affinity for lipid-bound factor Va (17). After factor V activation by thrombin in plasma triggered with low tissue factor concentrations, the factor Va concentrations are about two orders of magnitude higher than the factor Xa concentrations. Thus, virtually all factor Xa will be bound to factor Va, which implicates that the rate of thrombin generation is determined by the factor Xa concentration at that moment. This amount is directly dependent on the tissue factor concentration used to trigger coagulation. Therefore, inhibition of factor Xa by any means would lead directly to a decrease in the rate of thrombin generation. This is confirmed by the experiments with the inhibitor BIBG 64 BF. The factor Xa concentration at the moment of the thrombin burst is about 190 pM in the absence of inhibitor, and about 90 pM in the presence of BIBG 64 BF in a concentration of 400 nM. The maximal thrombin generation rates, calculated as described in chapter 4, are 348 nM/min for the control experiment, and 190 nM/min in the presence of BIBG 64 BF.

Another point of consideration in this should be the presence of phospholipid vesicles in our plasma samples. We chose not to use saturating amounts of phospholipid vesicles in order to stay reasonably close to the *in-vivo* situation. 1.5 μ M of phospholipid bilayer corresponds to about 3 cm²/ml of phospholipid surface. Blood platelets in a 'normal' concentration of $250 \cdot 10^9$ / l, make for a surface of about 15 cm²/ml. Thus, we may seem to underestimate the physiological phospholipid concentration somewhat. However, platelets, when activated under more or less physiological conditions using thrombin and collagen, attain a

phosphatidyl serine content of no more than 5% in the outer mono-layer of their cell membrane (18), as compared to 20% PS in our phospholipid vesicles. A concentration of $1.5 \mu\text{M}$ of phospholipid in small vesicles with diameters $\leq 20 \text{ nm}$ results in a vesicle concentration of about 300 pM . It has recently been shown that thrombin formation by the prothrombinase complex is so efficient that a single prothrombinase complex almost instantaneously converts all prothrombin molecules landing on a small phospholipid vesicle (19). Therefore, the concentration of phospholipid used in our experiments may start limiting the activity of prothrombinase if higher factor Xa concentrations are reached.

This has implications for the anti factor Xa activity of heparins. It has been shown that the prothrombinase activity in conditions very similar to the ones prevailing in our experiments is not or hardly inhibited by the presence of standard heparin up to concentrations of 0.05 U/ml (20). Combined with the low, and probably limiting concentrations of factor Xa we observed, this would indicate that the factor Xa generated in plasma is not readily inhibited by these concentrations of standard heparin. However, Pieters et.al. found that factor Xa concentrations can be inhibited considerably without much influence on prothrombinase activity in plasma (2). Considering the high concentrations factor Xa reached in their experiments it seems likely that the concentration of phospholipid has been rate limiting. Unfortunately, since human brain thromboplastin was employed as the source of phospholipid, the concentration and composition of the phospholipid were not well defined.

The observed slow decrease of factor Xa concentrations in plasma is partly explained by the action of the alternative extrinsic pathway, or Josso loop, the activation of factor IX by the factor VIIa/tissue factor complex (21,22), as shown in fig 5. Without the presence of factor VIIIa the initial decrease in the factor Xa concentration is markedly more rapid. Thus it is clear that the Josso loop contributes significantly to the concentration of factor Xa in plasma. The higher factor Xa concentrations in the presence of added factor VIII also lead to higher thrombin concentrations.

Even in hemophilia A plasma, decrease of factor Xa concentrations is relatively slow, with a halflife time of more than two minutes. It has often been shown that factor Xa bound in a prothrombinase complex is protected from activation by ATIII and ATIII-heparin (23,24,25). Even the presence of non-activated factor V and a phospholipid surface is reported to bring some protection (26). The concentration of factor Xa seems to level off towards the end of the curve. This might be explained by continuing factor X activation by the intrinsic tenase complex. However, we cannot completely exclude the possibility that part of the factor Xa bound to TFPI

Prothrombinase complex containing factor Xa is inhibited by TFPI. Inhibition of factor Xa will decrease the initial rate of the prothrombin

is liberated from this inhibitor during the prothrombinase assay, when the factor Xa containing sample is diluted 200 fold.

BIBG 64 BF

BIBG 64 BF is a synthetic boroarginine containing peptide. Peptides of this type were recently shown to be efficient, slow binding inhibitors of thrombin with a high degree of selectivity (27). The kinetic characteristics of BIBG 64 BF do not deviate much from those reported for other peptides of this kind (27). The k_{on} value for the association between BIBG 64 BF and thrombin is such that initially, with BIBG 64 BF in excess at a concentration of 400 nM and thrombin concentrations being very low, the first order decay constant of thrombin to this inhibitor is 1.2 s^{-1} , or 72 min^{-1} , which is equivalent to a half-life time for thrombin of a little more than half a second. Furthermore, the complex of thrombin with BIBG 64 BF is essentially irreversible at the time scale of our experiments, with a half-life time of the complex of about 46 minutes. Still, thrombin concentrations can be measured very soon after addition of tissue factor to plasma in the presence of 400 nM of inhibitor. Also the concentrations of the cofactors Va and VIIIa slowly raise after triggering plasma. The rate of these activations is dependent on the concentration of inhibitor initially added. Thus, BIBG 64 BF is not fast enough to keep thrombin from activating the cofactors to a small extent. Small amounts of complete prothrombinase then form so that thrombin formation is proceeding somewhat more efficient. When all BIBG 64 BF has been 'titrated' away by thrombin generated in this way, the burst of thrombin generation may occur. Hirudin, a specific thrombin inhibitor with a more than ten fold higher k_{on} does not let any thrombin 'leak' through its inhibition (28).

cofactor activation

It is clear from the experiments with BIBG 64 BF, as well as from the experiments with very low tissue factor concentrations, that cofactor activation is always concomitant with the burst of thrombin generation so that, as reported earlier by Pieters et.al. (28), factor Xa indeed does not appreciably activate the cofactors *in vivo*. It can, however, on the basis of the experiments described in this chapter, and of the experiments described by Pieters not completely be excluded that an initial activation of traces of the cofactors by factor Xa may occur, which then might lead to a somewhat faster thrombin generation than by factor Xa alone followed by full-scale cofactor activation by thrombin. In that case very little activated factor VIII ($< 2\text{ pM}$, the detection limit of the factor VIIIa assay) must be enough to cause detectable factor X activation by intrinsic tenase.

Factor Va and factor VIIIa are structurally very much alike (29). However, functionally they differ in two important ways. First, factor V is present in a much higher concentration than factor VIII, and second, factor Va is much more stable in plasma than factor VIIIa. This has the effect that factor Va concentrations reach much higher values than factor VIIIa concentrations do, and that those concentrations remain available for a much longer time. This difference is clearly demonstrated by fig. 8 and 9. Increasing concentrations of the inhibitor BIBG 64 BF lead to decreasing initial rates of activation of these cofactors, as shown in the insets of fig. 8 and 9. In the case of factor Va this has no further effect than postponing the burst of factor Va formation. In the case of factor VIIIa however, also the amount of activated cofactor generated decreases. By the time of the Va burst, all factor VIII has been activated in the case of higher inhibitor concentrations, so that hardly any factor VIIIa is detectable.

When no heparin is present factor IXa in plasma does not decrease appreciably (30). Thus factor IXa 'waits' for factor VIIIa to become available, just as factor Xa waits for factor Va. In contrast to the prothrombinase situation, the amount of intrinsic tenase that is formed in plasma is probably not dependent on the concentration of enzyme (factor IXa) but on the concentration of cofactor, since its concentrations remain well below 1 nM.

the emerging picture

The experiments described in this chapter give evidence to several points relevant to coagulation in plasma. First, factor Xa is present immediately after addition of tissue factor to plasma. The height of its peak, which it reaches within 20 seconds, is dependent on the tissue factor concentration. In the case of high tissue factor dilutions, as used in our experiments, and likely occurring in physiological situations, the maximal concentration of factor Xa is low compared to concentration of unactivated enzyme. Second, the decrease of factor Xa concentrations in plasma is slow, so that enough factor Xa is available when factor Va is generated later on in the coagulation process, even when this moment has been artificially delayed by the presence of a thrombin inhibitor. This slow decrease is at least partly caused by the enduring activation of factor X by intrinsic tenase. Third, the initial rate of activation of thrombin, which is dependent on the factor Xa concentration, determines the initial rate of activation of the cofactors. Therefore, the amount of tissue factor added, indirectly determines the lag time of explosive thrombin formation. Fourth, the amount of factor Xa is limiting in the formation of the prothrombinase complex during the burst of thrombin formation. Thus, inhibition of factor Xa will decrease the maximal rate of the prothrombin

converting enzyme. However, phospholipid may, under slightly different conditions, such as a higher concentration of tissue factor, take factor Xa's place as the limiting factor. Fifth, a slow rate of activation of factor VIII results in a lower maximal concentration of factor VIIIa. This may lead to a lower concentration of the intrinsic tenase enzyme.

The availability of accurate techniques to determine factor Xa, factor Va, and factor VIIIa concentrations in plasma has given us the opportunity to start investigating the coagulation process in plasma in greater detail. Much more experimentation is necessary, however, to elucidate the roles of the many factors that may play important roles in the intricate blood coagulation reaction.

Acknowledgements

We would like to thank 'De Broeders van Den Beijaard' for their generous donation of blood.

References

1. Hemker HC, Willems GM, Béguin SA. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. *Thromb Haemostas* 1986;56:9-17.
2. Pieters J, Lindhout T. The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin activated plasma. *Blood* 1989;74:1021-4.
3. Kessels H, Béguin S, Wagenvoord R, Hemker HC. A method for measuring activated factor VIII in plasma. *Thromb Haemost* 1990;66(4):430-4.
4. Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. *Thromb Haemostas* 1991;66(1):67-79.
5. Lindhout T, Govers-Riemslog JWO, Waart van de P, Hemker HC, Rosing J. Factor Va - factor Xa interaction. Effects of phospholipid vesicles of varying composition. *Biochemistry* 1982;21:5494-502.
6. Fujikawa K, Legaz ME, Davie EW. Bovine factor X₁ and X₂ (Stuart factor). Isolation and characterization. *Biochemistry* 1972;11:4882-91.
7. Fujikawa K, Legaz ME, Davie EW. Bovine factor X₁ (Stuart factor). Mechanism of activation by a protein from Russel's viper venom. *Biochemistry* 1972;11(26):4892-9.
8. Wagenvoord R, Hendrix H, Soria C, Hemker HC. Localization of the inhibitory site(s) of pentosan polysulphate in blood coagulation. *Tromb Haemostas* 1988;60:220-5.

9. Hendrix H, Lindhout T, Mertens K, Engels W, Hemker HC. Activation of human prothrombin by stoichiometric levels of staphylocoagulase. *J Biol Chem* 1983;258:3637-44.
10. Miller-Andersson M, Gaffney PJ, Seghatchian MJ. Preparation and stability of a highly purified human thrombin standard. *Thromb Res* 1980;20:109-22.
11. Mertens K, Bertina RM. Pathways in the activation of human coagulation factor X. *Biochem J* 1980;185:647-58.
12. Lindhout T, Kop-Klaassen BHM, Hemker HC. Activation of decarboxyfactor X by a protein from Russell's viper venom. Purification and partial characterization of activated decarboxyfactor X. *Biochim Biophys Acta* 1978;533:327-41.
13. Rosing J, Tans G, Govers-Riemslog JWP, Zwaal RFA, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. *J Biol Chem* 1980;255(1):274-83.
14. Béguin S, Kessels H, Dol F, Hemker HC. The consumption of antithrombin III during coagulation, its consequences for the calculation of prothrombinase activity and the standardisation of heparin activity. *Thromb Haemostas* 1992;68(2):136-42.
15. Morrison JF, Walsh CT. The behavior and significance of slow-binding enzyme inhibitors. *Adv Enzymol*, 1988;61:201-301.
16. Williams JW, Morrison JF. The kinetics of reversible tight binding inhibition. *Methods in enzymology*, 1979;63:437-67.
17. Giesen PLA, Willems GM, Hemker HC, Hermens WTh. Membrane-mediated assembly of the prothrombinase complex. *J Biol Chem* 1991;266(28):18720-5.
18. Bevers E, Comfurius P, van Rijn JMM, Hemker HC, Zwaal RFA. Generation of prothrombin converting activity and the exposure of phosphatidylserine at the outer surface of platelets. *Eur J Biochem* 1982;122:429-36.
19. Giesen PLA, Willems GM, Hermens WTh. Production of thrombin by the prothrombinase complex is regulated by membrane-mediated transport of prothrombin. *J Biol Chem* 1991;266(3):1379-82.
20. Béguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. *Thromb Haemostas* 1988;60:457-62.
21. Josso F, Prou-Wartelle O. Interaction of tissue factor and factor VII at the earliest phase of coagulation. *Thromb Diath Hemorrh* 1965;171:35-44.
22. Østerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation. *Proc Natl Acad Sci USA*. 1977;74(12):5260-4.
23. Lindhout T, Baruch D, Schoen P, Franssen J, Hemker HC. Thrombin generation and inactivation in the presence of antithrombin III and heparin. *Biochemistry* 1986;25:5962-9.
24. Ellis V, Scully MF, Kakkar VV. Inhibition of prothrombinase complex by plasma proteinase inhibitors. *Biochemistry* 1984;23:5882-7.

25. Schoen P, Lindhout T, Willems G, Hemker HC. Antithrombin III-dependent anti-prothrombinase activity of heparin and heparin fragments. *J Biol Chem* 1989;264:10002-7.
26. Barrowcliffe TW, Havercroft SJ, Kemball-Cook G, Lindahl U. The effect of Ca^{2+} , phospholipid, and factor V on the anti-factor Xa activity of heparin and its high affinity oligosaccharides. *Biochem J* 1987;243:31-7.
27. Kettner C, Mersinger L, Knabb R. The selective inhibition of thrombin by peptides of boroarginine. *J Biol Chem* 1990;265:18289-97.
28. Pieters J, Lindhout T, Hemker HC. In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. *Blood* 1989;74:1021-4.
29. Kane WH, Davie EW. Blood coagulation factors V and VIII: Structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. *Blood* 1988;71:539-55.
30. Pieters J, Willems G, Hemker HC, Lindhout T. Inhibition of factor IXa and factor Xa by antithrombin III / heparin during factor X activation. *J Biol Chem* 1988;263(30):15313-5.

References

1. ...
2. ...
3. ...
4. ...
5. ...
6. ...
7. ...
8. ...
9. ...
10. ...
11. ...
12. ...
13. ...
14. ...
15. ...
16. ...
17. ...
18. ...
19. ...
20. ...
21. ...
22. ...
23. ...
24. ...

chapter 6

analysis of bleeding from bleeding time wounds*

summary

The bleeding time test suffers from a large variability which sheds serious doubt on its clinical usefulness. It is dependent on many parameters, which is not favourable for its use as an epidemiological test, or as an indicator of pharmacologically important changes in haemostasis. By using a strictly 'protocolled' technique which measures the rate of bleeding in time, instead of bleeding time alone, we tried to minimize instrumental variability as much as possible. This also allowed us to assess the usefulness of other parameters, such as the amount of blood lost. Our results indicate that of the parameters that can be determined from the obtained bleeding patterns, the bleeding time has the lowest variability. This variability however, be it inter or intra-individual, is still very large and in the same range as reported earlier in the literature. The high variability ensures a relatively high degree of overlap of the bleeding times between two populations, unless they are very far apart. Since bleeding time values are very likely dependent on a number of parameters that cannot be controlled, the power of the bleeding time as a clinical or pharmacological test is small and arguably not prone to much improvement by changing the technique of measuring.

introduction

Bleeding times are used for diagnostic and prognostic purposes since their first description at the beginning of the this century by Milian (1,2,3). Many variations were introduced into the technique of measuring bleeding times (reviewed in ref. 4), which already hints at a generalized dissatisfaction with the technique. The modifications include different localisations of the skin puncture, including the finger, the earlobe and the volar side of the fore arm. The instruments used to make skin cuts range

* based on: Kessels H, Kester ADM, Hemker HC. submitted for publication

from needles to various kinds of lancets often placed in some sort of mechanical stylet set to obtain a uniform depth. Sometimes, the instrument is not reported (5). The well known bleeding time according to Ivy (6) is measured at the volar surface of forearm. He was the first to increase venous pressure by inflating a blood-pressure cuff around the upper arm to a pressure of 40 mm Hg. Mielke (7) designed a template system in order to obtain bleeding time wounds of standard size and depth. Sutor (8) described a technique for continuous measurement of the rate of blood loss from bleeding time wounds, which allowed the assessment of more parameters than bleeding time alone. Rather interestingly, Milian, in his original first description of a bleeding time, also attempted to give more information than bleeding time alone, as he noted the rate of bleeding and the coagulation time of the individual drops of blood.

The reasons for the large number of modifications made to the bleeding time test are its large variability and poor reproducibility. These were partly due to poor standardisation of the test, and subsequent differences between labs and operators (4). The difficulty to reproducibly make bleeding time wounds of the same dimensions on identical locations has often led to the recommendation to have bleeding times of the same patient be recorded by the same operator. Not all of this variability is likely to stem from instrumental reasons however. A large number of uncontrollable variables do have an influence on the bleeding time as well. Among these may be differences in thickness of the epidermis, local skin vascularisation, haematocrit, number and function of platelets, medication and the state of the coagulation system.

No matter where high variability and mediocre reproducibility come from, they do have their influence on the power of the bleeding time as a diagnostic, pharmacological and epidemiological test. They lead to overlapping ranges of bleeding times of populations whose average value may be relatively far apart, and thus to decreased sensitivity and specificity of the test.

Our approach was to measure bleeding times in such a way that the maximum amount of information is obtained. For this we measured bleeding patterns, continuous recordings of the rate of bleeding from bleeding time wounds, using a technique based on a method originally described by Sutor et.al. (8), and later modified by Bowie et.al.(9). Blood, as it flows from the wound is taken up in a waterstream through a circuit of tygon tubing, and lead to a photometer, where the measured absorbance indicates the bleeding rate. We then investigated whether we were able to improve upon the variability of the present day bleeding time measurement, and whether other parameters of the bleeding pattern might be useful.

materials and methods

volunteers

Volunteers had a mean age of 37.8 ± 9.0 years, 10 were male, 7 were female. None of them used any medication in the week preceding the experiment.

bleeding time wounds

A standard bleeding time wound is made on the volar surface of the forearm at about two thirds between the wrist and the elbow, and parallel to the antecubital crest, using a Knoll automatic lancet loaded with a Swann-Morton blade no.11. The depth of the incision is set to 2.5 mm, which typically results in an actual depth of 3/4 to 1 mm as estimated from the width of the wound in relation to the shape of the blade. Superficial veins and scar tissue are avoided. No pressure is applied on the automatic lancet.

bleeding pattern recording

A roller pump propagates sterile distilled water containing 0.05 (v/v) tween 20 (Sigma Chemical Co, St Louis USA) through a circuit of tygon® PVC tubing (fig. 1). A small lucite chamber with a longitudinal aperture on one side is part of the circuit. Immediately after the bleeding time wound has been made, the chamber is placed on top, so that blood from the wound is taken up into the fluid flowing through the chamber. The stream is interrupted by airbubbles at two second intervals in order to prevent tailing of the erythrocytes. After the chamber, the stream passes through about 1.5 m of tubing before entering a debubbling cuvette, in order to lyse the erythrocytes. Optical density is read at 546 nm, using a single wavelength photometer. The flow rate of the water stream over the bleeding time wound was $46 \mu\text{l/s}$. Airbubbles entered at a rate of $26 \mu\text{l/s}$. The water stream was diluted further in the system, such that the flow rate increased to $139 \mu\text{l/s}$. The two second interval time between the airbubbles poses a theoretical limit to the time resolution of the bleeding time monitor. However due to some unavoidable mixing before the entrance of air bubbles and after debubbling in the cuvette, the actual time resolution of the system is a little worse than this 2 s theoretical limit.

figure 1. circuit diagram of the automated bleeding time monitor.

Tubing of specified diameters was used to flow distilled water over a bleeding time wound. Airbubbles are pulled into the stream immediately after the chamber, which is placed over the wound. A dilution step reduces optical density to measurable values. Before entering the debubbling cuvette, 1.5 meters of tubing cause a time delay long enough to lyse the erythrocytes.

Diameters of the various tubes in the roller pump were chosen such (fig. 1) that a slight negative pressure was present in the tubing. This serves two purposes. First, it is the driving force for air bubbles to enter the circuit. Second, it helps keeping the chamber well in place on the bleeding time wound. The concentration of tween 20 used does not have an influence on the haemostatic process, while reducing surface tension of the distilled water so as to facilitate the flow of the water through the circuit. A mild venostasis is created using a manometer cuff on the upperarm at a pressure of 40 mmHg.

bleeding pattern analysis

The following parameters were extracted from the recorded optical density time curve: The bleeding time was defined as the time between making the bleeding time wound and the moment when the optical density value dropped below 20 mOD units for the last time. Blood loss was calculated as the area under the optical density vs. time curves, and converted to μg of hemoglobin using a standard line of hemoglobin concentration vs optical density. Using the blood hemoglobin concentration of each volunteer, the volume of blood lost was found. Peak blood flow was determined from the highest point in the optical density vs. time curve, and average blood flow was calculated as the amount of blood lost divided by the bleeding time.

For each volunteer, four bleeding patterns were recorded, two on their left and two on their right arms. They were performed in random sequence and with minimal delay between them. All bleeding pattern determinations were carried out by the same operator.

results

Bleeding was quantitated in 17 healthy volunteers. Curves obtained show highly irregular patterns of bleeding with bumps and waves of all

figure 2. example of a bleeding pattern.

The bleeding pattern was recorded using the automated bleeding time monitor, as described in the materials and methods section. Optical density values were converted into blood flow (in $\mu\text{l} / \text{min}$) using the blood hemoglobin concentration of the volunteer and the flow rate of distilled water through the tubing circuit.

frequencies, with no clear tendency to any standard or typical pattern. Fig. 2 shows an example of a bleeding pattern thus obtained.

None of the parameters determined from these bleeding patterns appeared to be normally distributed. Log transformed data tends to adhere better to the Gaussian distribution, which is confirmed by the Shapiro-Wilk W-statistic (table 1).

parameter	W-statistic	significance level
bleeding time	0.9547	0.0376
blood loss	0.7994	0.0000
peak flow	0.8641	0.0000
average flow	0.8847	0.0000
log bleeding time	0.9636	0.1226
log blood loss	0.9786	0.5764
log peak flow	0.9666	0.1759
log average flow	0.9704	0.2686

table 1. Shapiro Wilk W-statistic.

The Shapiro Wilk W-statistic was calculated using the 2D program of the BMDP statistic software package. Values closer to 1 indicate better adherence to the normal distribution, with a significance level as specified.

Subsequently, the intra-individual standard deviation was estimated as the square root of the average of the variance of the four measurements in each individual. Inter-individual variance is estimated as the variance of the mean log values per individual minus $\frac{1}{4}$ times the intra-individual variance (10). This gives a theoretical value assuming no intra-individual variation. The actual inter-individual variation is dependent on the number of replicates. Table 2 shows that the uncertainty of individual measurements is large, whether in the same individual or between different persons. Since all data are log transformed, 95% confidence limits of a single measurement x are given by $x \cdot 10^{\pm 2SD}$, where SD is the standard deviation as stated in table 2. The 95% intra-individual confidence limits for a value for the bleeding time equal to the mean are 1 min 53 s and 5 min 47 s, whereas the inter-individual confidence limits (assuming 4 determinations) are 1 min 47 s and 6 min 5 s. Of the assessed parameters, the bleeding time is the least variable by a relatively large margin. In contrast to individual measurements, values for the population mean of the parameters can be assessed with relative certainty.

No significant differences were observed in bleeding time, blood loss, peak blood flow or average blood flow, when comparing sex, left or right arm, or the order in which the bleeding time wounds were made.

	bleeding time (min)	blood loss (μ l)	peak flow (μ l / min)	average flow (μ l / min)
mean	3.30	10.6	7.12	2.85
overall s.e.m.	0.230	1.90	0.954	0.332
mean (log)	0.481	0.843	0.728	0.362
intra individual SD (log)	0.122	0.296	0.254	0.208
inter individual SD (log)				
single measurement	0.170	0.444	0.353	0.304
2 replicates	0.146	0.392	0.304	0.266
4 replicates	0.133	0.363	0.276	0.246
∞ replicates	0.118	0.331	0.245	0.223

table 2. Inter and Intra-Individual standard deviations.

The values of the inter and intra-individual standard deviations were calculated from the log transformed data obtained from bleeding pattern recordings, as described. The mean and overall s.e.m. values are calculated directly from the non-transformed data.

Linear correlations were calculated between bleeding time, blood loss, age, and depth of wound. None of these correlations were anywhere near significance (table 3). There is some correlation between bleeding time and blood loss, but this should be no surprise since the two are obviously interrelated. When eliminating this relationship by dividing blood loss by bleeding time so as to obtain the average blood flow during bleeding, the correlation disappears.

parameters	r^2
bleeding time - age	0.006
bleeding time - depth of wound	0.132
bleeding time - blood loss	0.571
bleeding time - peak flow	0.244
bleeding time - average flow	0.258
blood loss - age	0.070
blood loss - depth of wound	0.103

table 3. regression analysis.

Linear regression analysis was performed on a number of parameter pairs. No significant correlations could be detected

discussion

The widespread clinical use of the bleeding time shows that there is a great need for a good overall test of primary haemostasis. An important factor influencing the clinical applicability of the bleeding time has been

its large inter-individual variability. This causes the range of normal values of bleeding times, and the range of values of bleeding times of individuals with a certain disorder to overlap considerably. As a result of this, the positive predicting value of a prolonged bleeding time has been far from optimal (see ref. 11 for a recent review).

On the other hand, bleeding time values can be used successfully in discriminating between some well defined populations. The average bleeding time in a group of people taking aspirin for instance is significantly longer than the average bleeding time in a similar group taking no medication (11). Given the narrowing of the confidence limits with the square root of the number of observations, it is possible to show the significance of any difference in population average, no matter how small, by increasing the number of measurements. However, the large variability of bleeding time values within one population renders a demonstration of significant differences between population averages only practical if those averages are far enough apart. This explains part of the difficulty of showing significant increases of bleeding times for certain disorders or medications such as hemophilia and several platelet inhibitors (12,13,14).

It is therefore important, both for clinical and epidemiological usefulness of the bleeding time test, to lower the variability of the bleeding time values as much as possible. During the almost a century long history of the bleeding time, this has been an important motive for further development and refinement of the technique used. Much of the instrumental variability stemmed from the fact that the bleeding time wound was not made exactly in the same way, and having the same dimensions, by each worker, nor by the same worker at different times. It was improved upon by Mielke et.al. who made a device which did create bleeding time wounds with more or less controllable dimensions (7). However, the range spanned by the confidence limits of a single measurement remained rather broad. We tried to minimize instrumental variability by using a strictly standardized measurement. By employing a pseudo-continuous recording of the velocity of the bloodflow from the bleeding time wound, bleeding time data could be obtained much more precisely. To standardize bleeding time wounds we used an automatic lancet set to a fixed depth. The actual depth of the wound could be determined from the width of the wound, and was found to vary somewhat. It did however not correlate with the bleeding time or any of the other assessed parameters.

As mentioned before, not all of the variability is due to the technique of measuring bleeding times, part is due to the intrinsic dependency on a whole range of factors. In the present study we attempted to keep the

instrumental variability as low as possible. The other part of our approach was to measure not only bleeding time, but to record the complete bleeding pattern, i.e. the bleeding velocity as a function of time. This allowed us to determine other parameters related to bleeding as well: the amount of blood lost, and the average and peak velocities of blood flow.

The bleeding time values we measured lead to 95% confidence limits for individual measurements that are large, and do not deviate much from what has been reported earlier (7,9). The variabilities of the other three parameters we investigated appear to be worse than the bleeding time. The intra individual variability, a property that has hardly been investigated in the past seems to do no better.

It is not always an easy task to attribute part of the total variation to a certain assignable cause. The usual way to proceed would be to determine the variation in a situation with, and in a situation without that cause. The condition that must be met in this case is that the alleged cause is a controllable parameter. Regrettably this is not the case when analyzing which part of the variability of bleeding times is instrumental, and which part is intrinsic. It is not possible to know exactly how much the technique of measuring bleeding times contributes to the overall variability of the results. The best that can be done is try and improve on the technique on some rational ground and compare to the results of older techniques. Bleeding time techniques have changed considerably over the years, and although progress has been made with respect to variability and reproducibility, it has not been overwhelming, especially during the last two decades. This leads one to suspect that there may not be much room for improvement. Considering the large number of variables other than the technique of measuring that may have an influence on bleeding times it is difficult to escape the conclusion that there may be an intrinsic limit to the variability of this test, and that current tests are not far off this limit.

references

1. Milian MG. Influence de la peau sur la coagulabilité du sang. C R Soc Biol (Paris) 1901;53:576-8.
2. Milian MG. Contribution à l'étude de la coagulation du sang. C R Soc Biol (Paris) 1901;53:556-7.
3. Milian MG. Technique pour l'étude clinique de la coagulation de sang. Bull Mem Soc Méd Hôp Paris 1901;18:777-83.
4. Bowie EJ, Owen CA. The bleeding time. Progr Hemost Thromb 1974;2(0):249-71.

5. Duke WW. The relation of blood platelets to hemorrhagic disease. Description of a method for determining the bleeding time and coagulation time and report of three cases of hemorrhagic disease relieved by transfusion. *JAMA* 1910;55: 1185-92.
6. Ivy AC, Nelson D, Bucher G. The standardization of certain factors in the cutaneous "venostasis" bleeding time technique. *J Lab Clin Med* 1941;26:1812-22.
7. Mielke CH, Kaneshiro MM, Maher IA, Weiner JM, Rapaport SI. The standardized normal Ivy bleeding time and its prolongation by aspirin. *Blood* 1969;34:204-15.
8. Sutor AH, Bowie EJW, Thompson JH, Didisheim P, Mertens BF, Owen CA. Bleeding from standardized skin punctures: automated technic for recording time, intensity and pattern of bleeding. *Am J Clin Pathol* 1971;55:541-50.
9. Bowie EJ, Owen CA, Hansen RJ, Isaacson J. Electronic method for quantitation of bleeding time. *Am J Clin Pathol* 1972;58: 255-60.
10. Fleiss JL. The design and analysis of clinical experiments. New York: Wiley, 1986.
11. Rodgers RPC, Levin J. A critical reappraisal of the bleeding time. *Semin Thromb Hemost* 1990;16:1-20.
12. Byster ME, Gordon RA, Ballard JO. The bleeding time is longer than normal in hemophilia. *Blood* 1981;58(4):719-23.
13. Schulman S, Johnsson H. Heparin, DDAVP and the bleeding time. *Thromb Haemostas* 1991;65(3):242-4.
14. Praga C, Cortellaro M, Pogliana E. Standardized bleeding time in the study of drugs interfering with platelet function. *Adv Exp Med Biol* 1972;34:149-58.

chapter 7

summary and conclusions

Thrombin, the end product of the coagulation cascade, plays a central role in the process of hemostasis. It is both the effector enzyme, able to clot fibrinogen and to activate platelets, and a central regulatory protein, being at the origin of several important positive and negative feedback loops of the coagulation system.

Qualitatively, the course of events during coagulation in plasma is largely known. Mostly, the reactions involved and their consequences have been deduced from observations in systems of purified proteins. Plasma, however, contains a large number of proteins, among which, presumably, a considerable number with unknown function. This implies that a fair number of reactions may be taking place simultaneously. It is a well known fact that the effort of analysis increases rapidly as the number of reactions that has to be taken into account grows bigger. Making reliable quantitative predictions about reactions in plasma, therefore, is very difficult. Significant uncertainty accompanies even a qualitative deduction. As thrombin is involved in so many reactions simultaneously, the task of predicting its behaviour *in vivo*, from experiments carried out in purified systems becomes daunting. We therefore chose to stay close to the physiological milieu of the coagulation system, and set up measurements in plasma and whole blood. In doing so it was inevitable that we sacrificed, to a certain extent, the exact definition of the experimental system used. But it should be kept in mind that we could fall back on a solid base of knowledge of the proteins involved and their interactions, and that experiments in purified or partially purified systems still served as valuable tools for testing hypotheses.

Techniques for accurately measuring concentrations of activated clotting factors in plasma are a *sine qua non* of this kind of experiment. This is not always a triviality. Complicating factors, such as the interference of other clotting factors which are present in plasma, the low prevailing concentrations of several coagulation enzymes, and the instability of some of these proteins, often render existing assays unusable, so that new techniques had to be developed.

Chapter 1 gives a general introduction to the subject of this thesis.

Chapter 2 describes a technique for the measurement of thrombin generation in freshly collected whole blood without added anticoagulants. In this way the reaction medium more closely approximates the physiological conditions of coagulation. The assay is based on the chromogenic measurement of thrombin concentrations after centrifugal discarding of cellular components from the blood sample, like it is done when preparing plasma. The difference is that this separation takes place in subsamples which are drawn from the clotting blood, and which have been diluted in buffer containing the chromogenic substrate for thrombin. In this way processing of the original blood sample can be avoided. This technique was used first to analyse the differences between coagulation in blood without an added anticoagulant, and blood collected on citrate as usual. The procedure of collecting blood on citrate and subsequent recalcification may, because of a number of reasons, influence the function of blood platelets and the coagulation system. It is shown that thrombin generation after triggering coagulation with low concentrations of thromboplastin occurs sooner in native whole blood than in citrated whole blood. This acceleration is not a consequence of a suboptimal Ca^{2+} to citrate ratio. Furthermore, the lag time of thrombin generation was shortened relatively more in the presence of heparin, so that the effect of heparin, as measured in citrated blood or platelet rich plasma is somewhat overestimated. Thus it is evident that anticoagulation of blood using citrate has a clear influence on the coagulation process. Possible explanations for this influence include a change of pH, lowering of the concentration of Mg^{2+} ions, and a direct interaction of citrate with platelets.

Since activated platelets provide the negatively charged phospholipid surface necessary for efficient reactions in the coagulation system, and since thrombin, especially in combination with collagen, is the most potent physiological activator of platelets, the coagulation system and platelet activation are closely linked. This linkage, as well as a much clinical evidence for the antithrombotic action of anticoagulant drugs, also in the platelet rich (arterial) thrombus, suggest that affecting the concentration of free thrombin might be the principal mechanism of action of antithrombotic drugs. This hypothesis, however, seems to be falsified by the well known antithrombotic action of aspirin, a drug of which no influence on thrombin generation was known. Chapter 2 describes that intake of 500 mg of aspirin delays and inhibits thrombin generation in non-anticoagulated, thromboplastin triggered whole blood. This observation lends support to the notion that inhibition of thrombin is on a common pathway of the various sorts of antithrombotic therapy. In this view it does not matter whether affecting the thrombin concentration be

achieved by inhibition of thrombin formation (oral anticoagulation), increase of thrombin inactivation (heparin) or inhibition of platelet function (aspirin).

Determination of thrombin concentrations in plasma is a relatively simple technique in comparison to the measurement of other enzymes of the coagulation system. Furthermore we recently showed that this measurement can be automated considerably by measuring the time integral of the thrombin concentration, instead of the thrombin concentration itself, in clotting plasma. Chapter 3 describes a mathematical procedure to extract from both normal and integral thrombin generation curves information that accurately describes the state of the coagulation system and that would be difficult to obtain otherwise. Thrombin in plasma is inhibited by a number of serine protease inhibitors. The most important of these is antithrombin III. A minor part of the thrombin is inhibited by α_2 -macroglobulin. The complex of thrombin and α_2 -macroglobulin, however, introduces a significant difficulty in the analysis of thrombin generation curves, as it retains some activity towards the small chromogenic substrates used to measure thrombin concentrations. Therefore, the first step in the analysis of thrombin generation curves is the determination of the time course of the concentration of free thrombin. This is done by calculating the value of the first order decay constant for thrombin to α_2 -macroglobulin directly from thrombin generation curves.

The decay constant of thrombin due to the other inhibitors has to be measured in separate experiments. The velocity of thrombin inhibition at any timepoint can be determined from these decay constants and the time course of the free thrombin concentration. From this, the velocity of prothrombin conversion, i.e. the activity of the prothrombin converting enzyme, can be calculated. In this way a lower thrombin concentration can be pin-pointed as inhibition of thrombin, or as inhibition of thrombin formation.

The thrombin potential is a parameter which is influenced by all sorts of antithrombotic medication. It is, therefore, a useful candidate to supplement or even replace some of the present clinically used parameters describing the state of the coagulation system. It is defined as the surface under a time curve of the free thrombin concentration, and can readily be obtained from thrombin generation curves.

Since carrying out thrombin generation experiments involves a significant amount of experimental work, it is not a likely procedure to be carried out routinely in a hospital laboratory. We recently developed a new, largely automated, method to monitor the time integral of the

thrombin concentration in clotting plasma. Chapter 3 extends the analysis of thrombin generation curves to these time curves of the integral of the thrombin concentration, and shows how all the information obtainable from a classical thrombin generation curve, notably the thrombin potential, can, in an analogous manner, also be obtained from integral thrombin curves.

During the initial phase of blood clotting, traces of thrombin are generated. These thrombin traces provoke the generation of more thrombin by starting several positive feedback loops. Activation of coagulation factor VIII constitutes one of these feedback mechanisms. Chapter 4 describes a technique for measuring concentrations activated factor VIII (factor VIIIa) in clotting plasma. This measurement is hampered by the fact that factor VIIIa is generated only in very low concentrations, less than 1 nM, and that it is very instable, having a half life time shorter than 30 seconds. The complex of factor IXa and factor VIIIa on a phospholipid surface has the ability to activate factor X. In this process, factor IXa is the enzyme, and factor VIIIa functions as a cofactor, accelerating the activation reaction. The determination of factor VIIIa concentrations is based on this property. Subsamples drawn from clotting plasma are diluted in a buffer containing excess factor IXa, factor X, phospholipid vesicles and Ca^{2+} ions. In this system factor Xa is generated with a rate proportional to the concentration of factor VIIIa. This factor Xa is subsequently measured using a chromogenic substrate. The measurements is complicated by the capability of free factor Xa to activate non-activated factor VIII present in a plasma sample. This increases the factor X activation velocity in the measurement system, and thus causes the concentration of factor VIIIa to be overestimated. Furthermore, factor Xa is inactivated by antiproteases also originating from the plasma sample. These complicating factors necessitated the development of a novel technique in order to measure concentrations of factor VIIIa in plasma in a quantitatively reliable manner. When a surplus of chromogenic substrate is present during factor Xa generation in the factor VIIIa assay, the chromogenic substrate acts as a competitive inhibitor of factor Xa, inhibiting all reactions of factor Xa except chromogenic substrate hydrolysis. Thus, the 'side reactions' of factor Xa are inhibited and at the same time the rate of substrate conversion is a measure of the amount of factor Xa present.

The presence of chromogenic substrate during the factor Xa generating reaction results in timecurves of optical density that follow a parabolic pattern. Mathematical analysis of this parabola shows that the factor VIIIa concentration appears in the quadratic coefficient, and can be obtained by

a simple quadratic least squares fit procedure. The resulting assay of factor VIIIa was shown to be linear with the factor VIIIa concentration and to be specific for factor VIIIa.

The principle of the presence of chromogenic substrate during proenzyme activation, as developed for the measurement of factor VIIIa, was subsequently applied, in the experiments described in chapter 5, to the measurement of factor Xa concentrations in plasma. This was necessary because the concentrations of factor Xa in plasma after triggering with physiologically low concentrations of tissue factor appeared to remain very low. For this reason, and because of a too low specificity, direct measurement using a chromogenic substrate was not feasible. Measuring factor Xa via a two-stage prothrombinase assay was hindered too much by the high concentrations of thrombin that were generated simultaneously in clotting plasma. The presence of a chromogenic substrate for thrombin during the thrombin generating step of the assay resolves this difficulty, since analysis of the parabolic time curves of optical density showed that the factor Xa concentration only appeared in the quadratic coefficient of these curves. Thus, factor Xa can be said to be responsible for the acceleration chromogenic substrate conversion, whereas the plasma thrombin concentration appears only in the linear coefficient, causing the initial velocity of the optical density time curve. In this way, factor Xa and thrombin are effectively separated, and it is possible to measure factor Xa concentrations in the presence of thrombin concentrations that are up to four orders of magnitude higher.

We used this technique, together with the method for measuring factor VIIIa, and assays for factor Va and thrombin published earlier, to investigate the events occurring during the early phase of coagulation in plasma. In these experiments, coagulation was triggered with recombinant tissue factor in a concentration range of 0.2 to 1 pM. These concentrations are much lower than what is usual in most existing tests of the coagulation system, but they are probably much closer to the values occurring in coagulation *in vivo*.

The first remarkable observation was that the peak concentration of factor Xa, which was dependent on the tissue factor concentration, was reached within 20 seconds after triggering. In addition, the height of this peak was very low (25 - 200 pM) in comparison to the high concentration on non-activated factor X circulating in plasma (± 180 nM). Still, the concentration is high enough to cause fast and efficient thrombin generation. The early occurrence of the peak value of the factor Xa concentration was shown to be a consequence of the presence of the recently discovered Tissue Factor Pathway Inhibitor (TFPI), which shuts

down factor Xa generation by the complex of VIIa and tissue factor very soon after addition of tissue factor to plasma. This followed from an experiment in which TFPI was inhibited by anti-TFPI antibodies. A rise of the factor Xa concentrations was observed which lasted for several minutes, leading to peak concentration which was more than one order of magnitude higher than the peak concentration in the absence of antibodies.

The factor Xa concentration in plasma declined slower than could be expected from its decay constant. Factor Xa seemed to 'wait' for factor V activation, even when this was artificially retarded quite considerably by the presence of a thrombin inhibitor. Part of the apparent slow decrease was found to be due to on going activation of factor X by intrinsic tenase, the complex of factor IXa with its cofactor VIIIa. This was deduced from the measurement of factor Xa concentrations in plasma from a patient with hemophilia A, demonstrating a considerably faster decay of factor Xa. This experiment also serves as a direct demonstration of the role of the alternative extrinsic pathway, or 'Josso loop' in clotting plasma.

Apart from thrombin also factor Xa has the capacity to activate the cofactors V and VIII in purified systems. Experiments with the synthetic thrombin inhibitor BIBG 64 BF, which delays thrombin formation without influencing the onset of factor X activation, showed that cofactor activation was concomitant with thrombin generation and not with factor Xa generation. The kinetic behaviour of the cofactors Va and VIIIa after slow activation was shown to differ markedly. The peak values of the concentration of factor VIIIa were dependent on the rate of its activation, whereas maximal concentrations for factor Va were, apart from being 2 orders of magnitude higher, not influenced. This appears to be caused by the stability of factor Va in plasma, which contrasts with the high degree of lability of factor VIIIa. Since the activation of factor V and VIII was not completely inhibited at the lower inhibitor concentrations, the minimal first order constant of inhibition necessary to shut down cofactor activation altogether can be estimated at 2 s^{-1} . Finally, the concentrations of factor Va attained in plasma after the initial phase of the coagulation process are much higher than the factor Xa concentrations, so that the maximal rate of the extrinsic prothrombinase enzyme is probably limited by the factor Xa concentration.

A logical sequel to the experiments described in the chapters 2 and 5 seemed the investigation of coagulation in a system even closer to physiology: i.e. in blood flowing from a bleeding time wound. However, the bleeding time test suffers from a large variability which not only sheds serious doubt on its clinical usefulness, but also would introduce significant, and very difficult to handle, variations when investigating the

involvement of the coagulation process in the hemostasis of a bleeding time wound. Our first goal was therefore minimizing the instrumental variability, as described in chapter 6. We employed a strictly protocolled technique which measures the rate of bleeding in time, instead of only the time needed to stop bleeding. Blood flowing from a bleeding time wound is taken up into a tubing circuit and led to photometer, where the concentration of hemoglobin is measured. The Hb concentration is a measure for the rate of bloodflow from the wound. This method also allowed us to assess the usefulness of other parameters, such as the amount of blood lost, and the average and peak velocity of bloodflow from the wound. Our results indicate that of the parameters that can be determined from the obtained bleeding patterns, the bleeding time still has the lowest variability. This variability however, be it between individuals or between different measurements within a person, is still very large and in the same range as reported earlier in the literature. The high variability ensures a relatively high degree of overlap of the bleeding times between two populations, unless they are very far apart. Since bleeding time values are very likely dependent on a number of parameters that cannot be controlled, the power of the bleeding time as a clinical or pharmacological test is small and arguably not prone to much improvement by improvement of technique of measurement. This implicates that any analysis of the clotting process in blood from bleeding time wounds will be restricted with respect to a quantitative description.

In vivo clotting is usually initiated upon vessel wall damage. The clotting factors circulating in blood plasma are then exposed to tissue factor present on the cell membranes of cells of the perivascular tissues. Procoagulant surfaces are provided by damaged cells and activated platelets. The physical and biochemical conditions prevailing may be very different for different 'instances' of clotting. The flow conditions are influenced by the type and size of the vessel. The availability of tissue factor and procoagulant phospholipid surface is a function of the extent of the vessel wall damage. Important is also whether the actual clotting process occurs in the lumen of the vessel or in the extravascular tissue, where flow may be completely absent. All this makes it very difficult to extrapolate experimental data to the situation *in vivo*. Therefore, the type of experiments described in this thesis produces quantitative results that are, in principle, valid only for the circumstances under which they were performed. Although it may be tempting to generalize the conclusions reached to laws governing clotting as a whole, care has still to be taken to take into account the conditions prevailing at the particular time and place.

The availability of accurate techniques to determine thrombin, factor Xa, factor Va, and factor VIIIa concentrations in plasma and blood has given us the opportunity to start investigating the coagulation process in near physiological conditions in greater detail. It is a small step, however, in the task of elucidating the rules governing hemostasis *in vivo*. Many more experiments, together with thorough analyses and model building, are necessary, not only in plasma, but also in experimental systems incorporating the important factor of flow, and, ultimately, in *in vivo* situations. This, however, is only sensible when enough information has been gained by other means to make a meaningful interpretation of the data possible, just as it would not have been possible to place the experiments described in this thesis in perspective, without the extensive knowledge about the coagulation system obtained in systems of purified proteins.

hoofdstuk 7

samenvatting en conclusies

Trombine, het eindproduct van de stollingscascade, speelt een centrale rol in de hemostase. Zij is zowel het effector enzym, in staat om fibrinogeen te doen stollen en bloedplaatjes te aktiveren, als het belangrijkste regulerende eiwit, omdat zij aan de basis staat van enkele belangrijke positieve en negatieve terugkoppelingsmechanismen van het stollingssysteem.

In kwalitatieve zin is de loop van de gebeurtenissen tijdens de stolling in plasma grotendeels bekend. De betrokken reacties en de gevolgen van die reacties zijn voor het merendeel afgeleid uit waarnemingen in testsystemen met een zeer beperkt aantal gezuiverde eiwitten. Plasma echter bevat een groot aantal eiwitten, waaronder een aanzienlijk aantal met een nog onbekende functie. Dit betekent dat een fors aantal reacties tegelijkertijd kan optreden. Het is een bekend gegeven dat de complexiteit van analyse sterk toeneemt naarmate het aantal reacties waarmee rekening gehouden moet worden groter wordt. Derhalve is het uiterst moeilijk om betrouwbare kwantitatieve voorspellingen te doen omtrent reacties in plasma. Zelfs een kwalitatieve deductie gaat gepaard met een niet te verwaarlozen mate van onzekerheid. Omdat trombine in plasma betrokken is bij veel reacties die tegelijkertijd kunnen optreden, is het een lastige opgave haar gedrag *in vivo* te voorspellen uit de gegevens verkregen met experimenten in gezuiverde systemen. Om die reden hebben wij besloten ons onderzoek uit te voeren onder reactieomstandigheden die dichter staan bij het fysiologische milieu van de stolling en hebben we meetsystemen opgezet in plasma en vol bloed. Daarbij is het onvermijdelijk iets van de exacte definitie van het experimentele systeem prijs te geven. Men moet hierbij echter bedenken dat we konden terugvallen op een solide basis aan kennis over de betrokken eiwitten en hun interacties, en dat proeven in systemen met gezuiverde eiwitten nog steeds een waardevol gereedschap zijn voor het testen van hypothesen.

De beschikbaarheid van technieken voor het accuraat meten van concentraties van geaktiveerde stollingsfactoren in plasma is een *conditio sine qua non* voor het onderzoek van de stolling onder meer fysiologische omstandigheden. Dit soort meetmethoden is niet altijd triviaal. Complicerende factoren, zoals interferentie van andere stollingsfactoren

die in plasma voorkomen, de lage concentraties van verscheidene stollingsenzymen, en de instabiliteit van enkele van deze eiwitten, maken bestaande meetmethoden vaak onbruikbaar zodat nieuwe experimentele technieken moesten worden ontwikkeld.

Hoofdstuk 1 geeft een algemene introductie over het onderwerp van dit proefschrift.

In hoofdstuk 2 wordt een techniek beschreven voor het meten van trombinevorming in vers afgenomen bloed, dat geen bewerkingen heeft ondergaan en waaraan geen anticoagulantia zijn toegevoegd. Dit om zo dicht mogelijk bij de fysiologische omstandigheden te blijven waarin stolling optreedt. De meetmethode is gebaseerd op een chromogene meting van trombine na het centrifugaal verwijderen van de cellulaire componenten van bloed, zoals dat ook plaats vindt bij het prepareren van plasma. Het verschil is echter dat deze scheiding pas gebeurt in monsters die zijn genomen uit het stollende bloed, zodat bewerking van het bloed omzeild kon worden. Deze techniek werd allereerst gebruikt om eventuele verschillen in de bloedstolling te analyseren tussen bloed waaraan geen anticoagulans werd toegevoegd, en bloed dat, zoals gebruikelijk, op citraat werd opgevangen. De procedure van het afnemen van bloed op citraat en vervolgens recalcificeren kan vanwege een aantal bekende en minder bekende effecten van citraat, de werking van bloedplaatjes en het stollingsstelsel beïnvloeden. De vorming van trombine na het op gang brengen van de stolling met lage concentraties tromboplastine bleek eerder plaats te vinden in bloed waaraan geen citraat was toegevoegd dan in gecitreerd bloed. Deze kortere latentietijd was niet het gevolg van een suboptimale Ca^{2+} /citraat ratio. Bovendien was de latentietijd relatief nog verder verkort wanneer heparine in het bloed aanwezig was, zodat het effect van het heparine, indien gemeten in gecitreerd bloed of plaatjesrijk plasma, enigszins wordt overschat. Het is derhalve duidelijk dat antistolling van bloed met citraat een aanmerkelijke invloed heeft op het stollingsproces. Mogelijke verklaringen hiervoor zijn een verandering van de pH, het wegvangen van Mg^{2+} ionen, of een directe interactie van citraat met bloedplaatjes.

Omdat geactiveerde plaatjes het negatief geladen fosfolipide oppervlak leveren dat nodig is voor efficiënte reacties in het stollingsstelsel, en omdat trombine de beste fysiologische aktivator van plaatjes is, hangen het stollingsstelsel en plaatjesreacties nauw met elkaar samen. Deze onderlinge band en de aanwijzingen uit klinische studies voor de antitrombotische werking van antistollingsmiddelen, zelfs in geval van een plaatjesrijke (arteriële) trombus, suggereren dat het beïnvloeden van de

concentratie vrij trombine het belangrijkste werkingsmechanisme zou kunnen zijn van antitrombotische medicijnen. Deze hypothese echter wordt schijnbaar gefalsificeerd door de bekende antitrombotische werking van aspirine, een middel waarvan geen invloed op de trombinevorming bekend was. In hoofdstuk 2 wordt beschreven dat de inname van 500 mg aspirine door gezonde proefpersonen de trombinevorming zowel vertraagt als remt in bloed zonder anticoagulans. Deze observatie geeft steun aan het concept waarin remming van trombine gemeenschappelijk is aan de verscheidene soorten antitrombotische therapie. Het beïnvloeden van de trombineconcentratie kan worden bewerkstelligd door remming van trombinevorming (orale antistolling), door het versnellen van de trombineremming (heparine), of door remming van de plaatjesfunctie (aspirine).

De bepaling van trombine concentraties in plasma is een relatief eenvoudige techniek in vergelijking met de meting van andere enzymen van het stollings systeem. Bovendien hebben we recentelijk aangetoond dat deze meting grotendeels kan worden geautomatiseerd door in plaats van trombineconcentraties, de tijdsintegraal van de trombineconcentratie in stollend plasma te volgen. Hoofdstuk 3 beschrijft een mathematische procedure om zowel uit normale als uit integrale trombine generatie curves, informatie te extraheren die de staat van het stollingssysteem accuraat beschrijft, en die moeilijk te verkrijgen zou zijn op een andere manier. Trombine in plasma wordt geïnactiveerd door een aantal serine protease remmers. De belangrijkste hiervan is het antitrombine III. Een klein deel van alle trombine wordt geremd door α_2 -macroglobuline. Echter, het inactieve complex van trombine en deze laatste remmer bemoeilijkt de analyse van trombine generatie curves, omdat dit complex nog enige activiteit heeft ten opzichte van de kleine chromogene substraten die gebruikt worden om trombine concentraties te meten. Derhalve is de eerste stap in de analyse van trombine generatie curves het bepalen van het tijdsverloop van de concentratie vrij trombine uit een curve die zowel de concentratie vrij trombine als de concentratie van het α_2 -macroglobuline - trombine complex weergeeft. Dit wordt bewerkstelligd door een procedure die de waarde van de eerste orde afbraakconstante van trombine voor α_2 -macroglobuline direct bepaalt uit een trombine generatie curve.

De afbraakconstante voor de inaktivering van trombine door de andere remmers moet worden gemeten in aparte experimenten. Uit de totale afbraakconstante en de curve van de vrije trombineconcentratie kan de snelheid van trombine inaktivering op ieder tijdstip bepaald worden. Vervolgens kan dan hieruit de snelheid van protrombine conversie, ofwel de activiteit van het protrombine converterende enzym, berekend worden.

Op deze wijze kan worden bepaald of een lagere trombineconcentratie het gevolg is van remming van trombine, of van remming van trombinevorming.

Een parameter die beïnvloed wordt door alle soorten antitrombotische medicatie is de trombinepotentiala. Derhalve is dit een zeer bruikbare kandidaat is om bestaande, in de kliniek gebruikte parameters die de staat van het stollingssysteem beschrijven aan te vullen of zelfs te vervangen. De trombinepotentiala is gedefinieerd als de oppervlakte onder de curve van de vrije trombine concentratie, en kan op een gemakkelijke manier worden berekend uit trombine generatie curves.

Omdat het uitvoeren van trombine generatie experimenten een aanzienlijke hoeveelheid experimenteel werk met zich meebrengt, is dit geen procedure die op een gemakkelijke wijze zou kunnen worden toegepast in de routine van een ziekenhuis laboratorium. Recentelijk hebben we een nieuwe, grotendeels geautomatiseerde techniek ontwikkeld waarmee de tijdsintegraal van de trombineconcentratie in stollend plasma continu kan worden gevolgd. In hoofdstuk 3 wordt beschreven hoe alle informatie die verkregen kan worden uit een klassieke trombine generatie curve, en met name de trombine potentiala, op analoge wijze, kan worden gedestilleerd uit een integrale trombine curve.

Tijdens de eerste fase van de bloedstolling zorgt een kleine hoeveelheid geactiveerd factor X ervoor dat spoortjes trombine gevormd worden. Dit trombine zorgt voor de vorming van grotere hoeveelheden trombine door enkele positieve terugkoppelingsmechanismen op gang te brengen. Eén van deze mechanismen is de aktivering van stollingsfactor VIII. In hoofdstuk 4 wordt een techniek beschreven om de concentraties van geactiveerd factor VIII (factor VIIIa) in stollend plasma te meten. Deze meting wordt bemoeilijkt doordat factor VIIIa slechts in zeer lage concentraties, minder dan 1 nM, wordt gevormd gedurende de stolling, en omdat het uiterst instabiel is, met een halfwaardetijd korter dan 30 seconden. Het complex van factor IXa en factor VIIIa op een fosfolipiden oppervlak zorgt voor het aktiveren van factor X. In dit proces is factor IXa het enzym en functioneert factor VIIIa als een cofactor die de reactie versnelt. De meetmethode van factor VIIIa concentraties is gebaseerd op deze eigenschap. Monsters, genomen uit stollend plasma, worden verdund in buffer met een overmaat aan factor IXa, factor X, fosfolipiden vesicles en Ca^{2+} ionen. In dit systeem wordt factor Xa gevormd met een snelheid die afhankelijk is van de factor VIIIa concentratie. Dit factor Xa wordt vervolgens gemeten met behulp van een chromogeen substraat. Een complicatie bij deze meting is het feit dat het gevormde factor Xa de capaciteit heeft om niet geactiveerd factor VIII afkomstig uit het

plasmamonster te activeren. Dit verhoogt de vormingsnelheid van factor Xa in het meetsysteem en leidt derhalve tot een overschatting van de factor VIIIa concentratie. Bovendien bleek het gevormde factor Xa gedeeltelijk ten prooi te vallen aan protease remmers, eveneens afkomstig uit het plasma monster. Dit alles maakte de ontwikkeling van een nieuwe techniek noodzakelijk teneinde factor VIIIa concentraties in plasma op een kwantitatief betrouwbare manier te kunnen meten. Wanneer een hoge concentratie chromogeen substraat al tijdens de factor X aktiveringsstap in het meetsysteem aanwezig is worden alle reacties van factor Xa behalve de hydrolyse van het chromogeen substraat competitief geremd. Zodoende worden alle ongewenste nevenreacties van factor Xa geblokkeerd en is tegelijkertijd de snelheid van de conversie van chromogeen substraat een maat voor de hoeveelheid factor Xa die aanwezig is.

De aanwezigheid van het chromogeen substraat tijdens de factor Xa vormende reactie resulteert erin dat de optische dichtheid volgens een parabool toeneemt in de tijd. Mathematische analyse toonde dat de factor VIIIa concentratie in de kwadratische coëfficiënt verschijnt van de vergelijking die de parabool beschrijft. Deze concentratie kan vervolgens worden verkregen door middel van een eenvoudige kleinste kwadraten fit procedure. De aldus ontwikkelde meetmethode voor factor VIIIa in plasma bleek lineair met de factor VIIIa concentratie en specifiek voor factor VIIIa.

Het principe van de aanwezigheid van chromogeen substraat gedurende proenzym aktivering, zoals dat werd ontwikkeld voor de meting van factor VIIIa in plasma, werd vervolgens, in de experimenten beschreven in hoofdstuk 5, toegepast op de meting van factor Xa concentraties in stollend plasma. Dit was noodzakelijk omdat de concentraties van factor Xa in plasma, na toevoegen van fysiologisch lage concentraties weefselfactor, erg laag blijven. Om die reden, en vanwege een te lage specificiteit was een directe meting met behulp van chromogeen substraat voor factor Xa niet haalbaar. Bovendien bleek het meten van factor Xa met een twee-staps protrombinase meting te veel hinder te ondervinden van de hoge concentraties trombine die gelijktijdig in stollend plasma worden gevormd. De aanwezigheid van chromogeen substraat gedurende de stap waarin trombine wordt gegenereerd bood oplossing, omdat analyse van de kwadratische tijdcurves van de optische dichtheid liet zien dat de factor Xa concentratie slechts voorkomt in de kwadratische coëfficiënt, terwijl de trombine concentratie alleen in de lineaire coëfficiënt zit. Factor Xa kan derhalve worden beschouwd als verantwoordelijk voor de versnelling van de omzetting van chromogeen substraat, terwijl de trombineconcentratie aanleiding geeft tot de initiële snelheid van de deze

reactie. Hierdoor zijn factor Xa en trombine effectief van elkaar gescheiden en kunnen factor Xa concentraties worden gemeten in de aanwezigheid van trombine in concentraties die tot 4 orden van grootte hoger zijn.

Deze meettechniek werd gebruikt, samen met de meetmethode voor factor VIIIa, en eerder gepubliceerde bepalingen van factor Va en trombine, om de gebeurtenissen in de eerste fase van de bloedstolling in plasma te onderzoeken. De stolling in plasma werd hierbij op gang gebracht door het toevoegen van weefselfactor in een concentratiebereik van 0.2 tot 1 pM. Deze concentraties zijn veel lager dan gebruikelijk is bij de meeste bestaande stollingstesten, doch ze komen hoogstwaarschijnlijk veel dichterbij de waarden die bij stolling *in vivo* voorkomen.

De eerste opmerkelijke waarneming was dat de piekconcentratie van factor Xa, die afhankelijk was van de concentratie toegevoegd weefselfactor, al binnen 20 seconden bereikt werd. De hoogte van de piek was bovendien erg laag (25 tot 200 pM) in verhouding tot de concentratie van niet geactiveerd factor X in het plasma (± 180 nM). Toch was die concentratie hoog genoeg om een snelle en efficiënte trombinevorming te bewerkstelligen. Het vroege maximum van factor Xa bleek het gevolg van de aanwezigheid van de recent ontdekte fysiologische remmer Tissue Factor Pathway Inhibitor (TFPI), die, zeer snel na het toevoegen van weefselfactor aan plasma, de factor Xa vorming door het factor VIIa/TF complex stillegt. Toevoegen van anti-TFPI antilichamen leidde er namelijk toe dat een minuten durende stijging van de factor Xa concentratie werd geobserveerd. De maximale factor Xa concentratie die werd bereikt was meer dan een orde van grootte hoger dan de factor Xa piek in de afwezigheid van de antilichamen.

De afname van de factor Xa concentratie in plasma was trager dan verwacht werd op basis van de uit de literatuur bekende afbraakkonstante. Factor Xa 'wachtte' als het ware tot er voldoende factor V was geactiveerd, zelfs wanneer dit moment artificieel was uitgesteld met behulp van een trombineremmer. Het trage verdwijnen van factor Xa wordt gedeeltelijk verklaard door een voortdurende relatief trage factor X aktivering door het intrinsieke tenase enzym, het complex van IXa met zijn cofactor VIIIa. Dit werd afgeleid uit metingen in plasma van een patient met hemofilie A, waarin de afname van de factor Xa concentratie aanmerkelijk sneller bleek te zijn. Deze proef laat op directe wijze de rol zien die de alternatieve extrinsieke route, ook wel de 'Josso lus' genoemd, speelt in stollend plasma.

In gezuiverde systemen heeft naast trombine ook factor Xa de capaciteit om de cofactoren V en VIII te aktivieren. Proeven met de synthetische trombineremmer BIBG 64 BF, die de trombinevorming vertraagt zonder

de snelheid van factor Xa vorming noemenswaardig te beïnvloeden, toonden dat in stollend plasma aktivering van de cofactoren V en VIII gelijktijdig plaatsvond met de trombinevorming, en niet met de vorming van factor Xa. Tussen het kinetische gedrag van factor Va en VIIIa in plasma blijken opmerkelijke verschillen te bestaan. Omdat de snelheid van inaktivering van factor VIIIa in plasma erg hoog is, terwijl factor Va slechts zeer langzaam geremd wordt, zijn de piekwaarden van de factor VIIIa concentratie, in tegenstelling tot die van factor Va, sterk afhankelijk van snelheid van aktivering. Omdat bij lagere concentraties remmer de aktivering van factor V en VIII niet volledig werd geremd, en een initiële snelheid van aktivering kon worden gemeten, kan de minimale eerste orde snelheidskonstante die een remmend proces dient te hebben ten einde de cofactor aktivering volledig te blokkeren geschat worden op 2 s^{-1} . Tenslotte kan worden opgemerkt dat de concentraties van factor Va in plasma die worden bereikt na de initiële fase van de stolling veel hoger zijn dan de concentraties van factor Xa, zodat de maximale snelheid van het protrombinase complex in die fase wordt bepaald door de factor Xa concentratie.

Een logisch vervolg op de serie proeven beschreven in de hoofdstukken 2 en 5 leek het onderzoek van de bloedstolling in een systeem dat nog dichter staat bij de fysiologische situatie: bloed stromend uit een bloedingstijd wondje. De bloedingstijd echter, kent een grote variabiliteit die niet alleen twijfel zaait over diens nut als een klinische test, maar die ook significante en lastig te omzeilen variaties zou introduceren bij onderzoek naar de rol van het bloedstollingsproces in de hemostase van een bloedingstijd wondje. Derhalve was ons eerste doel het zoveel mogelijk minimaliseren van de instrumentele variabiliteit van een bloedingstijd bepaling, hetgeen beschreven is in hoofdstuk 6. Hiertoe maakten we gebruik van een techniek, uitgevoerd volgens een strict protocol, die de snelheid meet van bloeding in de tijd, in plaats van uitsluitend de tijd benodigd voor het stoppen van de bloeding. Bloed dat uit een bloedingstijd wondje stroomt wordt door een slangensysteem naar een fotometer gevoerd, waar de hoeveelheid hemoglobine wordt gemeten. De Hb concentratie is dan een maat voor de uitstroomsnelheid van het bloed. Deze techniek maakte het mogelijk ook de bruikbaarheid van andere parameters te bepalen, zoals de totale hoeveelheid verloren bloed en de maximale en gemiddelde uitstroomsnelheid van het bloed. Onze resultaten laten zien dat van alle parameters afgeleid uit de gemeten bloedingspatronen, toch de bloedingstijd de laagste variabiliteit kent. Deze variabiliteit echter is zowel bij metingen tussen individuen als bij verschillende metingen bij dezelfde persoon nog steeds aanzienlijk en in de

zelfde orde van grootte als in eerder gepubliceerde onderzoeken. De hoge variabiliteit zorgt voor een relatief hoge mate van overlap van bloedingstijden tussen verschillende populaties, tenzij hun gemiddelde erg ver uit elkaar ligt. Omdat bloedingstijden hoogstwaarschijnlijk afhankelijk zijn van een aantal niet controleerbare parameters, is de kracht van de bloedingstijd als een klinische of farmacologische test niet erg groot en wellicht niet vatbaar voor veel verbetering als gevolg van veranderingen in de meettechniek. Dit impliceert dat analyse van het proces van bloedstolling in bloed stromend uit een bloedingstijd wondje zijn beperkingen heeft ten aanzien van een kwantitatieve beschrijving.

Stolling *in vivo* wordt gewoonlijk op gang gebracht door een beschadiging van de vaatwand. Weefselfactor, aanwezig op de celmembranen van het perivasculaire weefsel, komt dan in contact met de stollingsfactoren die in het bloed circuleren. Beschadigde cellen en geactiveerde bloedplaatjes leveren de procoagulante oppervlakken die nodig zijn voor efficiënte reacties. De fysische en biochemische condities die zich voordoen kunnen zeer verschillend zijn voor verschillende stollingsvoorvallen. De stromingscondities worden beïnvloed door grootte en het type van het bloedvat. De mate van beschikbaarheid van weefselfactor en procoagulant fosfolipiden oppervlak wordt bepaald door de grootte van de vaatwandbeschadiging. Van belang is ook de plaats waar de stolling optreedt, hetzij in het lumen van het bloedvat, hetzij in het perivasculaire weefsel, waar stroming volledig afwezig kan zijn. Dit alles maakt extrapolatie van experimentele gegevens naar de *in vivo* situatie erg lastig. Derhalve levert het soort proeven beschreven in dit proefschrift kwantitatieve resultaten die in principe alleen geldig zijn voor de omstandigheden waarin de proeven werden uitgevoerd. Hoewel de verleiding groot kan zijn de conclusies te generaliseren naar wetmatigheden die gelden voor bloedstolling in het algemeen, moet men zich nog steeds rekenschap geven van de precieze omstandigheden op een gegeven plaats en tijdstip.

De beschikbaarheid van nauwkeurige meettechnieken om concentraties van trombine, factor Xa, factor VIIIa en factor Va in plasma en bloed te bepalen, heeft ons de mogelijkheid gegeven een begin te maken met het in detail bestuderen van het proces van de bloedstolling onder bijna fysiologische omstandigheden. Dit is echter niet meer dan een kleine stap in het ophelderen van de wetten die hemostasis *in vivo* bepalen. Veel meer experimenten, in combinatie met de juiste analyses en modelvorming, zijn nodig, niet alleen in plasma, maar ook in experimentele systemen waarin de belangrijke factor stroming is opgenomen, en, uiteindelijk, in de *in vivo* situatie zelf. Dit is echter alleen verstandig wanneer genoeg

informatie is verkregen op andere wijze, om een betekenisvolle interpretatie van de gegevens mogelijk te maken, net zoals het niet mogelijk zou zijn geweest om de in dit proefschrift beschreven experimenten in hun juiste context te plaatsen zonder de uitgebreide kennis van het stollingssysteem verkregen in meetsystemen met gezuiverde eiwitten.

curriculum vitae

Han Kessels werd geboren op 1 maart 1966 te Sittard. In 1984 behaalde hij het diploma Atheneum B aan de scholengemeenschap 'Serviam' te Sittard. Hij studeerde geneeskunde aan de Rijksuniversiteit Limburg te Maastricht van 1984 tot 1988. In de periode 1986 tot 1988 was hij aangesteld als student assistent bij de vakgroep Pathologie. Daarna werkte hij als Assistent In Opleiding bij de vakgroep Biochemie van de Rijksuniversiteit Limburg aan het onderzoek dat tot dit proefschrift heeft geleid.

Naast zijn hoofdwerk, werd als medisch wetenschappelijk assistent in de kliniek bij de afdeling Pathologie van het Sittard Ziekenhuis gewerkt. In deze functie werd de verandering van de morfologie van de cellen van de darm bij de ziekte van Crohn bestudeerd.

Naast zijn hoofdwerk, werd als medisch wetenschappelijk assistent in de kliniek bij de afdeling Pathologie van het Sittard Ziekenhuis gewerkt. In deze functie werd de verandering van de morfologie van de cellen van de darm bij de ziekte van Crohn bestudeerd.

Naast zijn hoofdwerk, werd als medisch wetenschappelijk assistent in de kliniek bij de afdeling Pathologie van het Sittard Ziekenhuis gewerkt. In deze functie werd de verandering van de morfologie van de cellen van de darm bij de ziekte van Crohn bestudeerd.

Naast zijn hoofdwerk, werd als medisch wetenschappelijk assistent in de kliniek bij de afdeling Pathologie van het Sittard Ziekenhuis gewerkt. In deze functie werd de verandering van de morfologie van de cellen van de darm bij de ziekte van Crohn bestudeerd.

Naast zijn hoofdwerk, werd als medisch wetenschappelijk assistent in de kliniek bij de afdeling Pathologie van het Sittard Ziekenhuis gewerkt. In deze functie werd de verandering van de morfologie van de cellen van de darm bij de ziekte van Crohn bestudeerd.

Naast zijn hoofdwerk, werd als medisch wetenschappelijk assistent in de kliniek bij de afdeling Pathologie van het Sittard Ziekenhuis gewerkt. In deze functie werd de verandering van de morfologie van de cellen van de darm bij de ziekte van Crohn bestudeerd.

dankwoord

Dit proefschrift luidt voor mij het einde in van een periode van vijf jaar werken in Maastricht. Het was een fijne tijd, en ik wil iedereen die daaraan heeft bijgedragen graag bedanken. Sommigen wil ik, in verband met dit proefschrift, nog even in het bijzonder noemen.

Prof. Hemker, Coen, ik wil je allereerst natuurlijk bedanken voor de gelegenheid die je me gegeven hebt om, onder jouw begeleiding, in je lab te komen werken, eerst als student, en later als promovendus. Ik denk dat de vrijheid die je me vanaf het begin gegeven hebt een goede leerschool zal blijken.

Suzette, jij hebt me, om het zo maar eens te zeggen, ingewijd in de praktische geheimen van de bloedstolling, toen ik als niets vermoedende student een keuzevak bij je kwam lopen. Je hebt dat zo goed gedaan dat ik na die paar weken al zeker wist dat ik in het onderzoek verder wilde.

Simone, als er iemand is geweest die in de afgelopen jaren z'n stempel heeft gedrukt op de sfeer in het lab dan ben jij het wel. Een vrolijke stempel wel te verstaan. Bovendien was je altijd bereid om me te helpen als ik weer eens 750 buisjes moest vullen voor de proef van de volgende dag.

Khaled, jouw grote verdienste is dat, sinds jij bij ons op het lab werkt, niemand ook maar de minste gelegenheid krijgt om stiekem in slaap te vallen.

Theo en George, jullie wil ik bedanken voor het feit dat het werkelijk nooit voorkwam dat jullie geen tijd voor me hadden als ik weer eens om advies kwam.

Peter en Danny, fijn dat jullie de (zware) taak van paranimf op je durfden te nemen. Peter, ik hoop dat ik niet alsnog de rekening krijg van alle koffie die ik bij jullie op het lab gedronken heb...

Harry, Harry en Peter, tijdens onze discussies zijn, ondanks (dankzij?) het bier, de nodige bruikbare ideeën geboren.

Trees, Mariet en Gertie, jullie stonden steeds voor me klaar als ik weer eens een klein of minder klein klusje voor jullie had.

I want to thank Prof. Smits, Dr. Barrowcliffe, Prof. Vermeylen, Prof. Ramaekers and Prof. Vrieze for critically evaluating this thesis.

Rob en Hans, Ron en Jo, bedankt voor de eiwitten die ik altijd van jullie gekregen heb.

Peter Laudy, jouw hulp op pascal en fotometer gebied was onmisbaar.

Hu Kai, Paul, Frederique, Dirk, Ma Xi, Vicky, Tomas, Richard, en Rachana, ook jullie droegen bij aan de gezellige sfeer op het lab.

Theo, Suzette, Peter, Harry, Sanne, Johan en George, ik ben jullie erkentelijk voor de tijd die jullie hebben gestoken in het kritisch doorlezen van (delen van) het manuscript.

Tenslotte wil ik alle leden van de vakgroep Biochemie en iedereen die op directe of minder directe wijze een bijdrage heeft geleverd en die ik niet met name heb genoemd, van harte bedanken.